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Pseudomonas aeruginosa causes a wide range of infections. Ciprofloxacin is one of 
the most widely used antibiotics for the treatment of these infections. Antibiotic 
resistance in P. aeruginosa has made its eradication complicated and commonly 
leads to treatment failures. The genetic basis of ciprofloxacin resistance in P. 
aeruginosa is partially understood and a more complete understanding may improve 
chemotherapeutic regimens for treatment of this pathogen. 
The overall aim of this thesis was to identify genes associated with ciprofloxacin 
resistance. Ciprofloxacin-resistant mutants were obtained from an antibiotic sensitive 
reference strain, P. aeruginosa PAO1, through experimental evolution, and genomic 
analysis of mutants was carried out. Mutations were found in gyrA, parC, parE, and 
nfxB, which are genes previously associated with ciprofloxacin resistance, and in 
genes not previously known to be associated with resistance such as PA3491, and pil 
genes. The mutation in gyrA was a key determinant of ciprofloxacin resistance. 
Mutation in the PA3491 gene was shown to be involved in increasing the 
ciprofloxacin resistance for the first time and was shown to influence the expression 
of the mexCD efflux pump genes. To quantify the contribution of mutations to 
ciprofloxacin resistance, mutations were engineered into the PAO1 genome 
individually and in multiple combinations, and Minimum Inhibitory Concentration 
(MIC) testing was carried out. Combinations of multiple mutations led to the high 
level of resistance. MICs of engineered mutants showed that gene-gene interactions 
were involved in the development of a high level of ciprofloxacin resistance. This 
information was used to predict the resistance of 237 clinical isolates through 
analysis of their genome sequences. 71%, 24%, and 7% clinical isolates had actual 
MICs equal, greater, and less than the predicted MICs, respectively.  
Overall, this study enhanced our understanding of the genetic basis of ciprofloxacin 
resistance evolution in P. aeruginosa. This study has also shown that gene-gene 
interactions can play an important role in antibiotic resistance and can be 
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This chapter is based on the following published review paper: 
 
Rehman A, Patrick W & Lamont I (2018) Mechanisms of ciprofloxacin resistance in 
Pseudomonas aeruginosa: new approaches to an old problem. Journal of Medical 
Microbiology 68: 1-10. 
AR reviewed the literature and prepared a draft. Patrick, W and Lamont, I revised the 
draft thoroughly and refined it further.  
Sections 1.1 to 1.7, 1.15 and 1.16 were prepared for this thesis. Sections 1.1 to 1.7 
include a general overview of P. aeruginosa and antibiotic resistance in P. 
aeruginosa. Sections 1.15 and 1.16 elaborate the main question of the project.  
Sections 1.8 to 1.14 were taken from the abovementioned review. These sections 
describe ciprofloxacin as an antibiotic for P. aeruginosa infections, the mode of 















1.1 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a Gram-negative bacterium which belongs to the 
Pseudomonadaceae family. It is a rod-shaped encapsulated bacterium with one 
flagellum for mobilisation. P. aeruginosa has a broad habitat. It is found in soil, 
water, plants, and animals skin flora, and it can tolerate a wide range of temperatures 
(Fraise, 1995). It causes a wide range of infections. It is an opportunistic pathogen, is 
notorious for nosocomial infections, and has become a serious clinical concern. For 
example, the occurrence rate of healthcare-associated P. aeruginosa infections is 
51,000 every year in the USA (Centers for Disease Control and Prevention, 2016). 
This chapter will outline P. aeruginosa’s genomic diversity, virulence, antibiotic 
resistance mechanisms briefly, and ciprofloxacin resistance mechanisms in detail. 
1.2 P. aeruginosa genome flexibilities  
P. aeruginosa genome is comprised of a circular chromosome. It consists of 5500 to 
6000 open reading frames (Klockgether et al., 2011). Different strains of P. 
aeruginosa can also have different plasmids. The genome sequencing of PAO1 strain 
(laboratory reference strain) showed that out of all predicted genes, 8.4 % are 
regulatory genes, which is higher than any other bacterial genomes (Stover et al., 
2000). The P. aeruginosa genome has a high GC content (65-67%) (Wu et al., 2015).  
The P. aeruginosa genome has a mosaic structure comprised of a conserved core 
genome, commonly containing inserted DNA elements of the accessory genome. The 
P. aeruginosa core genome represents around ~88% of the average of 
different/multiple genomes sizes (Valot et al., 2015). The core genome is defined as 
the part of the genome sequence that is conserved in almost all strains of P. 
aeruginosa, and independent of the strain origin, for example, clinical, 
environmental, or laboratory strains. The core genome contained genes associated 
with resistance to commonly used antibiotics. Most metabolic, respiratory, and 
virulence genes are also present in the core genome (Valot et al., 2015). Gene 
encoding the antibiotic efflux pumps MexAB-OprM, MexCD-OprJ, MexXY/OprM, 
and MexEF-OprN, genes encoding target proteins for antibiotics e.g., 




the core genome (Valot et al., 2015). The presence of virulence and antibiotic 
resistance-associated genes in the core genome indicates that all the isolates, either 
environmental or clinical isolates, could acquire antibiotic resistance and have basic 
machinery for pathogenesis.  
Different strains of P. aeruginosa have different genome sizes (Subedi et al., 2019). 
The difference in genome sizes is due to the accessory genome. The accessory 
genome contains genes that are not conserved and are found in some P. aeruginosa 
strains but not in others. The accessory genome is comprised of plasmids and DNA 
inserted into the chromosome at various loci (Freschi et al., 2018). The accessory 
genome encodes a range of transporters, transcriptional regulators, and two-
component regulatory systems that indicate its capacity to utilise a wide range of 
nutrients. Accessory DNA regions are scattered in the genome, leading to genomic 
diversity in P. aeruginosa which, in turn, enhances its adaptability to a variety of 
conditions/settings. The accessory genome also has a significant role in P. 
aeruginosa persistence, most importantly, in multiple antibiotic resistance. The 
accessory genome also encodes virulence factors (Kung et al., 2010, Freschi et al., 
2018, Subedi et al., 2019).  
Therefore, an overall great genetic capacity makes P. aeruginosa adaptable to 
environmental changes. The lifestyle of ubiquitously found P. aeruginosa could be 
attributed to its genetic capacity that makes it thrive in a wide range of habitats in the 
general environment, and it has a large set of hosts including human and animals, 
and gives it metabolic versatility and capability to readily become resistant to almost 
all classes of antibiotics (Valot et al., 2015).  
1.3 P. aeruginosa infections 
P. aeruginosa causes a wide range of severe infections in people who are in diseased 
conditions or have a weak immune system (Driscoll et al., 2007, Bassetti et al., 
2018). It has become a serious clinical concern because it is a common cause of 
infections in hospitalised patients (Gaynes & Edwards, 2005, Vincent et al., 2009), 
and immunocompromised hosts (Jugulete et al., 2012), and it is a most significant 




In 2017, Cystic Fibrosis Foundation Patient Registry, P. aeruginosa was diagnosed 
in 44.6% of respiratory cultures from CF patients. Approximately 80% of CF 
patients get chronic P. aeruginosa infection by the age of 20 (Tingpej et al., 2007, 
Döring et al., 2011, Folkesson et al., 2012). P. aeruginosa can adapt to the 
environment of CF lungs by switching the expression of the specific gene set, which 
makes it able to overcome different challenges such as osmotic stress, competition 
between different bacterial colonies, nutritional insufficiency, antibiotics, and 
oxidative stresses (Goodman et al., 2004). Chronic P. aeruginosa infections in CF 
patients worsens the health of patients (Zemanick et al., 2013). 
Nosocomial P. aeruginosa infections include cases of pneumonia (Ramirez-Estrada 
et al., 2016), urinary tract infections (Lamas Ferreiro et al., 2017), bloodstream 
infections (Shi et al., 2019), surgical site infections and skin infections in the case of 
burn wounds (Gonzalez et al., 2016). Common examples of community-acquired P. 
aeruginosa infections include ulcerative keratitis (common in contact lens users) (Sy 
et al., 2012), otitis externa in diabetic patients (Kaya et al., 2018) and skin and soft 
tissue infections (Sarkar et al., 2016, Bassetti et al., 2018). P. aeruginosa also causes 
bacteraemia in acute leukaemia patients (Kim et al., 2017). P. aeruginosa infections 
are associated with an increased rate of mortality and morbidity in cases of CF, 
pneumonia, and bacteraemia (Bassetti et al., 2018). Because of diverse hospital-
acquired infections and their association with high mortality and morbidity rates, P. 
aeruginosa has become a critical clinical concern.  
1.4 Pathogenic features of P. aeruginosa 
A wide range of P. aeruginosa infections, colonisation, and the ability to thrive in a 
variety of human organs could be attributed to its significantly diverse range of 
pathogenic features (Moradali et al., 2017). Pathogenic characteristics of P. 
aeruginosa include the production of virulence factors (Moradali et al., 2017) and 
pigments, biofilm formation (Milivojevic et al., 2018), anaerobic growth (Schobert 
& Tielen, 2010), quorum sensing (Lee & Zhang, 2015, Ahmed et al., 2019) and pili 





Table 1.1: Pathogenic features of P. aeruginosa and their mode of actions. 
Pathogenic features Mode of action References 
Siderophores Provide bacteria with a crucial nutrient iron required for the growth of P. aeruginosa. 
Signal molecule for the expression of major virulence factors that increases the iron 
availability to bacteria during infection. Siderophores remove iron from host cell 
mitochondrial proteins and damages the organelle. 
(Wilderman et al., 2001, 
Llamas et al., 2014) 
Virulence factors 
Type III secretion system** 
Effector proteins/Exoenzymes (ExoS, ExoT, 
ExoU and ExoY) 
ExoU targets the host cell plasma membrane and cleaves the phospholipids in 
membrane resulting in cell lysis. 
Hauser (2009) 
Extracellular exotoxin A 
 
Inhibits the activity of host cells elongation factor 2 and consequently, makes host cell 
unable to synthesize proteins and necrotise 
Michalska &  Wolf (2015) 
extracellular proteases,  Degrading multiple host immunoregulatory proteins, including surfactant proteins A 
and D, complement, immunoglobulin and antibacterial peptides 
Balasubramanian et al. 
(2013) 
Elastases Tissue invasion and infection; degrades host elastin, collagen and fibrin and damages 
host tissues. Inactivates important elements of the immune systems 
(Hoge et al., 2010, Casilag et 
al., 2016) 
Lipase, phospholipases Host cell membrane destruction and tissue invasion 
 
Moradali et al. (2017) 
Alkaline protease Degrades host tissue proteins and causes haemorrhagic tissue necrosis which is 
crucial for tissue invasion 
Laarman et al. (2012) 
Rhamnolipids Causes tissue damage and invasion Gellatly &  Hancock (2013) 
Pili and flagella Adherence to host receptors at surfaces of lung epithelial cells and induction of 
successive host signalling and pathogenic events 
(Bucior et al. (2012), Persat 




Pathogenic features Mode of action References 
Quorum sensing QS* Expression of number of genes for virulence factors and pyocyanin production is under 
the control of quorum sensing 
Switching of acute infection to chronic infections is controlled by quorum sensing-
dependent gene expression. This system regulates genes that involves motility-sessility 
switch, formation of biofilm and the regulation of metabolic signalling for stress 
responses 
Barr et al. (2015). 
Pigments 
Pyocyanin and several different phenazine 
Causes ciliary dysfunction in the respiratory tract and exert proinflammatory and 
oxidative effects that damage host cells  
Quorum sensing and iron acquisition 
Hall et al. (2016) 
Biofilm formation  
Biofilm is a group of bacteria, packed in a self-
produced polymer matrix consisting of 
polysaccharide, protein and DNA. 
P. aeruginosa produces biofilm in chronic infections particularly in 
immunocompromised patients. 
Biofilm formation is one of the major challenges to eradicate the infection and makes 
treatments fail because of increased antibiotic resistance  
(defends P. aeruginosa from the host immune system and antibiotics) 
Vrany et al. (1997), Walters 
et al. (2003), Hoiby et al. 
(2010), Ahmed et al. (2018) 
 
 
Anaerobic growth P. aeruginosa can survive and thrive/proliferate in oxygen depleted environment by 
using nitrate or nitrite to respire anaerobically. Ability to grow in anaerobic 
environment enables it to adapt to certain lifestyles like in lung infection of CF patients. 
 P. aeruginosa does not get access to oxygen because of thick mucus in CF lungs and 
alginate produced by bacteria.  
Worlitzsch et al. (2002) 
Yoon et al. (2002), Wu et al. 
(2005), Filiatrault et al. 
(2006).  
 
* P. aeruginosa produces small molecules called autoinducers for cell to cell communication or quorum sensing, to adapt to the surrounding changing environment 
by the regulation of different genes expression (Winstanley & Fothergill, 2009). 




1.5 Increasing frequency of antibiotic resistance in P. aeruginosa  
Common antibiotics used to treat P. aeruginosa infections are listed in Table 1.2. 
Currently, eight categories of antibiotics are in clinical use to treat P. aeruginosa 
infections (Bassetti et al., 2018) (Table 1.2). However, P. aeruginosa could acquire 
resistance to multiple antibiotics belonging to almost all classes (Wang et al., 2006, 
Poole, 2011), and lead to treatment failures. P. aeruginosa is on the WHO reported 
list of pathogens for which new antibiotics are most urgently required (WHO, 2017), 
which highlights that the issue of antibiotic resistance in P. aeruginosa needs to be 
addressed. 
Several surveillance studies have shown that most P. aeruginosa infections are 
antibiotic-resistant and lead to longer stays in Intensive Care Unit (ICU) and higher 
mortality and morbidity rates (Gasink et al., 2006, Nathwani et al., 2014, Sonmezer 
et al., 2016, Righi et al., 2017). Multidrug-resistant P. aeruginosa (MDR) infections 
are highly associated with admissions to intensive care units and quinolone 
treatments, compared to non-MDR P. aeruginosa (Raman et al., 2018). The U.S 
Centre for Disease Control and Prevention (CDC) reported in 2016, that 33.9 % of P. 
aeruginosa isolates were resistant to at least one antibiotic. Hospital-acquired P. 
aeruginosa infections have shown increasing antimicrobial resistance (Potron et al., 
2015, Dou et al., 2017, Bassetti et al., 2018, Acar et al., 2019, Mhondoro et al., 
2019) and making treatment/eradication of infections difficult (Nguyen et al., 2018).  
The strong association of MDR P. aeruginosa and ventilator-associated pneumonia 
has been found and reported as a leading cause of hospital mortality in comparison to 
infections caused by non- MDR pathogens (Micek et al., 2015, Fernandez-Barat et 
al., 2017). Higher mortality rates in infections caused by antibiotic-resistant P. 
aeruginosa indicate that antibiotic resistance in P. aeruginosa complicates the 
situation and makes treatment almost always impossible. 
To overcome the antibiotic resistance in P. aeruginosa, it is of great significance to 
fully understand the antibiotic resistance mechanisms in P. aeruginosa. Complete 
information on antibiotic resistance mechanisms will facilitate making treatments 




Table 1.2:  List of antibiotics commonly used to treat P. aeruginosa infections, their mode of actions and resistance mechanisms 
Category of antipseudomonal 
antibiotics 
Examples in clinical use Mode of action Resistance mechanisms 
Penicillin with β-lactamase 
inhibitors 
 
Ticarcillin and piperacillin in 
combination with clavulanic acid or 
tazobactam 
Hampers the process of cell wall synthesis by 
inhibiting transpeptidase that catalyses the final 
step in cell wall biosynthesis (cross-linking of 
peptidoglycan) 
 
Reduced antibiotic uptake 
Deficiency in porin# OprD (Fang et al., 2014) 
 
Overexpression of efflux pumps## 
MexAB-oprM with mutations in regulator 
encoding genes; mexR, nalB, nalC or nalD 
(Braz et al., 2016), MexXY/OprM with 
mutation in mexZ (Baum et al., 2009), 
MexCD-OprJ with mutations in nfxB (Poole et 
al., 1996). 
 
Overexpression of antibiotic-inactivating 
enzymes (β-lactamase) (Meletis et al., 2012) 
 
Modification of target 
Modification of penicillin-binding proteins 













Interfere with DNA replication and 
transcription in bacteria by physically 




Target site modification (Bruchmann et al., 
2013) 
Mutations in gyrase-encoding genes 
gyrA, gyrB and topoisomeraseIV-encoding 
genes parC and parE  
Overexpression of efflux pumps 









Category of antipseudomonal 
antibiotics 






Inhibits bacterial protein synthesis by targeting 
30S ribosomal subunit 
 
Overexpression of efflux pumps 
MexXY/OprM with mutations in mexZ 
(Guenard et al., 2014) 
Target modification  






Inhibits bacterial cell wall biogenesis by 
inactivating the enzyme that catalyses 
a step of peptidoglycan biosynthesis  
Activity of antibiotic inactivating enzyme 
fosA 
inactivation of the fosfomycin transport 





Binds to lipopolysaccharide in the outer 
membrane bacteria, disrupt both the outer and 
inner membranes.  
Alterations of both PhoQ*, PmrA and 
PmrB** (Moskowitz et al., 2012) 
 
 
#Porins are channel proteins for the uptake of the nutrients and antibiotics e.g., β- lactams into the cell (Chevalier et al., 2017) 
## Efflux pump efflux the antibiotics out of the cell. Efflux pumps are composed of three proteins: Exporter protein, which is situated in the 
cytoplasmic membrane, a gated outer membrane protein in the outer membrane, and a membrane fusion protein that bridges the other two 
membrane proteins together. Efflux pumps activity is energy dependent. Overexpression of efflux pumps leads to increased efflux of antibiotics and 




*Signal transduction system responds to environmental signals and alters the cellular output for example presence of antimicrobial peptides, the 
sensor kinase (phoQ) autophosphorylates, transphosphorylates the response regulator, PhoP, which in turn binds DNA and leads to expression of 
enzymes that can modify the cell envelope and consequently gives resistance to antimicrobial peptides (Shi et al., 2004). 
** Two-component regulatory system regulates the LPS modification operon that is required for resistance to cationic antimicrobial peptides and 




1.6 Antibiotic resistance mechanisms in P. aeruginosa  
P. aeruginosa has two kinds of antibiotic resistance mechanisms: one is intrinsic 
antibiotic resistance which involves outer membrane permeability, efflux systems 
and antibiotic inactivating enzymes, and the other is acquired antibiotic resistance. 
The acquisition of resistance genes through horizontal gene transfer and the 
occurrence of mutations results in acquired antibiotic resistance, which occurs during 

















Figure 1.1: Antibiotic resistance mechanisms in P. aeruginosa, details are given 











Acquisition of resistance 
















1.7 Fluoroquinolones and their use in treating different P. 
aeruginosa infections 
With the addition of fluoride to the quinolones, the resulted fluoroquinolones showed 
better activity against broader spectra of bacteria in addition to better 
pharmacokinetic properties. Different members of the fluoroquinolone class of 
antibiotics have different activity spectra (Table 1.3). With time, newer generations 
of fluoroquinolones were introduced in clinics with improved broader spectra 
activities. Ciprofloxacin is a second-generation fluoroquinolone and is majorly active 
against Gram-negative bacteria and some Gram-positive bacteria. Ciprofloxacin is 
more active against P. aeruginosa than other fluoroquinolones (Oliphant & Green, 
2002, Grillon et al., 2016). Second generation fluoroquinolones have enhanced 
activity against gram-positive bacteria. Third generation fluoroquinolones have 
enhanced activity against atypical and anaerobic bacteria. For the treatment of P. 
aeruginosa infections, the use of ciprofloxacin is higher than other fluoroquinolones 
in hospitals. Consequently, ciprofloxacin-resistant P. aeruginosa is rapidly emerging. 
Based on summary data from 36 countries, in hospital-acquired antibiotic-resistant P. 
aeruginosa infections, 42 % were fluoroquinolone-resistant (International 
Nosocomial Infection Control Consortium) (Rosenthal et al., 2012) and the 
proportion of ciprofloxacin-resistant P. aeruginosa reported by the SENTRY 
antimicrobial surveillance programme was 32% (Sader et al., 2014, Shortridge et al., 
2019). 













First generation quinolone 
No potency against P. aeruginosa  
Poor activity against Gram positive bacteria 
 
 
 (Rella & Haas, 1982) 
Ciprofloxacin  
Second generation FQ 
 
Most active against P. aeruginosa infections 
Extensively used against P. aeruginosa infections 
in comparison to other fluoroquinolones 
 
Chronic P. aeruginosa infections 
in CF, Bacteraemia, 
Osteochondritis, 
Ear and eye infections, Malignant 
externa otitis 
(Raz & Miron, 1995, Morrison 
& Bailey, 1988, Mosges et al., 
2011, Klodzinska et al., 2016, 
Remmington et al., 2016, 
Paulsson et al., 2017) 
Levofloxacin  
Third generation FQ 
 
(L-isomer of ofloxacin) 
Enhanced activity against gram positive bacteria 





P. aeruginosa urinary tract 
infections, VAP*, CAP# 
(Pakyz et al., 2012) 
Sitafloxacin  
Fourth generation FQ 
More highly potent than other fluoroquinolones 
Broad spectrum 
 
In vitro activity against chronic 
suppurative otitis media (CSOM) 





*VAP is ventilator associated pneumonia  




Fourth generation FQ 
Ineffective against quinolone resistant P. 
aeruginosa infections in human 
Enhanced activity against gram positive bacteria 
 
Rabbit model of Pseudomonas 
keratitis 
(Sanders et al., 2011, Grillon et 
al., 2016) 
Gatifloxacin 
Fourth generation FQ 
Good activity against anaerobic Gram positive 
and negative bacteria like Pneumococci  
 
Rabbit model of Pseudomonas 
keratitis 
(Sanders et al., 2011) 
Besifloxacin 
Fourth generation FQ 
Activity against a wide range of Gram positive 
and negative ocular pathogens 
 
Pseudomonas keratitis (Sanders et al., 2011) 
Garenoxacin  
Fourth generation FQ 




In vitro activity against chronic 
suppurative otitis media  




1.8 Ciprofloxacin and its use against P. aeruginosa 
Ciprofloxacin is a member of the fluoroquinolone class of antibiotics that has been 
used successfully to treat a wide range of bacterial infections since 1987 and it is 
included in the World Health Organization’s list of essential medicines. It remains 
one of the most important antibiotics in the treatment of P. aeruginosa infections. It 
is both the most effective fluoroquinolone against P. aeruginosa (Hooper, 2000, 
Andriole, 2005), and one of the most widely used antibiotics against this bacterium. 
It can be delivered orally or intravenously, and recently an inhalable ciprofloxacin 
formulation was developed for treating chronic P. aeruginosa infections in CF 
patients (Klodzinska et al., 2016). It has been used to treat a variety of P. aeruginosa 
infections including bacteraemia (Paulsson et al., 2017), osteochondritis (Raz & 
Miron, 1995), ear and eye infections (Mosges et al., 2011) and malignant externa 
otitis (Morrison & Bailey, 1988). It is commonly used for treatment of P. aeruginosa 
in children and adults with CF (Remmington et al., 2016). However, an increasing 
proportion of P. aeruginosa clinical isolates are resistant to ciprofloxacin (Rosenthal 
et al., 2012). Here we review current understanding of the mechanism of action of 
ciprofloxacin and the biochemical and genetic changes underlying ciprofloxacin 
resistance in P. aeruginosa. 
 
1.9 Ciprofloxacin mechanism of action 
 
Fluoroquinolones bind noncovalently to two target proteins, DNA gyrase and 
topoisomerase IV (Hooper, 1999). DNA gyrase is a tetramer of two GyrA and two 
GyrB subunits. Its function is to cleave the DNA backbone and then, in an ATP-
dependent reaction, re-ligate it after introducing negative supercoils that are crucial 
for chromosome condensation, replication and transcription initiation (Levine et al., 
1998, Wang, 2002). The GyrA subunit binds to DNA and hydrolyses the backbone, 
while GyrB catalyses the ATP hydrolysis that drives the supercoiling process (Bush 
et al., 2015). Similarly, topoisomerase IV is a tetramer of two ParC and two ParE 
subunits. These have similar functions to GyrA and GyrB; indeed, in P. aeruginosa 
GyrA and GyrB have 33% and 32% amino acid sequence identity to ParC and ParE 




daughter chromosomes after DNA replication as well as relaxing supercoils in the 
DNA (Kato et al., 1990, Levine et al., 1998). Fluoroquinolones do not affect the 
strand breakage reactions catalysed by these enzymes but inhibit the re-ligation step, 
resulting in cleaved DNA complexes that halt DNA replication. Thus, 
fluoroquinolones are generally bacteriostatic. However, high doses of 
fluoroquinolone can result in double-strand DNA breaks that are fatal to the affected 
cells (Drlica & Zhao, 1997, Drlica et al., 2009). 
The three-dimensional structures of DNA gyrase and topoisomerase IV from P. 
aeruginosa have not been determined but insights into their interactions with 
ciprofloxacin can be obtained from orthologous enzymes. In particular, the structure 
of the Mycobacterium tuberculosis DNA gyrase has recently been solved in complex 
with ciprofloxacin (Blower et al., 2016), and topoisomerase IV from Acinetobacter 
baumannii has been solved in complex with the ciprofloxacin analogue moxifloxacin 
(Wohlkonig et al., 2010). Ciprofloxacin is bound with high affinity through 
hydrogen bonding to amino acid side chains, with the interaction of enzyme and drug 
being bridged by magnesium (Mg2+) ions and water molecules (Wohlkonig et al., 
2010).  
The P. aeruginosa GyrA protein has 43% sequence identity (60% similarity) to 
GyrA from M. tuberculosis. We took advantage of this similarity to build a 
homology model of P. aeruginosa DNA gyrase A to shed light on its interactions 
with ciprofloxacin. In this model two key ciprofloxacin-binding residues are 
threonine 83 and aspartate 87 (Figure1.2). Identical or similar (serine and glutamate, 
respectively) residues are present at the corresponding positions in DNA gyrase and 
topoisomerase enzymes from other bacteria. These residues are at the DNA-binding 
site of DNA gyrase and topoisomerase and the presence of ciprofloxacin inhibits the 
resealing of DNA breaks, explaining why ciprofloxacin leads to DNA breakage in 
affected cells (Drlica & Zhao, 1997, Hooper, 1999, Mitscher, 2005). However, 
moxifloxacin and gatifloxacin have shown different molecular binding sites on target 
enzymes DNA gyrases, than ciprofloxacin and levofloxacin in different bacterial 
















Figure 1.2: Interaction of ciprofloxacin with DNA gyrase. A homology model of the P. 
aeruginosa DNA gyrase A was constructed, based on the structure of the DNA gyrase-
ciprofloxacin complex of M. tuberculosis (Blower et al., 2016) and using Phyre 2 (Kelley et al., 
2015). The ciprofloxacin binding site is shown, with DNA gyrase subunit A in green, DNA 
in orange and blue and ciprofloxacin shown as sticks. In this model ciprofloxacin interacts 
through hydrogen bonding (dotted lines) with residues Thr 83 and Asp 87 of the DNA 









     




1.10 Physiological responses to ciprofloxacin 
Ciprofloxacin induces oxidative stress and the formation of hydroxyl radicals in P. 
aeruginosa through an unknown mechanism (Jensen et al., 2014). These may 
enhance the effectiveness of ciprofloxacin in killing P. aeruginosa; indeed, growth 
of the bacteria in the presence of hyperbaric oxygen increases their sensitivity to 
ciprofloxacin (Gade et al., 2018). 
Bacteria respond to DNA damage including single- and double-stranded breaks and 
replication blockage through the SOS response (Friedberg et al., 1995). As might be 
expected, sub-inhibitory concentrations of fluoroquinolones, which results in the 
presence of double stranded DNA breaks, induce the SOS response in a number of 
bacterial species including P. aeruginosa (Cirz et al., 2006, Breidenstein et al., 
2012). This response involves increased expression of multiple genes encoding 
proteins associated with DNA repair, error-prone DNA polymerases and other 
related proteins (Courcelle et al., 2001). Transcriptomic analysis of P. aeruginosa 
after exposure to sub-clinical levels of ciprofloxacin also showed induced expression 
of genes associated with DNA repair and recombination as well as genes encoding 
error-prone DNA polymerases (Brazas & Hancock, 2005, Cirz et al., 2006, Murray 
et al., 2015). 
Enhanced production of error-prone DNA polymerases results in ciprofloxacin-
induced increases in mutation frequencies in Escherichia coli (Cirz et al., 2005, 
Lopez et al., 2007) and Streptococcus pneumoniae (Henderson-Begg et al., 2006). 
The same is likely to be the case in P. aeruginosa although so far as we are aware, 
the effect of ciprofloxacin on mutation rates has not been studied in P. aeruginosa.  
Ciprofloxacin is thought to be more effective against actively growing cells. In P. 
aeruginosa, treatment with ciprofloxacin led to reduced expression of genes 
encoding proteins involved in cell division, motility, quorum sensing and cell 
permeability (Cirz et al., 2006). Down regulation of these genes may lead to 
reduction in cell growth rate which might reduce the detrimental effects of 
ciprofloxacin. (Drlica & Zhao, 1997). Sub-inhibitory concentration of ciprofloxacin 
also induced biofilm formation (Linares et al., 2006). Growth in biofilms enhances 




including ciprofloxacin (Vrany et al., 1997, Walters et al., 2003, Ahmed et al., 
2018).  
1.11 Genetics and mechanisms of ciprofloxacin resistance 
 
There are two primary well studied mechanisms of ciprofloxacin resistance in P. 
aeruginosa, target site modification and upregulation of efflux pumps (Figure 1.3). 
Mutations in the ciprofloxacin target-encoding genes gyrAB and parCE reduce the 
affinity of DNA gyrase or topoisomerase for ciprofloxacin. Overexpression of efflux 
pumps increases the expulsion of ciprofloxacin from P. aeruginosa cells and occurs 
through mutations in regulatory genes of efflux pumps. It has become clear that a 
large number of other genes can also play a role in ciprofloxacin resistance and 
resistance is evolved by combination of alleles, highlighting the complexity and 
multifactorial nature of the ciprofloxacin resistance development process 
(Breidenstein et al., 2008, Zhang et al., 2015).  
 
1.11.1 Target site modification 
 
Mutations in genes encoding DNA gyrase and topoisomerase IV are major 
contributors to ciprofloxacin resistance in P. aeruginosa (Table 1.4). Mutations 
associated with ciprofloxacin resistance in P. aeruginosa were first identified in gyrA 
(Robillard & Scarpa, 1988). Subsequent studies have shown that sequence variants in 
which the threonine at position 83 in GyrA is replaced by an isoleucine and the 
serine at position 87 in ParC is replaced by a leucine are the most frequently 
occurring alterations associated with ciprofloxacin resistance in P. aeruginosa from 
CF, non-CF and in vitro evolved isolates (Higgins et al., 2003, Lee et al., 2005, 
Wydmuch et al., 2005, Pasca et al., 2012, Bruchmann et al., 2013). The second most 
frequent variant in GyrA is at position 87, with asparagine, tyrosine or glycine 
residues being present in place of aspartate. In our model of GyrA Thr83 and Asp87 
play key roles in the binding of ciprofloxacin by DNA gyrase through water-ion 
bridges (Figure 1.2). The presence of different amino acid residues at these sites 
reduces the affinity of gyrase for ciprofloxacin, providing a mechanistic explanation 




Maxwell, 1993, Aldred et al., 2013, Aldred et al., 2014). This resistance mechanism 
was supported when drug binding assays showed reduced affinity of mutant E. coli 
GyrA for ciprofloxacin, compared to wild type gyrase enzyme (Barnard & Maxwell, 
2001). GyrA and ParC variants occur more frequently than GyrB and ParE variants 
(Table 1.4), perhaps because changes in the sequences of GyrB and ParE confer 
lower-level resistance to ciprofloxacin. Reduced binding of ciprofloxacin to DNA 
gyrase or topoisomerase will reduce the frequency of single- and double-strand DNA 
breaks (Figure 1.3). 
 
The high prevalence of the isoleucine variant at position 83 in GyrA implies that 
other than greatly increasing resistance to ciprofloxacin this has little or no effect on 
the fitness of P. aeruginosa. This is consistent with studies in other species that 
showed that equivalent mutations reduced quinolone binding without affecting 
enzyme activity (Aldred et al., 2012, Aldred et al., 2013). Other factors such as 
secondary site mutations may also play a role in reducing disadvantageous effects of 



















Table 1.4: Target site resistance alleles in ciprofloxacin resistant isolates of P. 
aeruginosa. 
 






(Akasaka et al., 2001, Higgins et al., 
2003, Lee et al., 2005, Llanes et al., 
2011, Pasca et al., 2012, Bruchmann et 





(Akasaka et al., 2001, Higgins et al., 






(Lee et al., 2005, Llanes et al., 2011, 
Bruchmann et al., 2013, Cho et al., 
2014) 
3-29% 
Glu468Asp/His (Akasaka et al., 2001, Lee et al., 2005, 
Pasca et al., 2012, Bruchmann et al., 







(Lee et al., 2005, Pasca et al., 2012, 
Bruchmann et al., 2013, Cho et al., 
2014, Lucchetti-Miganeh et al., 2014, 










(Lee et al., 2005)  
Ala473Val 
 
(Akasaka et al., 2001, Pasca et al., 
2012) 
 
Ser457Arg (Pasca et al., 2012)  
 
*Amino acid changes associated with ciprofloxacin resistance  
























Figure 1.3: Classical mechanisms of ciprofloxacin action and resistance in P. 
aeruginosa A. Ciprofloxacin-sensitive P. aeruginosa; Ciprofloxacin inhibits DNA 
gyrase and topoisomerase IV stalling DNA replication and leading to production of 
double stranded DNA breaks. Basal expression of efflux pumps such as MexCD-
OprJ gives low level efflux of ciprofloxacin. B. Ciprofloxacin-resistant P. aeruginosa; 
Mutations (red star) in the gyrA/gyrB (DNA gyrase) genes and parC/parE 
(topoisomerase IV) genes reduce affinity of the enzymes for ciprofloxacin. 
Mutations in genes such as nfxB that encode regulatory proteins result in 





                                        
          
                        
                          
                
             
                     
              
      
                
                            
              
      
                
                                        




1.11.2 Efflux overexpression 
The second major mechanism of ciprofloxacin resistance is increased efflux from 
cells, to reduce the intracellular concentration (Figure 1.3). Efflux pumps secrete 
small molecules such as antibiotics, dyes, detergents, inhibitors, disinfectants, 
organic solvents and homoserine lactones (Poole, 2011). Efflux pumps commonly 
secrete multiple chemically-related substrates. Efflux is an energy-dependent process 
driven by ATP hydrolysis, proton motive force (PMF), or sodium gradient (Mousa and 
Bruner, 2016). The efflux pump systems are grouped into five well-characterised families 
depending on the amino acid sequence identities, energy sources required to function, and 
substrate specificities. These are ATP-binding cassette (ABC) (Szakács et al., 2008, Locher, 
2009), the small multidrug resistance (SMR) (Schuldiner, 2009), the major facilitator 
superfamily (MFS) (Kumar et al., 2013; Yan, 2015), the resistance-nodulation-cell division 
(RND) (Du et al., 2014; Yamaguchi et al., 2015; Daury et al., 2016; Vargiu et al., 2016) and 
the multidrug, and toxic compound extrusion (MATE) (Hvorup et al., 2003; Kuroda and 
Tsuchiya, 2009) families. P. aeruginosa contains 12 RND efflux pumps (Poole, 2005). Four 
key RND efflux systems export fluoroquinolones are MexCD-OprJ, MexEF-OprN, MexAB-
OprM, and MexXY/OprM (Masuda et al., 2000, Oh et al., 2003, Llanes et al., 2011, Morita 
et al., 2015, Goli et al., 2016). RND transporter systems are composed of a cytoplasmic 
membrane-spanning substrate-proton antiporter protein that is activated by the PMF, an 
outer membrane channel-forming protein and a bridging periplasmic membrane fusion 
protein (Nikaido, 1998, Zgurskaya, 2009). Expression of efflux pump genes is controlled 
by system-specific regulatory proteins and efflux pump overexpression occurs 
through mutations in these regulators (Llanes et al., 2011, Sun et al., 2014, Tai et al., 
2015).  
Overexpression of two efflux pumps MexCD-OprJ and MexEF-OprN have been 
most commonly reported as contributing in ciprofloxacin resistance. Overexpression 
of MexCD-OprJ arises through mutations in the nfxB gene (Wong & Kassen, 2011, 
Jorgensen et al., 2013) and occurs in P. aeruginosa isolates from CF and non-CF 
patients (Jalal et al., 2000, Higgins et al., 2003, Henrichfreise et al., 2007). 
Mutations resulting in overexpression of MexCD-OprJ occur at a range of positions 
in nfxB in fluoroquinolone-resistant isolates of P. aeruginosa (Jalal & Wretlind, 
1998, Jalal et al., 2000, Kiser et al., 2010). Wild type NfxB binds to the promoter of 




dimerisation and DNA binding of NfxB, enhancing production of the MexCD-OprJ 
efflux pump, which leads to multidrug resistance (Monti et al., 2013, Purssell & 
Poole, 2013). Overexpression of MexEF-OprN also occurs in isolates of P. 
aeruginosa from CF and non-CF patients due to mutations in the mexS gene which 
result in overexpression of MexT (Sobel et al., 2005). MexT is an activator involved 
in upregulation of the mexEF-oprN genes (Jalal et al., 2000, Llanes et al., 2011) 
although there are likely to be additional regulators that remain to be identified 
(Richardot et al., 2016). In addition, overexpression of mexXY/oprM has also been 
shown to confer ciprofloxacin resistance at lower levels in clinical isolates of P. 
aeruginosa (Hocquet et al., 2008, Bruchmann et al., 2013). Overexpression of 
mexXY/oprM has mostly been attributed to mutations in the regulator gene mexZ 
(Aires et al., 1999, Smith et al., 2006). Association of mutations in mexR gene with 
fluoroquinolone resistance has been showing contradictory results (Cabot et al., 
2016, Nguyen et al., 2018). 
1.12 Resistance is enhanced by combinations of alleles 
Clinically resistant P. aeruginosa isolates often have mutations associated with 
ciprofloxacin resistance in multiple different genes. These are typically alleles 
associated with high level expression of efflux pumps accompanied by resistance 
alleles of ciprofloxacin target site proteins (Jalal & Wretlind, 1998, Lee et al., 2005, 
Alekshun & Levy, 2007, Rejiba et al., 2008, Lister et al., 2009, Wei et al., 2011, 
Bruchmann et al., 2013, Lucchetti-Miganeh et al., 2014). Ciprofloxacin-resistant 
isolates frequently have target site mutations in both DNA gyrase (gyrA and/ or 
gyrB) and topoisomerase IV (parC and/ or parE). A combination of gyrA and parC 
resistance alleles confers higher ciprofloxacin resistance than resistance alleles in 
only gyrA in clinical isolates of P. aeruginosa (Mouneimne et al., 1999, Le Thomas 
et al., 2001, Lomholt & Kilian, 2003, Cho et al., 2014, Wang et al., 2014, Yang et 
al., 2015, Nouri et al., 2016). Though, no mutation was found in parE (Yang et al., 
2015). Bacteria with target-site mutations as well as efflux overexpression had higher 
ciprofloxacin resistance than bacteria with only individual mutations (Dunham et al., 
2010, Bruchmann et al., 2013). Overexpression of two efflux systems did not further 




The relative contributions of mutant gyrA and of other genes to resistance has been 
investigated by restoring gyrA to the wild-type sequence in ciprofloxacin-resistant 
isolates of P. aeruginosa (Bruchmann et al., 2013). Restoration of wild type gyrA 
reduced the ciprofloxacin Minimum Inhibitory Concentration (MIC) in all cases, but 
by different amounts in different isolates. The different MICs of different isolates 
with restored wild type gyrA indicate the presence of additional strain-variable 
resistance mechanisms. 
Experimental evolution studies suggest that mutation to a gyrA resistance allele is 
essential for ciprofloxacin resistance, with other mutations further increasing 
resistance (Feng et al., 2016). Bacteria with mutations in regulatory genes of efflux 
pumps but with a wild type gyrA allele may remain ciprofloxacin-susceptible due to 
the high affinity of wild type GyrA for ciprofloxacin (Mouneimne et al., 1999, 
Jacoby, 2005, Bruchmann et al., 2013).  
The presence of ciprofloxacin-resistant P. aeruginosa within patients may arise from 
infection by a ciprofloxacin-resistant strain, or alternatively through infection with a 
ciprofloxacin-sensitive strain that evolves during the course of infection to become 
resistant. Whole genome sequencing of P. aeruginosa isolated at different times from 
the lungs of chronically infected CF patients provides an opportunity to identify 
mutations that occur during infection. In an analysis of 26 samples isolated over a 19 
year period from patients in Denmark who had received ciprofloxacin treatment, 
positive selection had occurred for mutations in gyrA, gyrB, mexA, mexB, nfxB and 
mexZ (Marvig et al., 2015), all of which are associated with ciprofloxacin resistance 
(Bruchmann et al., 2013, Masuda et al., 2000). 
 
1.13 Other ciprofloxacin resistance genes 
The development of tools for high-throughput whole genome analysis has provided 
additional approaches to identify genes and proteins that contribute to ciprofloxacin 
resistance. The availability of transposon mutant libraries, collections of mutants that 
between them have a transposon insertion in each mutable gene, has led to the 
identification of more than 100 genes in which mutations alter the resistance of P. 




mutS and mutL that encode mismatch repair proteins, bacteriophage genes, nuoD that 
encodes a component of NADH dehydrogenase and iron transport genes 
(Breidenstein et al., 2008). Thirty-five of the mutants had lower resistance than wild 
type, identifying genes that contribute to basal resistance and may represent novel 
targets for future drug interventions. The clinical relevance of these genes has not yet 
been studied.  
1.14 Experimental evolution studies  
A few studies have used an alternative approach of developing ciprofloxacin-
resistant mutants from sensitive strains in laboratory culture and then using whole-
genome sequencing of clinical isolates to identify the mutations (Table 1.5). These 
experimental evolution studies have advantages over investigating ciprofloxacin-
resistant clinical isolates, which often have thousands of genetic differences masking 
those associated with ciprofloxacin resistance. A number of genes including gyrA, 
gyrB, nfxB and parC were commonly mutated in laboratory-evolved ciprofloxacin-
resistant mutants, as might be expected. Notably, mutations gyrA T83I and parC 
S87L/N were frequently obtained, indicating that these mutations are strongly 
associated with ciprofloxacin resistance. In addition, some novel genes associated 
with ciprofloxacin resistance were identified (Table 1.5). However, how these 
mutations contribute to resistance and their clinical relevance has not been studied 
yet. These studies show the potential of experimental evolution to reveal previously 
unidentified resistance mechanisms.  
Laboratory-evolved mutants of P. aeruginosa with increased ciprofloxacin resistance 
have also been analysed using proteomics approaches (Su et al., 2010, Peng et al., 
2017). Increased phosphorylation of two proteins, succinate-semialdehyde 
dehydrogenase and methyl malonate-semialdehyde dehydrogenase, and increased 
expression of a protein of unknown function occurred during development of 
resistance (Su et al., 2010). The protein changes may contribute to resistance by 
affecting the production of energy in the form of PMF that is required for the activity 
of efflux pumps processes or may be involved in increased production of NADH to 
reduce the oxidative stress (Su et al., 2010). A second study also found that reduced 




anaerobic respiration and upregulation of catalase and peroxidase (Peng et al., 2017). 
Other changes associated with resistance involved increased production of proteins 
involved in DNA repair and of proteins for import of iron and polyamine. Highly 
resistant mutants showed overexpression of MexCD-OprJ and reduced expression of 
quorum sensing proteins (Peng et al., 2017).  
In other Gram negative bacteria, ciprofloxacin resistance can involve acquisition of 
resistance genes on mobile genetic elements such as plasmids (Correia et al., 2017). 
This mechanism is rare in P. aeruginosa, although a few examples have been 
reported (Ogbolu et al., 2011, Chavez-Jacobo et al., 2018, Liu et al., 2018). In the 
clearest case a plasmid-borne gene encodes an enzyme that catalyses 
phosphorylation of ciprofloxacin, inactivating it (Chávez-Jacobo et al., 2018). In 
three other examples genes associated with ciprofloxacin resistance in other species 
have been identified at a low frequency on mobile genetic elements in P. aeruginosa 
(Ogbolu et al., 2011, Liu et al., 2018) although their contributions to resistance in 
this species remains to be determined. 
Collectively, the diverse approaches described above show that ciprofloxacin 

















Table 1.5: Changes associated with ciprofloxacin resistance in laboratory-
derived mutants. 
 






Novel ciprofloxacin resistance 
genes 
 
gyrA Thr83Ile  
CPA2 
parC Pro85Leu and Ser87Asn, 
gyrB Glu458Asp 
 
~512-fold the MIC of 
ancestor strain 
(Feng et 





6 different mutations in gyrB 
Prevalent nfxB mutations; 
Thr39Pro, Glu146Lys, 
Gly180Ser 
deletion in orfN   
 
256-fold the MIC of 
ancestor strain 
(Wong et 
al., 2012)  
Predicted glycosyl transferase 
gene orfN,  
Sodium solute symporter gene 
PA14-46110 





 gyrB Ser465Tyr 
parC Ser87Leu 
 






gyrA Thr83Ile, Glu153Lys  
nfxB Trp115any amino acid 
mexR Arg83His  
parC Ser87Leu 
Deletion in pmrB 
64-fold the MIC of 
ancestor strain 
(Cabot et 
al., 2016)  
Deletion in two component 
regulator system signal sensor 
kinase B gene pmrB  
 
 











1.15 Prediction of bacterial antibiotic resistance from genome 
sequence analysis  
In the past, different molecular methods such as RFLP-PCR, allele-specific PCR and 
PCR sequencing of the quinolone resistance determining region (QRDR) have been 
proposed to be used as a diagnosis for antibiotic resistance in bacteria (Fluit et al., 
2001, Tuite et al., 2014, Onseedaeng & Ratthawongjirakul, 2016). Loci of the point 
mutations in genes gyrA, gyrB, parC, and parE that are generally associated with 
fluoroquinolone resistance are collectively termed the quinolone resistance 
determining region (QRDR). PCR-based assessments of antimicrobial resistance 
include the amplification of specific DNA regions and sequencing and to find 
mutations sequences that are aligned with a reference (wild-type) sequence. 
However, this approach has the limitation that mutations associated with resistance 
that is not previously known, and new antibiotic resistance mechanisms, could be 
missed (Tuite et al., 2014). With the progress made in the last years on DNA 
sequencing technologies, whole-genome sequencing (WGS) is emerging rapidly as a 
potential technique for the prediction of antibiotic resistance in bacteria (Su et al., 
2018). Whole-genome sequencing has been improved with the passage of time to the 
level where it is no longer expensive, and it is considered a robust technique (Pallen 
et al., 2010, Koser et al., 2012). It has shown its potential as a multipurpose 
technique. It has been used for different applications such as the characterisation of 
bacterial isolates, patient to patient and environment to patient transmission of 
infections, infection surveillance (Eyre et al., 2012, Turton et al., 2015, Cabot et al., 
2016, Thrane et al., 2016, López-Causapé et al., 2017), and above all, antibiotic 
resistance profiling (Jeukens et al., 2019, Su et al., 2018). The principle of antibiotic 
resistance prediction in isolates using whole-genome sequences is that the isolates 
are designated as resistant or susceptible, based on the presence or absence of 
antibiotic resistance determinants (which are present in antimicrobial resistance 





1.15.1 Antibiotic resistance predictions in different bacterial species using 
genome sequences 
In multiple studies, antibiotic resistance profiling has been determined in different 
bacterial species using whole-genome sequences and has shown promising results. In 
a study, the whole genome sequencing analysis of 193 S. aureus isolates was carried 
out. The molecular genetic basis was identified as 99.8% of the antimicrobial 
resistance phenotypes of the isolates from genome sequence analysis (Holden et al., 
2013). This analysis was based on a scan of 116 genes to predict the resistance for 12 
different antibiotics. For M. tb (Miotto et al., 2017), S. aureus (Holden et al., 2013) 
and Streptococcal species (Metcalf et al., 2016, Metcalf et al., 2017), predictions on 
a large sample size with a high diversity have shown higher accuracy rates of 
antibiotic resistance predictions that highlights the potential of WGS to be used for 
antibiotic resistance predictions in clinical isolates (Clausen et al., 2016, Zankari et 
al., 2017, Furusawa et al., 2018). However, a strong correlation between actual and 
predicted resistance profiling indicates that resistance mechanisms in S. aureus and 
Streptococcal species are well understood, and resistome is probably almost 
completely known (Su et al., 2018).  
1.15.2 Antibiotic resistance predictions in P. aeruginosa and limitations 
Antibiotic resistance predictions based on genome sequence analysis in P. 
aeruginosa could be complicated (Jeukens et al., 2017, Johnning et al., 2018) 
because resistance mechanisms are not fully known (Bruchmann et al., 2013, 
Jeukens et al., 2017), and P. aeruginosa has complex resistance mechanisms such as 
efflux overexpression and membrane permeability (Li et al., 2015). In addition, 
antibiotic resistance in P. aeruginosa is multifactorial i.e., it has many genes which 
when mutated, contribute to resistance.  
The correlation between antimicrobial resistance and quinolone resistance 
determining region (QRDR) mutations in genome sequences was evaluated in P. 
aeruginosa isolates (Kos et al., 2015). A total of 390 genomes were analysed, and 




resistance (Kos et al., 2015). In protein GyrA, amino acid positions 83 to 87, in GyrB 
429 to 585, in ParC 82 to 84, and in ParE 357 to 503 were considered as QRDR.  
Out of 390, 198 isolates were resistant (MIC ≥ 4mg/L) to levofloxacin. The presence 
of mutations gyrB, parC, and parE in both resistant and susceptible isolates were 
observed. A total of 163 out of 198 of the resistant isolates had a mutation in gyrA. A 
combination of QRDR mutations in gyrA and parC was the most frequent 
combination of mutations, indicating a strong association of gyrA and parC 
mutations with ciprofloxacin resistance. However, there were isolates that were 
phenotypically resistant and did not have a mutation in gyrA and had mutations in 
gyrB. However, in other studies, gyrA QRDR mutations have been found to be 
strongly associated with fluoroquinolone resistance (Akasaka et al., 2001, Higgins et 
al., 2003, Lee et al., 2005, Llanes et al., 2011, Pasca et al., 2012, Bruchmann et al., 
2013, Yang et al., 2015). Resistant isolates without genetic variation in gyrA or gyrB 
had mutations in either parC or parE.  
None of the QRDR mutations were present in 174 out of 190 susceptible isolates 
(MIC ≤ 2 mg/L) (Kos et al., 2015). Among the remaining 16 susceptible isolates, 5 
isolates had gyrA mutations and five had a mutation in gyrB. A combination of 
QRDR mutations found in one susceptible isolate was gyrA plus parE, and another 
isolate had gyrB plus parE. An additional five isolates had single parE mutations. 
The presence of gyrB, parC, and parE mutations in both resistant and susceptible 
isolates highlights the need for further investigations on the involvement of 
mutations in genes gyrB, parC, and parE in resistance.  
Overall, genomic analysis and susceptibility profiling were found consistent, with 
91% sensitivity and 94% specificity (Kos et al., 2015). However, the involvement of 
efflux-related genes in levofloxacin resistance was overlooked, and the involvement 
of gyrB, parC, and parE mutations in antibiotic resistance predictions was not 
investigated in detail in this study. There were fluoroquinolone-resistant samples that 
did not have mutations in gyrA, for which resistance was hypothetically attributed to 
parC and parE mutations, and analysis has not been done to find the causal 




There are several tools designed for antibiotics resistance predictions (Su et al., 
2019). Resistance gene identifier (RGI) was used to analyse resistome in 390 P. 
aeruginosa isolates (Freschi et al., 2015, Jeukens et al., 2019). The findings of this 
RGI analysis highlighted the complexity of antimicrobial resistance prediction and 
showed that antibiotic resistance-associated genes are not completely known. Only 
one gene that is gyrA showed a strong association with resistance out of hundreds of 
antimicrobial resistance genes (Freschi et al., 2015). This finding raises the questions 
of the involvement of genes other than gyrA in fluoroquinolone resistance and why 
genes other than gyrA did not show a correlation/association with antibiotic 
resistance. 
So far, tools to predict antibiotic resistance have not been applied to a multiple 
different bacterial species; therefore, it is difficult to infer that tools will predict 
antibiotic resistance in multiple bacterial species with high confidence. In addition, 
available tools have limitations, that is, epistasis between resistance mutations and 
strain-specific backgrounds has not been considered and neither have copy number 
variations of plasmids (San Millan et al., 2016). It is worth considering that antibiotic 
resistance is a complex phenotype, which involves epistasis between resistance 
mutation (Durao et al., 2018) and genetic background (MacLean et al., 2010).  
Another approach used for antibiotic resistance predictions is machine learning, 
which is probably more promising than a rule-based approach. The machine learning 
method was developed to predict resistance in different bacterial species C. difficile, 
M. tuberculosis, P. aeruginosa, and S. pneumoniae for 17 different antibiotics 
(Drouin et al., 2016). The machine learning approach proposed in Drouin et al., 2016 
showed high accuracy rates in the majority of datasets. For some datasets of P. 
aeruginosa, accuracy rates were not high with any of the different methods of 
machine learning evaluated in Drouin et al., 2016. Low accuracy was attributed to 
the low quality of sequences, a small number of samples, and the possibility of 
additional genomic factors associated with antibiotic resistance. 
The majority of the approaches used, and tools developed so far, designate isolates as 
resistant or susceptible and they are not able to determine the resistance 




important because isolates with a lower level of resistance could probably be treated 
/eliminated with higher dosages of antibiotics, which is not possible if isolates with a 
lower level of resistance were designated as susceptible (Balloux et al., 2018). In 
addition, predicting antibiotic resistance quantitatively might lead to revealing 
additional genes and genetic variations in P. aeruginosa.  
To understand the genetic basis of ciprofloxacin resistance, it is pertinent to ask how 
much resistance is conferred by individual mutations and combinations of mutations. 
To predict the antibiotic resistance in the clinical isolates of P. aeruginosa with 
higher accuracy, the attribution of resistance to the alleles needs to be experimentally 
proven. In addition, the role of gene-gene interactions between ciprofloxacin 
resistance-associated genes needs to be investigated in detail to fully understand the 
genetic basis of ciprofloxacin resistance. In this thesis, antibiotic resistance in 
isolates was predicted from whole-genome sequences of clinical isolates to enhance 
the understanding of the genetic bases of ciprofloxacin resistance in P. aeruginosa. 
In addition, ciprofloxacin resistance prediction criteria were designed that could be 













1.16 Aims of the thesis  
The overall aim of this thesis was to better understand the genetic basis of 
ciprofloxacin resistance in P. aeruginosa in order to predict the ciprofloxacin 
resistance of clinical isolates. There were 4 specific objectives: 
• To comprehensively identify mutations associated with ciprofloxacin 
resistance in P. aeruginosa using experimental evolution and whole-genome 
sequence analysis. 
• To thoroughly investigate the quantification of resistance conferred by 
individual mutations and different combinations of mutations by 
characterising experimental evolutionary trajectories and constructing 
isogenic mutants.  
• To use the resulting information to predict ciprofloxacin resistance in clinical 
isolates of P. aeruginosa from genome sequences.  
• To investigate the roles of mutations in gene PA3491 that was not previously 
















Ciprofloxacin resistance associated mutations 
in Pseudomonas aeruginosa 
Results in this chapter have been published in the following manuscript: 
Wardell SJT*, Rehman A*, Martin LW, Winstanley C, Patrick WM & Lamont IL 
(2019) A Large-Scale Whole-Genome Comparison Shows that Experimental 
Evolution in Response to Antibiotics Predicts Changes in Naturally Evolved Clinical 
Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 63: e01619-
01619. 
*Authors contributed equally 
This chapter is comprised of the following Sections  
1. Experimental evolution of ciprofloxacin resistant P. aeruginosa mutants and 
their whole genome sequence analysis 
2. Growth analysis and minimum inhibitory concentrations (MICs) of 
experimentally evolved mutants for different antibiotics  
3. PROVEAN analysis of whole genome sequences from clinical and 
environmental isolates of P. aeruginosa. 
Research described in the third Section of this chapter was carried out by laboratory 
colleague Samuel J. T. Wardell. This Section has been discussed briefly in this 
chapter where required. Details of this Section are given in the above mentioned 
manuscript (Wardell et al., 2019). 
The methods Section of this chapter have been taken from the manuscript, which was 











• Laboratory reference strain PAO1 was evolved experimentally to select 
ciprofloxacin-resistant mutants. The whole genome sequence analysis of 
PAO1 and experimentally-evolved mutants was carried out to identify 
mutations associated with ciprofloxacin resistance. 
• Mutations in genes that encode ciprofloxacin target proteins, gyrA, parC, 
parE, and gene nfxB that encodes the efflux pump negative regulator, 






P. aeruginosa becomes resistant to antibiotics by acquiring mutations (López-
Causapé et al., 2018). Generally, under exposure to antibiotics, mutations that confer 
antibiotic resistance are selected after several generations. Antibiotic resistance 
mainly occurs through mutations, although genes obtained via horizontal gene 
transfer also occasionally confer a resistant phenotype (Jiang et al., 2014, Yang et 
al., 2015, Chavez-Jacobo et al., 2018).  
There are two major mechanisms of ciprofloxacin resistance in P. aeruginosa. These 
are target site modification and increased expression of efflux pumps. Mutations in 
the ciprofloxacin target-encoding genes gyrA, gyrB, parC, and parE result in the 
reduced affinity of DNA gyrase or topoisomerase IV for ciprofloxacin (Willmott & 
Maxwell, 1993, Aldred et al., 2013, Aldred et al., 2014). Mutations in the regulatory 
genes of efflux pumps can lead to an overexpression of efflux pumps that, in turn, 
increases the efflux of ciprofloxacin from P. aeruginosa cells (Wong & Kassen, 
2011, Jorgensen et al., 2013).  
In the past, to identify the fluoroquinolone resistance-associated mutations, most 
studies analysed the quinolone-resistance determining region (QRDR) sequences of 
the clinical isolates of P. aeruginosa (Wang et al., 2014, Kos et al., 2015, Yang et 
al., 2015, Nouri et al., 2016, Farahi et al., 2018). The QRDRs are specific DNA 
regions in genes gyrAB and parCE, and mutations in these DNA regions lead to 
fluoroquinolone resistance in other bacteria. The emergence of whole-genome 
sequencing (WGS) technologies has provided new approaches for understanding the 
genetic basis of antibiotic resistance (Price et al., 2013, Klemm & Dougan, 2016). 
Whole-genome sequences of fluoroquinolone-resistant clinical isolates were 
investigated in several studies (López-Causapé et al., 2017, Sherrard et al., 2017, 
López-Causapé et al., 2018, Wee et al., 2018, Bianconi et al., 2019, Nakanishi et al., 
2019). Whole-genome sequence analysis has been shown to give better insight into 
the genetic basis of antibiotic resistance and has highlighted the complexities of 




Clinical P. aeruginosa isolates face many challenges such as host immunity (Lavoie 
et al., 2011), inter-strain competition (Sibley et al., 2008, Nguyen & Oglesby-
Sherrouse, 2016), oxygen depletion (Schaible et al., 2012) and antibiotics (Tümmler, 
2019). For the adaptation to multiple challenges (Faure et al., 2018), different genetic 
variations are acquired. To identify genetic variations associated specifically with 
ciprofloxacin resistance out of thousands of genetic variations acquired and selected 
in response to other challenges in clinical isolates is complicated.  
The experimental evolution of antibiotic-resistant mutants from sensitive parent 
strains, followed by whole-genome sequencing to identify resistance-conferring 
mutations, is an approach that has been applied to several species (Pereyre et al., 
2004, Drago et al., 2005, Banerjee et al., 2008, Drago et al., 2010, Diaz Caballero et 
al., 2015, Jahn et al., 2017), including P. aeruginosa (Jorgensen et al., 2013, Melnyk 
et al., 2015, Cabot et al., 2016, Feng et al., 2016, Yen & Papin, 2017, Lopez-
Causape et al., 2018). Different experimental evolution-based studies have found 
different mutations associated with ciprofloxacin resistance in addition to common 
mutations. The variation in mutations in different experimental evolution-based 
studies could be attributed to multiple factors e.g., the number of mutants evolved, 
the level of resistance achieved through experimental evolution, and the method of 
experimental evolution. For example, continuous exposure to increasing amounts of 
the antibiotic in broth culture may give different outcomes compared to intermittent 
antibiotic exposure (Melnyk et al., 2017). Small numbers of mutants may overlook 
mutations that can contribute to resistance but do not always arise, making it more 
difficult to draw robust conclusions. In addition, an analysis of evolved mutants that 
had a lower level of resistance (just above the resistance breakpoint, i.e., MIC of 1-4 
mg/L) would not have mutations that are associated with only a higher level of 
resistance. Moreover, other laboratory evolution-based studies on P. aeruginosa 
were not extended to find if mutations identified in laboratory-evolved ciprofloxacin-
resistant mutants are clinically relevant. 
The genes gyrA, gyrB, and parC were commonly mutated in experimentally-evolved 
ciprofloxacin-resistant mutants of P. aeruginosa (Wong & Kassen, 2011, Jorgensen 




T83I was strongly associated with ciprofloxacin resistance, as all the recently 
reported experimental evolution-based studies found gyrA T83I in ciprofloxacin-
resistant mutants (Wong et al., 2012, Jorgensen et al., 2013, Cabot et al., 2016, Feng 
et al., 2016). The gene nfxB was not mutated in experimentally-evolved mutants 
reported by Feng et al. (2016) and Jorgensen et al. (2013), in contrast to Wong et al. 
(2012) and Cabot et al. (2016) in which multiple mutations were identified in nfxB 
gene. None of the experimental evolution-based studies found the mutation in parE 
gene which has previously been reported as a ciprofloxacin resistance-associated 
gene in clinical isolates (Akasaka et al., 2001, Pasca et al., 2012). This indicates that 
it is important to analyse a high number of replicates of experimentally-evolved 
mutants with a higher level of resistance to find the complete spectrum of mutations 
associated with ciprofloxacin resistance and to compare experimentally-evolved 
bacteria with clinical isolates that evolved naturally during infection to find the 
clinical relevance of mutations identified in experimentally-evolved mutants.  
In addition to gyrA, gyrB, and parC, some experimental evolution-based studies on 
P. aeruginosa found genes that were not associated with ciprofloxacin resistance 
previously (reviewed in Rehman et al., 2018). For example, mutations in genes 
encoding monovalent cation: proton antiporter 2, group 4 glycosyltransferase, 
sodium solute symporter, predicted oxidoreductase, and the two-component regulator 
system signal sensor kinase B were found in experimentally-evolved mutants. 
However, the role of these mutations found in experimentally-evolved mutants in 
ciprofloxacin resistance and clinical relevance has not been investigated yet. Such 
studies have shown the potential of experimental evolution to reveal previously 
unidentified resistance mechanisms. It has become clear that a large number of 
genes, in addition to those that have been previously associated with ciprofloxacin 
resistance, can also play a role in ciprofloxacin resistance, and resistance is evolved 
by a combination of alleles, highlighting the complexity and multifactorial nature of 
the ciprofloxacin resistance development process (Breidenstein et al., 2008, 





Another clinically important perspective of ciprofloxacin resistance is that it is 
usually associated with multidrug resistance (Poole et al., 1996, Köhler et al., 1997, 
Wolter et al., 2007, Tanimoto et al., 2008, Lister et al., 2009, Poole, 2011) because 
of the increased frequency of mutations (Tanimoto et al., 2008) or the increased 
activity of efflux pumps which contributes to ciprofloxacin resistance and can also 
increase resistance to other antibiotics (Kiser et al., 2010). In contrast, several studies 
have reported the occurrence of collateral sensitivity in fluoroquinolone-resistant 
mutants that showed increased sensitivity to ticarcillin and an aminoglycoside 
(Masuda et al., 2001, Vettoretti et al., 2009, Lazar et al., 2013, Pál et al., 2015). The 
mechanisms involved in collateral sensitivity in P. aeruginosa are not well 
understood. Possible mechanisms for collateral sensitivity of ciprofloxacin-resistant 
P. aeruginosa to other antibiotics could be the altered proton motive force (PMF)-
mediated efflux pump activity (Lazar et al., 2013), decreased induction of AmpC b-
lactamase (Masuda et al., 2001), mutations in nfxB (Masuda et al., 2001, Lister et al., 
2009, Vettoretti et al., 2009, Fernandez & Hancock, 2012) and genomic 
reprogramming, resulting from alterations in DNA supercoiling (Pál et al., 2015).  
To overcome fluoroquinolone resistance, it is of high significance to understand the 
genetic basis of fluoroquinolone resistance in P. aeruginosa fully and to identify the 
complete spectrum of mutations associated with ciprofloxacin resistance. In addition, 
the investigation of experimentally-evolved mutants to find cross-resistance and/or 
collateral sensitivity to other antibiotics is clinically important and could facilitate 
designing better chemotherapeutics to treat infections caused by antibiotic-resistant 
P. aeruginosa isolates. 
2.2 Objectives of the chapter  
• To identify ciprofloxacin resistance-associated genes using experimental 
evolution and whole-genome sequencing  
• To investigate the effects of ciprofloxacin resistance-associated mutations on 





Materials and Methods 
2.3 Materials 
2.3.1 Media 
Mueller-Hinton (MH) media  
To prepare MH agar, 38 g of Difco Mueller-Hinton Agar powder was mixed in 1L of 
ddH2O and then the media was autoclaved. 
Luria Bertani (LB) media 
To make 1 L of liquid LB, 10 g of casein hydrolysate, 5 g of yeast extract, and 10 g 
of sodium chloride was taken and dissolved in ddH2O (Sambrook et al., 2001). For a 
solid medium, 15 g of agar was added. The media was autoclaved before use.  
2.3.2 Antibiotics 
Ciprofloxacin 
Infusion Cipflox bags containing 2 mg/mL ciprofloxacin were purchased from 
Mylan New Zealand Ltd. 
Levofloxacin 
A stock solution (10 mg/mL) of levofloxacin (SIGMA) was prepared in double-
distilled water. 
Meropenem (trihydrate) 
A stock solution (10 mg/mL) of meropenem (Ranbaxy) was prepared in double-
distilled water. Meropenem was not stored for more than 24 hours.  
Imipenem 
The stock solution of imipenem plus cilastatin (Merck and Co., Inc) (10 mg/mL) was 





A stock solution (10 mg/mL) of tobramycin (Mylan New Zealand Ltd) was prepared 
in double-distilled water. 
Gentamicin  
A stock solution (10 mg/mL) of gentamicin (Pfizer) was prepared in double-distilled 
water. 
2.4 Methods 
2.4.1 Experimental evolution of antibiotic-resistant mutants 
The methodology used in this study to evolve ciprofloxacin-resistant mutants is 
shown in Figure 2.1. Antibiotic gradient plates were prepared according to the 
methodology described by Bryson and Szybalski (Bryson & Szybalski, 1952) to 
evolve ciprofloxacin-resistant P. aeruginosa mutants. Aliquots (15 mL) of molten 
DifcoTM Muller-Hinton (MH) agar (Section 2.3.1) were poured into a Petri dish 
tilted at an approximate incline of 15° to ensure a slanted slope of media. When 
cooled, the Petri dish was placed on a flat surface and an additional 15 mL of molten 
MH agar, supplemented with ciprofloxacin, was poured onto the slanted MH agar to 
create an antibiotic gradient across the plate.  
A broth culture of the reference strain P. aeruginosa PAO1 was prepared by 
streaking the bacteria from the glycerol stock, onto the LB agar plate and incubating 
it overnight at 37 °C. Then, 5 mL of LB media was inoculated with one colony of 
PAO1 picked from the LB agar plate and incubated overnight at 37 °C in an 
incubator at 200 rpm shaking. Overnight, the broth culture prepared from a single 
colony subculture of PAO1 was adjusted to OD600 = 0.01 (1.5 × 10
6 CFU/mL) and a 
2 mL aliquot was poured onto the antibiotic gradient plate. Excess liquid was 
removed by a pipette, following 10 minutes incubation at room temperature. 
Inoculated plates were incubated in aerobic conditions for 24 hours at 37°C. A single 
colony, isolated from an area of high antibiotic concentration from the gradient plate 




37°C/200rpm. Two mL of aliquot of this inoculum was then adjusted as described 
above and used to inoculate a subsequent gradient plate containing ciprofloxacin, one 
doubling concentration greater than the previous plate. A glycerol stock was 
prepared from the rest of the broth culture by taking 80% glycerol and culture in a 
1:1 ratio in screw cap tubes, mixed well, and stored at -80°C. This technique was 
repeated with increasing ciprofloxacin concentrations until it was no longer possible 
to identify mutants resistant to higher amounts of the antibiotic, and maximum 
resistance was reached. As a control, strain PAO1 was passaged six times without the 
















Figure 2.1: Graphical representation of the method used for experimental 
evolution of ciprofloxacin-resistant mutants of P. aeruginosa PAO1. Antibiotic 
gradient plate was set by the following method described in Bryson & Szybalski. (1952). 
Approximately 2000 times increase in ciprofloxacin resistance was achieved by passaging on 
the increasing concentration of antibiotic gradient agar plate 6 to 8 times. This process was 










2.4.2 Minimum Inhibitory Concentration (MIC) testing 
MIC testing was carried out following the protocol described by Wiegand and 
colleagues (Wiegand et al., 2008). Briefly, the overnight broth culture of the evolved 
mutants and the laboratory strain PAO1 were adjusted to OD600 = 0.01 (1.5x10
6 
CFU/mL), and 5 µL of aliquots were pipetted onto the MH agar plates containing 
doubling antibiotic concentrations. Control plates (MH agar without an antibiotic 
supplementation) were used as a growth comparison. All MIC plates were incubated 
in aerobic conditions at 37°C for 24 hours. The MIC for each isolate was defined as 
the lowest concentration that inhibited the growth. The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) guidelines (www.eucast.org) were 
used to interpret antimicrobial susceptibility patterns.  
2.4.3 Growth analysis 
Overnight, broth cultures of the antibiotic-resistant mutants and laboratory strain 
PAO1 were adjusted to OD600= 0.01 (1.5x106 CFU/mL) and 200 µL of aliquots were 
dispensed into 96-well tissue culture plates (JETbiofil®). LB media was pipetted in 
eight wells of each plate as a sterility control. The microtiter plates were incubated in 
a BMG FLUOstar Omega microplate reader at 37°C/200 rpm for 18 hours. Optical 
density (OD600) was recorded every 30 minutes. Absorbance readings were blank 
corrected with Omega Data Analysis software and were used to calculate the area 
under the curve (AUC). The AUC was used to give a measure of growth that 
incorporated the lag phase, the rate of growth during the log phase, and the final cell 
density. Growth dynamics were calculated by using the R package GrowthCurver 
version 0.2.1 (Sprouffske & Wagner, 2016). The logistic area under the curve (AUC) 
was used as the metric for quantifying growth. 
2.4.4 Genomic DNA extraction and genome sequencing 
Genomic DNA was extracted from the overnight cultures using the MoBio 
UltraClean® Microbial DNA isolation kit. Library preparation and sequencing was 





2.4.5 Bioinformatics analysis for mutation detection 
Raw sequencing reads were examined for quality pre- and post-trimming using 
FastQC version 0.11.5. The trimming of raw reads was done using Trimmomatic 
version 0.36 (Bolger et al., 2014) with a paired-end mode and the Phred quality score 
of 33. Trimmomatic (v 0.36) (Bolger et al., 2014) removes the sequence adapters, 
bases below the quality threshold, and excludes reads below the specified length. 
Adaptors and quality thresholds were specified in the command line. Trimmomatic 
(v 0.36) removed the sequence adapters, which were specified in the script as 
ILLUMINACLIP: TruSeq3-PE.fa:2:30:10, bases below the quality threshold at the 
start of the sequence read LEADING:5, and bases below the quality threshold at the 
end of the read, TRAILING:5. Sequence reads were scanned with a 4-base wide 
sliding window with Trimmomatic (v 0.36), cutting off the bases when the average 
quality per base dropped below 20, specified as, SLIDINGWINDOW:4:20 and 
excluded reads which had a length less than 20 bases MINLEN:20. Mutations in the 
experimentally-evolved resistant mutants were identified by comparisons with 
PAO1-Otago, using BreSeq version 0.30.0 (Deatherage & Barrick, 2014) (Section 
2.3.3). BREseq is a command-line tool originally designed to analyse 
experimentally-evolved mutants by analysing the Illumina sequence reads and 
finding the mutations in the sequence comparative to the reference sequence. The 
output of BREseq is annotated and provides multiple pieces of evidence of mutations 
found (Deatherage & Barrick, 2014). 
2.5 Results 
2.5.1 Ciprofloxacin resistance of experimentally-evolved mutants  
Highly ciprofloxacin-resistant mutants were evolved from a laboratory reference 
strain of P. aeruginosa PAO1 in thirteen parallel experiments. Each mutant was 
selected through the serial passage on antibiotic gradient agar plates containing 
increasing amounts of the antibiotic, interspersed with growth in antibiotic-free broth 
media (Figure 2.1). A representative antibiotic gradient agar plate is shown in Figure 
2.2. Mutants were considered to have reached maximum resistance (typically 




CC6, and so on where the letter 'C' denotes Ciprofloxacin, 'A' to 'R' are 
independently evolved lines, and the number represents passage numbers. Initially, 
nine mutants CA7-CK7 were evolved. After 6 months, four more mutants CL6-CR3 
were evolved to evaluate the reproducibility of results (Table 2.1). A control culture 
was passaged 6 times in the absence of the antibiotic.  
Figure 2.3 shows the MIC values for each of the 13 experimentally-evolved mutants 
for six different antibiotics belonging to three different classes. Compared to the 
parental strain PAO1, the evolved mutants had a minimum of 256-fold and a 






















Figure 2.2: Representative antibiotic gradient agar plate. the bacterial lawn on the 
left side of the plate where antibiotic concentration was minimum and resistant colonies 
towards the right side of the plate is shown. Antibiotic gradient plates were prepared by 




















2.5.2 Collateral sensitivity of ciprofloxacin-resistant mutants to other antibiotics 
Previously, ciprofloxacin resistance has been associated with multidrug resistance in 
clinical isolates (Kiser et al., 2010). In contrast, P. aeruginosa resistant to one drug 
and collaterally sensitivity to another have been reported in laboratory-evolved 
bacteria, as well as in isolates from CF and non-CF patients (Masuda et al., 2001, 
Vettoretti et al., 2009, Lazar et al., 2013, Pál et al., 2015, Yen & Papin, 2017). To 
investigate the effects of ciprofloxacin resistance-associated mutations on collateral 
sensitivities and cross-resistance to other antibiotics, MIC testing of ciprofloxacin-
resistant mutants was carried out for an antibiotic from the same class of 
fluoroquinolone (levofloxacin) and antibiotics from other classes: aminoglycosides 
(tobramycin and gentamicin), and carbapenems (meropenem and imipenem). As 
expected, most of the mutants had similarly increased resistance to levofloxacin that 
belongs to the same class of antibiotics such as ciprofloxacin.  
Eight out of thirteen of the ciprofloxacin-resistant mutants had increased (collateral) 
sensitivity by 4-fold or more relative to PAO1, for at least one carbapenem (mostly 


















Figure 2.3: Minimum inhibitory concentrations of experimentally evolved ciprofloxacin resistant P. aeruginosa to other antibiotics: 
fluoroquinolones (ciprofloxacin and levofloxacin), carbapenems (meropenem, imipenem) and aminoglycosides (tobramycin, gentamicin). Average MIC 
values of three biological replicates are shown in the boxes. The MIC values are in mg/L and MIC difference of 4-fold and above between lab 





2.5.3 Growth of ciprofloxacin-resistant mutants 
To assess the impact of antibiotic resistance-associated mutations on bacterial growth 
in the absence of antibiotic, growth analysis for each of the experimentally-evolved 
mutants was carried out by following the method given in Section 2.4.3. Growth was 
measured as Area Under Growth Curve (AUC) in order to capture differences in both 
growth rate and maximum bacterial cell density (Figure 2.4). In the absence of 
antibiotics, mutants showed significantly reduced growth compared to the parental 
strain PAO1. Mutants CR3 and CL6 had the greatest reduction in growth by 
approximately 3-fold, and CB7 and CF6 had similar growth to PAO1. There was 
heterogeneity in growth between mutants, with an average range of AUC of 396 to 
1132.4 (Figure 2.4). Growth curves of mutants and PAO1 are shown in Figure 2.5.  
 
Figure 2.4: Growth analysis of experimentally evolved ciprofloxacin resistant 
mutants. Area under the curve was calculated for comparison of growth between mutants 
and reference strain PAO1. Each dot represents a biological replicate of the experiment. 







Figure 2.5: Growth of experimentally evolved ciprofloxacin resistant mutants. 
Bacteria were grown in L-broth and optical density was measured at 600 nm (shown on the 
y-axis) every 30 minutes (time shown on the x-axis) for 18 hours. Average absorbance 
readings of 3 biological replicates for each ciprofloxacin resistant mutant were calculated to 
generate the growth curves. The colour key for each mutant is given below the graph. 
2.5.4 Identification of ciprofloxacin resistance associated mutations 
In order to assure that sequence read lengths and quality were valid/usable, the 
quality of whole genome sequences provided in quality reports as FastQC files were 
assessed. More than 95% of the reads had an average quality score above 35, and an 
average read length of approximately 250 bases. The sequences had an average 
coverage of 50X. To identify the mutations, BREseq software was used. BREseq 
uses a reference-based alignment approach to identify the mutations. First, BREseq 
maps the sequence reads on the reference genome sequence and identifies genetic 
variations by searching differences between sequence and reference sequences, and 
then annotates the variants. Genome sequences of mutants were compared with the 




and annotated (Wardell et al., 2019). The BREseq output file (HTML format) 
contained multiple evidence of mutations e.g., sequence alignments, coverage plots 
and statistical summary, in addition to an annotated list of mutations. Whole genome 
sequencing (WGS) and variant calling of the 13 ciprofloxacin resistant mutants 
showed that each mutant contained between 5 to 8 mutations. Mutations were present 
in 29 genes (Table 2.1 and 2.2). No mutations were present in PAO1 serially 
passaged 6 times in the absence of antibiotic selection.  
All of the mutants had a mutation in the gyrA gene, and 9 of the mutants also had 
mutations in the parC or parE genes that encode DNA topoisomerase, known targets 
of ciprofloxacin (Rehman et al., 2019). Twelve of the mutants also had mutations in 
nfxB which encodes an efflux pump regulator. Mutations in nfxB are known 
contributors to ciprofloxacin resistance (Rehman et al., 2019). Ten of the mutants 
had mutations in pilin-encoding pil genes (Table 2.1). The relationship between pil 
mutations and ciprofloxacin resistance is not clear, although very recently other 
studies have also showed an association between pil mutations and ciprofloxacin 
resistance (Ahmed et al., 2018). Eleven of the mutants had a mutation in the gene 
PA3491 that, to the best of our knowledge, has not previously been associated with 
antibiotic resistance. Each mutant also had line specific mutations (Table 2.2). None 





Table 2.1:  Summarized list of ciprofloxacin resistance associated mutations identified in experimentally-evolved ciprofloxacin 
resistant P. aeruginosa mutants (CA7-CR3), by comparing whole genome sequences of mutants with laboratory reference strain 
PAO1. 
Genes CA7 CB7 CC6 CF6 CG6 CH8 CI7 CJ7 CK7 CL6 CM6 CO5 CR3 
MIC mg/L 128 64 32 128 64 128 64 32 128 16 16 16 32 
gyrA# T83I T83I T83I T83I T83I T83I T83I T83I T83I 
S612L  
G81C 
T83I D87N T83I 
PA3491 H87P H87P H87P H87P H87P H87P H87P H87P H87P  H87P H87P  














parC# S87L S87L S87L S87L  S87L   S87L     






































































Deletions and insertions are denoted by Δ and ins respectively. Amino acid variants are listed where amino acids are represented by one letter codes for example, T83I 
denotes threonine at codon position 83 in GyrA is replaced by an isoleucine.  
# Genes gyrA and parC/parE encode ciprofloxacin target proteins subunits that are DNA gyrase subunit A and topoisomerase IV, respectively.   




Table 2.2: List of genes mutated in experimentally evolved ciprofloxacin resistant mutants of P. aeruginosa in comparison to 
reference strain PAO1. 
Gene Gene Description Frequency 
Nucleotide and amino acid changes 
CA CB CC CF CG CH CI CJ CK CL CM CO CR 
gyrA DNA gyrase subunit A 13/13 T83I T83I T83I T83I T83I T83I T83I T83I T83I 
G81C, 
S612L 
T83I D87N T83I 








T39P  *188C *188C S36N 
PA3491 Electron transport complex subunit C 11/13 H87P H87P H87P H87P H87P H87P H87P H87P H87P  H87P H87P  
parC DNA topoisomerase IV subunit A 6/13 S87L S87L S87L S87L  S87L   S87L     
parE DNA topoisomerase IV subunit B 3/13     V460G  V460G V460G      
pilF 
Type 4 fimbrial biogenesis protein PilF 
3/13     Δ1bp  Δ17bp Δ17bp      
pilT 
Twitching motility protein PilT 
3/13    Δ12bp  Δ12bp   Δ12bp     
ssg 
Cell surface-sugar biosynthetic 
glycosyltransferase, Ssg 2/13     Δ13bp  Δ13bp       
tpiA 
Triosephosphate isomerase 
2/13           Δ1bp Δ1bp  
aruE 
N-Succinylglutamate desuccinylase 
1/13         Δ12bp     
fptA 
Fe (III)-pyochelin outer membrane receptor 
precursor 1/13    Δ9bp          
ftsY 
Signal recognition particle receptor FtsY 
1/13    Δ48bp          
gloC 
Transcriptional regulator GlcC 




Gene Gene Description Frequency 
Nucleotide and amino acid changes 
CA CB CC CF CG CH CI CJ CK CL CM CO CR 
mexR 
Multidrug resistance operon repressor 




NADH dehydrogenase I chain M to 
hypothetical protein 
 
1/13       Δ3112bp       
obg 
GTP-binding protein Obg 
1/13 Δ3bp             
PA0093 
Tse6 
1/13      Δ13bp        
mexS 
MexS 
1/13  Δ6bp            
PA2940 
Probable acyl-CoA thiolase 
1/13          Δ12bp    
PA5438 
Probable transcriptional regulator 
1/13          Δ9bp    
pfeA 
Ferric enterobactin receptor, outer 
membrane protein PfeA precursor 1/13    G535D          
pheS 
Phenylalanyl-tRNA synthetase, alpha-
subunit 1/13      ins(GCT)        
pheT 
Phenylalanyl-tRNA synthetase, beta-
subunit 1/13             Δ6bp 
pilB 
Type 4 fimbrial biogenesis protein PilB 
1/13 Δ300bp             
pilE 
Type 4 fimbrial biogenesis protein PilE 
1/13  Δ11bp            
pilM 
Type 4 fimbrial biogenesis protein PilM 
1/13           ins(CGTCC)   
pilS 
Two-component sensor PilS 
1/13             Δ14bp 
pscD 
Type III export protein Psc 




Gene Gene Description Frequency 
Nucleotide and amino acid changes 
CA CB CC CF CG CH CI CJ CK CL CM CO CR 
rpsH 
30S ribosomal protein S8 





2.5.5 Frequencies of mutations in clinical isolates of P. aeruginosa 
It is common for mutations that confer antibiotic resistance in P. aeruginosa to arise 
during infection in CF patients (Sriramulu, 2013). Genomes from 558 clinical and 
172 environmental isolates were analysed to address the question: do mutations that 
arise in the experimental evolution experiments reflect those that have arisen in the 
clinical isolates of P. aeruginosa? For comparison, genomes of 172 P. aeruginosa 
isolated from the general environment were analysed, which are unlikely to have had 
antibiotic exposure. An analysis of genomes from clinical and environmental isolates 
was done by laboratory colleague Samuel J.T. Wardell (Wardell et al., 2019). Results 
are briefly given in this chapter due to the relevance to the content of this chapter (for 
details see Wardell et al., 2019). All genes that were mutated in two or more of the 
experimentally-evolved mutants were analysed in each clinical and environmental 
genome to determine whether resistance-associated mutations had occurred (Table 
2.2). The absence of genome sequences of the ancestral strains of clinical and 
environmental isolates prevented a direct identification of mutations. Instead, genetic 
variants that are likely to alter protein function in genes of interest were inferred 
using PROVEAN, a widely used tool for predicting the likelihood that amino acid 
differences affect protein function (Choi et al., 2012).  The results are summarised in 
Table 2.2. 
Genes that were mutated in experimentally-evolved ciprofloxacin-resistant mutants 
had higher frequencies of predicted function-altering variants in clinical isolates than 
in environmental isolates, for example, gyrA, nfxB, parC and parE (Table 2.3). The 
antibiotic target gene gyrA had the highest frequency of predicted function-altering 
variants in 33 % of the clinical isolates. Some genes such as tpiA and PA3491 that 
were mutated in experimentally-evolved mutants had frequencies of predicted 
function-altering differences in the clinical isolates less than in environmental 
isolates, implying that mutations in these genes may not be advantageous during 
infection. Interestingly, genes that have not been strongly associated with 
ciprofloxacin resistance previously, such as pilF and ssg, had higher frequencies of 
predicted function-altering variants in clinical isolates than in environmental isolates. 
The genes pilF and ssg encode type 4 fimbrial biogenesis protein PilF and cell 




investigations are required to reveal the role of such genes in ciprofloxacin resistance 
in P. aeruginosa and to confirm their clinical relevance. Investigation of the most 
frequently mutated genes in experimentally-evolved mutants was the main focus of 
this study.  
 
Table 2.3: Frequencies of predicted change-of-function mutations in clinical and 












n = 13 
Clinical isolates 
n = 558 (%) 
Environmental 
isolates 
n = 172 (%) 
gyrA 13 187 (33.5) 5 (2.9) 
nfxB 12 74 (13.2) 7 (4.1) 
PA3491 11 98 (17.5) 60 (34.9) 
parC 6 37 (6.6) 6 (3.9) 
parE 3 15 (2.7) 3 (1.7) 
pilT 3 4 (0.7) 0 (0) 
pilF 3 22 (3.9) 2 (1.2) 
tpiA 2 15 (2.7) 6 (3.5) 






To find the ciprofloxacin resistance-associated mutations in P. aeruginosa, strain 
PAO1 with a low level of ciprofloxacin resistance was evolved to highly resistant 
mutants, using the antibiotic gradient agar plate method (Figure 2.1). The MIC 
testing was carried out for mutants with maximum ciprofloxacin resistance from each 
of the thirteen independently evolved lines (Table 2.1). Mutants had an MIC of 16 to 
128 mg/L, which is 256-fold to 2048-fold higher than the parent strain PAO1 (MIC = 
0.0625 mg/L). To identify the mutations in laboratory-evolved mutants, whole-
genome sequencing was carried out, and sequences were analysed using BREseq 
software (Section 2.4.5). The spectrum of mutations was identified in mutants 
compared to laboratory strain PAO1. Mutations gyrA T83I, nfxB T39P, PA3491 
H87P, parC S87L, and parE V460G, and deletion mutation in pil genes were 
observed in higher frequencies (6 out of 13 and above) than other mutations in 
experimentally-evolved mutants (Table 2.1). Higher frequencies of these mutations 
in experimentally-evolved mutants indicated a strong association of mutations with 
ciprofloxacin resistance. In addition, PROVEAN analysis was carried out in 
genomes of clinical and environmental isolates to evaluate the clinical relevance of 
ciprofloxacin resistance-associated genes found through an analysis of 
experimentally evolved mutants. PROVEAN predicts function-altering mutations. It 
was found that a higher proportion of clinical isolates had predicted function-altering 
genetic variations in ciprofloxacin resistance-associated genes as compared to those 
in environmental isolates, indicating the clinical relevance of these genes.  
2.6.2 Experimental evolution method 
In contrast to previous experimental evolution studies (Jorgensen et al., 2013, Cabot 
et al., 2016, Feng et al., 2016, Jochumsen et al., 2016, Barbosa et al., 2017, Jorth et 
al., 2017, Melnyk et al., 2017, Yen & Papin, 2017, Ahmed et al., 2018), an agar-
based selection method, interspersed with growth in the antibiotic-free broth was 
used. An antibiotic selection on agar plates, combined with cycles of antibiotic-free 




the lungs of CF patients. In both circumstances, bacterial growth is on a semi-solid 
surface with intermittent exposure to antibiotics, and it also selects for mutations that 
are stably inherited in the absence of antibiotics (Melnyk et al., 2017). 
Genetic variations associated with ciprofloxacin resistance in P. aeruginosa were 
then characterised. This methodology for experimental evolution and the analysis of 
a large number of resistant mutants identified ciprofloxacin resistance-associated 
genes not found in other experimental evolution-based studies that are parE, 
PA3491, pil genes, tpiA, ssg, and some studies did not find mutants with nfxB 
mutations (Jorgensen et al., 2013, Feng et al., 2016), a contrast to this study. Out of 
these genes, nfxB and parE have long been associated with ciprofloxacin resistance 
in clinical isolates (Higgins et al., 2003, Lee et al., 2005), while tpiA (Hwang et al., 
2016), and ssg (Fernández et al., 2013) have recently been reported in the antibiotic-
resistant clinical isolates of P. aeruginosa. 
2.6.3 Frequencies of ciprofloxacin resistance-associated mutations in 
experimentally-evolved mutants 
Frequencies of mutations in resistant bacteria suggest how strongly a mutation is 
associated with resistance. Genome analysis of mutants showed that, among the 
genes that encode ciprofloxacin-target, gyrA was the most frequently (13/13) mutated 
gene in this study, followed by parC (6/13) and parE (3/13). The frequency of 
mutated genes gyrA and parC was consistent with previously reported studies in 
which ciprofloxacin-resistant P. aeruginosa was evolved by experimental evolution 
(Wong et al., 2012, Jorgensen et al., 2013, Cabot et al., 2016), and studies of isolates 
from CF and non-CF infections (Lee et al., 2005, Pasca et al., 2012, Bruchmann et 
al., 2013, Yang et al., 2015). None of the previous experimental evolution-based 
studies found a mutation in a parE gene in mutants. On the other hand, none of the 
mutants in this study showed a mutation in gyrB, contrary to other studies (Akasaka 
et al., 2001, Pasca et al., 2012, Wong et al., 2012, Bruchmann et al., 2013, Jorgensen 
et al., 2013, Cho et al., 2014).  
The gene nfxB was the second most frequently mutated gene in experimentally-




MexCD-OprJ. Mutations in nfxB are associated with an overexpression of MexCD-
OprJ which results in fluoroquinolone resistance (Monti et al., 2013, Purssell & 
Poole, 2013). However, mutations in other regulator-encoding genes, mexR of efflux 
pump MexAB-OprM and mexT of MexEF-OprN were not found in high frequency in 
this study. Two mutants had mutations in mexR and the oxidoreductase-encoding 
gene mexS. Mutations in mexS are associated with overexpression of MexEF-OprN 
(Sobel et al., 2005). Mutations in mexR, mexS, and mexT genes are generally 
associated with fluoroquinolone resistance in clinical isolates (Llanes et al., 2011, 
Adabi et al., 2015). Differences in the spectrum of mutations found in 
experimentally-evolved mutants in this study compared to other studies could be 
attributed to the different approaches used for experimental evolution used to evolve 
mutants.  
2.6.4 Ciprofloxacin resistance-associated mutations in the gyrA gene  
The gyrA gene encodes the primary target protein of ciprofloxacin, DNA gyrase. In 
this study, all mutants had a mutation in gyrA and agreement with other studies. A 
mutation leading to gyrA T83I was the most frequent mutation in ciprofloxacin-
resistant P. aeruginosa mutants, compared to other mutations in gyrA that lead to 
amino acid replacements D87G, D87N and D87Y (Yonezawa et al., 1995, 
Mouneimne et al., 1999, Wydmuch et al., 2005) in CF (Tam et al., 2010), non-CF 
(Lomholt & Kilian, 2003), and experimental evolution studies (Rehman et al., 2019). 
As described previously in Chapter 1, the possible role of this mutation is the 
disruption of the interaction between ciprofloxacin and its target protein gyrase 
subunit A, and has been characterised as playing a key role in the ciprofloxacin 
resistance of P. aeruginosa (Rehman et al., 2019). The strong selection (11/13) of the 
T83I variant of GyrA indicates that it gives likely a greater advantage of resistance 
compared to other GyrA variants (Wong & Kassen, 2011). In addition, mutations at 
both 83 and 87 codons are shown to be free of fitness cost (Melnyk et al., 2017).  
In contrast to other studies (Akasaka et al., 2001, Cabot et al., 2016), all the mutants 
had a single mutation in gyrA, except one mutant, which had two mutations in gyrA. 
Any other possible amino acid variation for codon 83 ACC such as Ala, which is 




2018), was not found in this study. This result highlighted that GyrA variant T83I is 
strongly associated with ciprofloxacin resistance in P. aeruginosa. In addition, it 
suggested that variable mutations in gyrA do not have equal contribution in 
resistance or they likely have variable fitness costs.  
Resistance alleles in gyrA that have not previously been associated with 
ciprofloxacin resistance were found in one of the 13 mutants, that lead to amino acid 
change G81C and S612L of GyrA. Amino acid change at G81D has been reported in 
fluoroquinolone susceptible clinical isolates (Kos et al., 2015). The gyrA mutations 
that have not previously been reported are also found in recent experimental 
evolution studies and studies on clinical isolates. The GyrA variants E153K (Cabot et 
al., 2016), T133M (Nguyen et al., 2018), and Q106L (López-Causapé et al., 2017) 
have been identified in fluoroquinolone-resistant P. aeruginosa. However, further 
investigations on such resistance alleles in gyrA are needed to confirm their 
involvement in the ciprofloxacin resistance of P. aeruginosa. 
2.6.5 Mutations in secondary ciprofloxacin target-encoding genes parC and parE 
Other than DNA gyrase, ciprofloxacin has secondary targets which are 
topoisomerase IV subunits ParC and ParE. Mutation in parC was found more 
frequently, compared to parE, which is consistent with other studies on clinical 
samples reviewed by Rehman et al. (2019). This result suggested that mutations in 
the parC gene are likely to increase resistance more than that of mutations in parE. 
This study identified a mutation in the parE gene that is known to contribute to 
clinical resistance when mutated but has not been identified in previous experimental 
evolution studies (Lee et al., 2005). Variability in results between this and other 
studies could be either because of a difference in the resistance level achieved 
through experimental evolution (Drago et al., 2005, Jorgensen et al., 2013, Cabot et 
al., 2016) or it might be because of a difference in the methodology of experimental 
evolution. Amino acid variation in ParE in laboratory-evolved mutants V460G has 
also been recently reported in clinical fluoroquinolone-resistant isolates (Treepong et 
al., 2018), indicating the clinical relevance of parE V460G. Only one mutation in 




gene have been associated with ciprofloxacin resistance in clinical isolates S457R, 
P438S, E459V and A473V (Akasaka et al., 2001, López-Causapé et al., 2017).  
The ParC variant S87L was found in 6 out of 13 experimentally-evolved mutants, 
and a strong association with the ParC variant S87L has also been reported in clinical 
isolates of P. aeruginosa (Nouri et al., 2016, Nguyen et al., 2018). This indicates the 
clinical relevance of parC S87L and highlights the potential of an experimental 
evolution approach to find clinically relevant mutations associated with antibiotic 
resistance. However, contrary to other experimental evolution studies and clinical 
isolates, mutants in this study did not have mutations leading to amino acid changes 
in ParC at positions other than 87, or other amino acid variation at position 87 other 
than S87L. For example, parC resistance alleles which have not been previously well 
studied but have been found recently are E91K (Cabot et al., 2016), S141H (Nguyen 
et al., 2018), S87N, and P85L (Feng et al., 2016) in experimentally-evolved mutants 
and clinical fluoroquinolone-resistant isolates.  
Overall, the spectrum of mutations in laboratory-evolved mutants indicated that a 
higher level of fluoroquinolone resistance is achieved by the combinatorial effect of 
both mechanisms, that are target site modification and the overexpression of efflux 
pump genes.  
2.6.6 Efflux-mediated ciprofloxacin resistance in P. aeruginosa 
Mutations in the nfxB gene were the second most frequent in laboratory-evolved 
mutants (12/13). The gene nfxB encodes a negative regulator NfxB of the efflux 
pump MexCD-OprJ (Poole et al., 1996). NfxB-inactivating mutations lead to the 
overexpression of the efflux pump mexCD-oprJ (Wong & Kassen, 2011, Jorgensen 
et al., 2013). An association of the overexpression of the efflux pump MexCD-OprJ 
with ciprofloxacin resistance has been reported in several studies (Jalal et al., 2000, 
Higgins et al., 2003, Henrichfreise et al., 2007). Four different mutations in gene 
nfxB T39P, small duplication, stop codon to C and S36N were found (Table 2.1). 
Among these four mutations, T39P was the most frequent mutation in mutants 
(6/13). Mutation T39P and the change of stop codon to amino acid have also been 




al., 2015). Amino acid replacement of threonine to proline at position 39 probably 
inhibits the interaction of NfxB with DNA (Purssell & Poole, 2013). Loss of function 
mutations usually are diverse and occur at variable positions in the gene. As 
expected, diverse types of mutations were observed in the nfxB gene to inactivate the 
function of NfxB; however, the frequency of the NfxB variant T39P was higher than 
other variants, indicating that different mutations in nfxB are not equally associated 
with resistance.  
One of the mutants which did not have a mutation in nfxB had a mutation in the 
mexR gene which encodes a negative regulator of the efflux pump MexAB-OprM. A 
mutation in gene mexR has been shown to increase fluoroquinolone resistance above 
gyrAmutation in the isogeneic double mutant (Nakajima et al., 2002). However, a 
recent analysis of clinical isolates of P. aeruginosa did not find an association of 
mexR mutations with fluoroquinolone resistance (Nguyen et al., 2018).  
2.6.7 Genes that were not previously associated with ciprofloxacin resistance  
Experimentally-evolved mutants in this study also had mutations in genes not usually 
associated with ciprofloxacin resistance. These include PA3491 (11/13) that encodes 
probable ferredoxin, ssg (2/13) that encodes cell surface-surface sugar biosynthetic 
glycosyltransferase Ssg, tpiA (2/13) that encodes triosephosphate isomerase, and 
pilin-encoding genes found in 2 or more mutants out of thirteen (Table 2.1). 
Consistent with this study, recent experimental evolution-based studies found genes 
associated with ciprofloxacin resistance that had not been previously reported. For 
example, CPA2 (Feng et al., 2016), orfN encoding predicted glycosyltransferase, 
sodium solute symporter, predicted oxidoreductase (Wong et al., 2012), and the two-
component regulator system signal sensor kinase B (Cabot et al., 2016). Overall, the 
gaining of mutations in genes that have not been previously associated with 
ciprofloxacin resistance suggested that the development of ciprofloxacin resistance is 
the outcome of mutations in multiple genes, and additional mechanisms or genes are 
probably involved in it. However, the roles of the mutated pil genes, ssg, and tpiA, 
CPA2, orfN, pmrB genes in ciprofloxacin resistance have not been investigated yet. 
The ssg and pmrB mutations possibly restrict the entrance of ciprofloxacin into the 




is that these mutations may make P. aeruginosa resistant to prophages. Ciprofloxacin 
likely induces phages that kill the P. aeruginosa (Goerke et al., 2006) and pil 
mutants are probably resistant to prophages. 
The gene dnpA is adjacent to ssg in an operon, and dnpA has been associated with 
fluoroquinolone resistance (Liebens et al., 2014, Liebens et al., 2016). Mutation in 
ssg might affect the dnpA expression that could lead to fluoroquinolone resistance. 
The tpiA mutation might facilitate efflux pump-mediated resistance. Efflux pump 
activity is PMF- dependent. A mutation in the tpiA gene has been shown to increase 
the rate of cellular respiration and carbon metabolism (Xia et al., 2020) that could 
result in increased PMF.  
2.6.8 Clinical relevance of ciprofloxacin resistance-associated genes found in 
experimentally-evolved mutants 
To assess the frequency of the likely change-of-function mutations in the isolates of 
P. aeruginosa from patients a POVEAN analysis was carried out by colleague 
Samuel J.T. Wardell. For comparison, a panel of isolates from the general 
environment (Table 2.2) was analysed. Details of the results are given in Wardell et 
al. (2019).  
A significant proportion of isolates from CF patients were antibiotic-resistant, 
whereas environmental isolates were typically sensitive to antibiotics (Ramsay et al., 
2019). A higher proportion of clinical isolates likely had function-altering differences 
in genes gyrA, nfxB, parC, and parE (Table 2.2) than environmental isolates. These 
genes are known to contribute to clinical resistance to fluoroquinolones in clinical 
isolates (Lee et al., 2005, Quale et al., 2006, Yang et al., 2015) and in other 
experimental evolution studies (Table 2.2) (Jorgensen et al., 2013, Cabot et al., 
2016).  
A few genes that were mutated in multiple experimentally-evolved mutants and were 
not commonly associated with antibiotic resistance previously, such as pilF and ssg, 
had a few or no predicted function-altering differences in isolates from the general 




pilF. However, the role of these genes in ciprofloxacin resistance needs further 
investigation. 
Conversely, PA3491, and tpiA had only low frequencies of predicted function-
changing differences in the clinical isolates. This finding suggests that mutations in 
these genes contribute to increased antibiotic tolerance in laboratory culture, but 
likely do not do so during infection, and further emphasises the importance of 
comparing experimentally-evolved mutants with clinical isolates.  
Mutations in gyrB are well-characterised in clinical isolates (Llanes et al., 2004, 
Jahandideh, 2013, Del Barrio-Tofino et al., 2017, Prickett et al., 2017, Frimodt-
Moller et al., 2018) but were not identified in this study, indicating that experimental 
evolution studies alone are not necessarily sufficient to identify all resistance-
associated mutations.  
Taken together, a whole-genome sequence analysis of experimentally-evolved 
mutants enhanced the understanding of the genetic basis of ciprofloxacin resistance 
in P. aeruginosa. In addition, mutations in some other genes have also been 
identified that may also contribute to ciprofloxacin resistance, and have not been 
previously associated with ciprofloxacin resistance. The importance of these genes in 
the clinical setting and their role in ciprofloxacin resistance remains to be 
determined. 
2.6.9 Collateral sensitivity of ciprofloxacin-resistant mutants to other antibiotics  
As found previously (Feng et al., 2016), the experimentally-evolved ciprofloxacin-
resistant mutants had increased resistance to an antibiotic (levofloxacin) of the same 
class as ciprofloxacin (fluoroquinolone) (Figure 2.2). Many of the mutants also had 
altered MICs of antibiotics belonging to different classes (aminoglycosides and β-
lactams), and some of these changes could be attributed to the mutations that were 
present in mutants. Several of the ciprofloxacin-resistant mutants had increased 
susceptibility to aminoglycosides and imipenem, as reported before (Imamovic et al., 
2018). The occurrence of collateral changes in antibiotic sensitivity as a result of 




the isolates of P. aeruginosa from patients (Masuda et al., 2001, Vettoretti et al., 
2009, Imamovic & Sommer, 2013, Pal et al., 2015). Collateral sensitivities of 
fluoroquinolone-resistant isolates to other antibiotics are likely due to the presence of 
nfxB mutations (Imamovic et al., 2018).  
However, twelve out of thirteen of the laboratory-evolved mutants had mutations in 
the nfxB gene, while only seven of these mutants had collateral sensitivity to either 
aminoglycosides or carbapenems (Figure 2.2). In addition, one of the mutants did not 
have a mutation in nfxB and had collateral sensitivity to the aminoglycoside. These 
results indicated that there are probably other genes or mechanisms involved in 
collateral sensitivity in addition to mutations in the nfxB gene. Further investigations 
are required to understand the mechanism of collateral sensitivity in antibiotic-
resistant mutants. A possible explanation of collateral sensitivity is that the 
overexpression of MexCD-OprJ likely puts bacterial cell under energy burden which 
consequently reduces the activity of other efflux pumps (MexAB-OprM and 
MexXY/OprM) and thus, the efflux of other substrates reduces β-lactams and 
aminoglycosides. Collateral sensitivity has important clinical implications because 
such outcomes during infection may affect treatment options for patients with CF or 
other chronic infections caused by antibiotic-resistant P. aeruginosa.  
In contrast to the collateral sensitivity of ciprofloxacin-resistant mutants to other 
antibiotics found in this study, several studies have shown the role of ciprofloxacin in 
cross-resistance to other antibiotics (i.e., meropenem) in clinical isolates (Poole et 
al., 1996, Köhler et al., 1997, Livermore, 2002, Wolter et al., 2007, Tanimoto et al., 
2008, Poole, 2011). This difference could be attributed to the fact that ciprofloxacin-
resistant mutants were experimentally evolved under the exposure of only 
ciprofloxacin, in contrast to clinical isolates which are usually treated with a 
combination of antibiotics (Worthington & Melander, 2013). Given the threat posed 
by multi-drug-resistant strains of P. aeruginosa, further research is needed to clarify 
the role of ciprofloxacin in the emergence of resistance and sensitivity to other 
antibiotics and, in particular, the implications for clinical treatment. Resistance can 
arise more readily because of the increased rate of mutation associated with 




the increased activity of efflux pumps that contributes to ciprofloxacin resistance can 
also increase resistance to other antibiotics (Kiser et al., 2010). 
2.6.10 Ciprofloxacin-resistant mutants had reduced growth 
In the absence of ciprofloxacin, the majority of the experimentally-evolved mutants 
showed significant reductions in growth relative to the wild-type strain PAO1, 
consistent with previous studies (Figure 2.3) (Wong & Kassen, 2011, Gifford & 
MacLean, 2013, Melnyk et al., 2015, Cabot et al., 2016). Reduction in growth could 
be attributed to the mutations in genes involved in an increased expression of efflux 
pumps such as nfxB and mexR (Andersson & Hughes, 2010, Melnyk et al., 2015, Lin 
et al., 2018). Mutants with nfxB mutations had reduced growth likely due to these 
two possibilities. The overexpression of efflux pumps might lead to an energetic 
burden, as efflux is an energy-dependent process. In addition, important metabolites 
could efflux from the bacterial cell with an overexpression of the efflux pump. It is 
noteworthy that the isolates of P. aeruginosa from patients are often slow-growing 
(Malone, 2015), although the extent to which this phenotype is related to antibiotic 
resistance is not clear.  
2.7 Conclusion 
In conclusion, this chapter demonstrated the potential of experimental evolution and 
whole-genome sequence analysis to identify the spectrum of mutations that are 
associated with increased ciprofloxacin resistance. Ciprofloxacin resistance-
associated genes gyrA, nfxB, parC, and parE were found mutated in high 
frequencies. The use of an agar-based method instead of the broth-based methods of 
earlier studies identified genes not previously associated with ciprofloxacin 
resistance that were PA3491 and pil genes, and showed that the spectrum of 
resistance mutations is influenced by the selection protocol. Ciprofloxacin resistant 
mutants were collaterally sensitive to aminoglycosides and imipenem. In addition, 
the analysis of resistance-associated genes in clinical isolates of P. aeruginosa 
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3.1 Introduction / Background  
The accurate and rapid diagnosis of antibiotic resistant bacterial isolates is important 
to administer timely and effective treatment. Analysis of genome sequences is 
emerging as a potentially robust approach to predict the antibiotic resistance of 
bacteria (Shelburne et al., 2017, Tamma et al., 2018, Su et al., 2019). A few studies 
predicted antibiotic resistance in isolates of P. aeruginosa using genome sequences 
(Kos et al., 2015, Drouin et al., 2016, Jeukens et al., 2017, Jeukens et al., 2019, 
Khaledi et al., 2019). Genome sequences were analysed to search known antibiotic 
resistance-associated genes and alleles. Based on the presence or absence of 
resistance alleles, bacterial isolates were predicted as resistant or sensitive, 
respectively. This approach has advanced more for other bacterial species than for P. 
aeruginosa. Currently, many tools to predict resistance from genome sequences are 
available, for examples RGI CARD, ARG-ANNOT and ResFinder etc (Su et al., 
2018). These antibiotic resistance prediction tools use databases of resistance-
associated genes and genetic variations from the curation of literature. One of the 
most sophisticated databases is the Comprehensive Antimicrobial Resistance 
Database (CARD) (Jia et al., 2017). However, none of these tools are designed 
specifically for P. aeruginosa.  
Whole genome sequencing has been used to predict resistance in different bacterial 
species, in particular, Mycobacterium tuberculosis, and Staphylococcus aureus, using 
a software Mykrobe predictor (Bradley et al., 2015) and E. coli using ResFinder 
(Moran et al., 2017, Su et al., 2018). In the case of P. aeruginosa, accuracies of 
antibiotic resistance predictions from genome sequences are less than in other 
bacterial species (Su et al., 2019). A lack of rapid advancement in antibiotic 
resistance predictions from genome sequences in the case of P. aeruginosa could be 
attributed to several issues. The genetic basis of antibiotic resistance in P. aeruginosa 
is not fully understood. Gene-gene interactions are not considered to predict 
resistance from genotypes (Su et al., 2019).  
A number of studies on P. aeruginosa have highlighted the complexities of genetics 
involved in ciprofloxacin resistance (Breidenstein et al., 2008, Bruchmann et al., 




aeruginosa for levofloxacin using genotypes (Kos et al., 2015). The presence of 
fluoroquinolone resistance-associated alleles in both fluoroquinolone-resistant and 
susceptible isolates highlighted that the genotype to phenotype correlations were 
complex (Kos et al., 2015). The analysis of P. aeruginosa PA14 mutants library 
showed that around 100-200 genes were associated with ciprofloxacin resistance 
(Breidenstein et al., 2008, Dötsch et al., 2009).  
To date, studies on the predictions of antibiotic resistance in clinical isolates of P. 
aeruginosa (Kos et al., 2015, Drouin et al., 2016, Khaledi et al., 2019) did not 
consider gene-gene interactions. The quantification of resistance conferred by gyrA 
T83I showed that gyrA T83I mutant had MIC of 2 mg/L (Bruchmann et al., 2013). 
However, clinical isolates containing gyrA mutations had a big range of MICs that 
was 1 – 256 μg/mL. Mutations in gyrA  (Kos et al., 2015, Jeukens et al., 2019, 
Khaledi et al., 2019) and parC (Kos et al., 2015, Khaledi et al., 2019) have been 
attributed to cause fluoroquinolone resistance, but the question remains whether only 
gyrA mutation and/or parC mutation give all the resistance up to 256 mg/L. These 
studies were not extended to determine causal mutations for high levels of resistance 
in clinical isolates of P. aeruginosa. Misattribution of  resistance to mutations has 
been a common limitation in previous studies on antibiotic resistance prediction from 
genotypes of P. aeruginosa isolates (Drouin et al., 2016, Piddock, 2016). 
Determining the contribution of mutations to resistance could address these issues. 
Quantification of resistance conferred by single and combinations of mutations will 
enhance the understanding of the genetic basis of antibiotic resistance and will give 
insight into gene-gene interactions in ciprofloxacin resistance.  
3.1.1 Quantification of resistance conferred by mutations 
Quantification of resistance conferred by mutations is very important to pinpoint the 
causal mutations of antibiotic resistance in clinical isolates of P. aeruginosa. It could 
advance the antibiotic resistance predictions based on genome sequences.  
One study partially addressed the question of how much ciprofloxacin resistance is 
conferred by individual and combinations of mutations by constructing isogenic 
mutants and determining MICs. Mutations were engineered into the genome of PA14 




encoding genes gyrA, gyrB and parC and the deletion of efflux regulator genes nfxB, 
mexR, mexS and mexZ on ciprofloxacin resistance were investigated. In addition, 
clinical isolates were analysed to find target site modifications in the Quinolone 
Resistance Determining Regions (QRDR), and the expression analysis of efflux 
pump-encoding genes was carried out.  It was found (Bruchmann et al., 2013) that 
target site mutations and the inactivation of efflux pump genes in engineered mutants 
lead to a synergistic increase in the resistance to ciprofloxacin. A combination of 
target site modifications in genes gyrA and parC enhanced resistance in engineered 
mutants. However, in clinical isolates, no correlation between MICs and a 
combination of QRDR mutations and a higher expression of efflux pump genes was 
found, which highlighted that additional mechanisms other than target site 
modification and an overexpression of efflux pump genes are probably involved in 
fluoroquinolone resistance (Bruchmann et al., 2013). It was shown that strain-
specific genetic background impacts the resistance level associated with mutations in 
clinical isolates. The contribution of mutated gyrA in fluoroquinolone resistance was 
investigated by replacing the mutated gyrA to the wild-type gyrA sequence in 
ciprofloxacin-resistant isolates of P. aeruginosa (Bruchmann et al., 2013). The 
replacement of a mutated to a wild type gyrA reduced the ciprofloxacin MIC in all 
isolates, but by different amounts in different isolates. The reduction in MICs was 
between 2 and 8-fold, regardless of the MIC values of the original/parent isolates 
containing a mutated gyrA. 
Another study used a combination of experimental evolution and the construction of 
single and double mutants using PA14, with the aim of exploring the fitness cost of 
ciprofloxacin resistance-associated mutations in genes gyrA, gyrB and nfxB (Melnyk 
et al., 2017). The fitness cost of an organism is the ability to grow and replicate in a 
competitive environment. The impact of different mutations on MIC and fitness were 
considered collectively for the understanding of the adaptation of P. aeruginosa to 
two different conditions that were a continuous and fluctuating antibiotic treatment. 
It was found that different mutations in target protein-encoding genes gyrA and gyrB, 
increased ciprofloxacin MIC by 4-8-fold, and 1-2-fold, respectively, relative to the 
MIC of PA14. Mutation in the efflux pump-regulatory gene nfxB increased resistance 




significantly high fitness cost in the absence of antibiotics, while gyrA and gyrB 
mutations showed no fitness cost. However, a study by Melnyk et al., 2017 was not 
extended to investigate whether the quantification of resistance assessed in 
engineered mutants was consistent with clinical isolates (Melnyk et al., 2017).  
3.1.2 The significance of epistasis or gene-gene interactions in the evolution of 
fluoroquinolones resistance  
Epistasis is the phenomenon in which mutations are dependent on each other to show 
a phenotype, for example antibiotic resistance. One mutation would confer or 
increase antibiotic resistance only if another gene was also mutated. Epistasis has a 
significant role in antibiotic resistance evolution (Wong, 2017). Epistasis controls the 
evolutionary mutational pathways of antibiotic resistance (Jochumsen et al., 2016). 
For example, under increasing concentrations of antibiotics, mutations or 
combinations of mutations which give higher advantages of resistance to be selected. 
Epistasis plays an important role in selecting which mutations, and in what order, 
accumulate to evolve bacteria from susceptible to resistant and then resistant to 
highly resistant (Wong, 2017).  
There are several examples of epistasis involved in antibiotic resistance. The 
influence of epistatic interactions between resistance mutations and strain-specific 
genetic backgrounds on antibiotic resistance evolution in P. aeruginosa are known 
(Bruchmann et al., 2013, Vogwill et al., 2016). Mutations on different genetic 
backgrounds could confer different levels of resistance, which indicates the presence 
of strain-specific resistance (Bruchmann et al., 2013). Epistatic interactions between 
different mutations associated with different antibiotics have also been shown in 
different bacterial species (Trindade et al., 2009, Ward et al., 2009, Borrell et al., 
2013, Jochumsen et al., 2016). In addition, epistatic interactions between plasmid 
and chromosomal mediated resistance have been reported (Wong, 2017). However, 
the involvement of epistatic interactions between ciprofloxacin resistance-associated 
mutations in P. aeruginosa remains a question.  
In the previous chapter (Chapter 2), experimentally evolved mutants with maximum 
resistance were analysed and ciprofloxacin resistance associated mutations were 




mutations remained unknown. Therefore, in this chapter, resistance conferred by 
mutations found in the previous chapter (Wardell et al., 2019) was quantified when 
present individually and in different combinations. 
3.1.3 Aims of this chapter 
The overall aim of this chapter was to quantify the resistance conferred by mutations 
and use these data to predict ciprofloxacin resistance of clinical isolates of P. 
aeruginosa from genome analysis. The specific aims were  
• To monitor resistance conferred by the accumulation of mutations during 
experimental evolution.  
• To investigate the effects of individual and different combinations of 
mutations on ciprofloxacin resistance by engineering mutations into the 
genome of PAO1 and determining the MICs.  
• To predict the ciprofloxacin resistance in the clinical isolates of P. 
aeruginosa from genomes, using the MICs data of experimentally evolved 





Materials and Methods 
3.2 Materials  
3.2.1 Bacterial strains  
Table 3.1: E. coli strain used in this study  
Strain Reference 
JM83 Yanisch-Perron et al. (1985) 
ST18 (Thoma & Schobert, 2009) 
 
Table 3.2: P. aeruginosa strains used and constructed in this chapter 
P. aeruginosa strain used in this chapter 
Strain/mutants name Description/contains References 
PAO1 Laboratory reference strain (Wardell et al., 2019) 
P. aeruginosa mutants constructed in this study 
gyrAT83I 
Mutation C to T in genome of PAO1 at 3558951, replaced 
amino acid T to I in GyrA (PA3168) at codon position 83 
gyrAD87G 
Mutation A to G in genome of PAO1 at 3558939, replaced 
amino acid D to G in GyrA (PA3168) at codon position 87 
gyrAD87N 
Mutation G to A in genome of PAO1 at 3558939, replaced 
amino acid D to N in GyrA (PA3168) at codon position 87 
nfxBT39P 
Mutation A to C in genome of PAO1 at 5155675, replaced 
amino acid T to P in NfxB (PA4600) at codon position 39 
PA3491H87P 
Mutation A to C in genome of PAO1 at 3908671, replaced 
amino acid H to P in PA3491 at codon position 87 
parCS87L 
Mutation C to T in genome of PAO1 at 5574227, replaced 




Strain/mutants name Description/contains References 
parEV460G 
Mutation T to G in genome of PAO1 at 5576539, replaced 
amino acid V to G in ParE (PA4967) at codon position 460 
pilTΔ12bp 
Deletion of 12 bp in genome of PAO1 at 437131-437142, in 
PilT (PA0395)  
pilFΔ17bp 
Deletion of 17 bp in genome of PAO1 at 4265167 to 4265184, 
in pilF (PA3805)  
PA3491 H87P + nfxBT39P + parCS87L 
Mutations in genome of PAO1 replaced amino acids H to P in 
PA3491 at 87, T to P in NfxB at 39 and S to L in ParC at 87 
PA3491 H87P + nfxBT39P + 
parEV460G 
Mutations in genome of PAO1 replaced amino acids H to P in 
PA3491 at 87, T to P in NfxB at 39 and V to G in ParE at 460 
Knock in WT gyrA in CK4ƚ 
Mutations in genome of PAO1 replaced amino acids H to P in 
PA3491 at 87, T to P in NfxB at 39 and S to L in ParC at 87 
Knock in WT gyrA in CH5ƚ 
Mutations in genome of PAO1 replaced amino acids H to P in 
PA3491 at 87, T to P in NfxB at 39 and S to L in ParC at 87 
gyrAT83I + parCS87L 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and S to L in ParC at 87 
gyrAT83I + parEV460G 
Mutations in genome of PAO1 replaced amino acids T to I in 
GyrA at 83 and V to G in ParE at 460 
gyrAT83I + PA3491 H87P 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and H to P in PA3491 at 87 
gyrAT83I + nfxBT39P 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 
gyrAT83I + nfxBT39P + PA3491 H87P 
X2 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 and H to P in PA3491 at 




Strain/mutants name Description/contains References 
gyrAT83I + parCS87L+ PA3491 H87P 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA, S to L in ParC at 87 and H to P in PA3491 at 87 
gyrAT83I + nfxBT39P + parCS87L 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 and S to L in ParC at 87 
gyrAT83I + nfxBT39P + parEV460G 
Mutations in genome of PAO1 replaced amino acids T to I in 
GyrA at 83, T to P in NfxB at 39 and V to G in ParE at 460 
Knock in WT PA3491 in CK3 X2 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 
Knock in WT PA3491  
in gyrAT83I + nfxBT39P + 
PA3491H87P X2 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 
gyrAT83I + nfxBT39P + PA3491 H87P 
+ parCS87L X2 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 and H to P in PA3491 at 
87 and S to L in ParC at 87 
gyrAT83I + nfxBT39P + PA3491 H87P 
+parEV460G 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 and H to P in PA3491 at 
87 and V to G in ParE at 460 
gyrAT83I + nfxBT39P + PA3491 H87P 
+ parCS87L + pilT12bp 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 and H to P in PA3491 at 
87, S to L in ParC at 87 and deletion of 12 bp in PilT 
gyrAT83I + nfxBT39P + PA3491 H87P 
+ parCS87L + pilF17bp 
Mutations in genome of PAO1 replaced amino acids T to I at 
83 in GyrA and T to P in NfxB at 39 and H to P in PA3491 at 
87, S to L in ParC at 87 and deletion of 17 bp in PilF 
ƚ CK4 and CH5 are experimentally evolved mutants containing mutations in gyrA T83I, nfxB 
T39P, PA3491 H87P and parC S87L 




Table 3.3: Clinical isolates of P. aeruginosa used in this chapter. 
 Isolates IDs *BioProject Host Country 
1.  37 PRJNA325248 Human Canada 
2.  38 PRJNA325248 Human Canada 
3.  65 PRJNA325248 Human Canada 
4.  66 PRJNA325248 Human Canada 
5.  88 PRJNA325248 Human Denmark 
6.  89 PRJNA294726 Human Belgium 
7.  90 PRJNA325248 Human USA 
8.  111 PRJNA325248 Human Canada 
9.  112 PRJNA325248 Human Canada 
10.  113 PRJNA325248 Human Canada 
11.  114 PRJNA325248 Human Canada 
12.  115 PRJNA325248 Human Canada 
13.  116 PRJNA325248 Human Canada 
14.  117 PRJNA325248 Human Canada 
15.  118 PRJNA325248 Human Canada 
16.  119 PRJNA325248 Human Canada 
17.  120 PRJNA325248 Human Canada 
18.  121 PRJNA325248 Human Canada 
19.  122 PRJNA325248 Human Canada 
20.  123 PRJNA325248 Human Canada 
21.  124 PRJNA325248 Human Canada 
22.  125 PRJNA325248 Human Canada 
23.  126 PRJNA325248 Human Canada 
24.  127 PRJNA325248 Human Canada 
25.  128 PRJNA325248 Human Canada 
26.  129 PRJNA325248 Human Canada 
27.  130 PRJNA325248 Human Canada 
28.  131 PRJNA325248 Human Canada 
29.  132 PRJNA325248 Human Canada 
30.  133 PRJNA325248 Human Canada 
31.  134 PRJNA325248 Human Canada 
32.  135 PRJNA325248 Human Canada 
33.  139 PRJNA325248 Human Canada 
34.  140 PRJNA325248 Human Canada 
35.  141 PRJNA325248 Human Canada 
36.  142 PRJNA325248 Human Canada 
37.  143 PRJNA325248 Human Canada 
38.  144 PRJNA325248 Human Canada 
39.  145 PRJNA325248 Human Canada 
40.  146 PRJNA325248 Human Canada 
41.  147 PRJNA325248 Human Canada 
42.  148 PRJNA325248 Human Canada 
43.  149 PRJNA325248 Human Canada 
44.  150 PRJNA325248 Human Canada 
45.  151 PRJNA325248 Human Canada 
46.  152 PRJNA325248 Human Canada 
47.  153 PRJNA325248 Human Canada 
48.  154 PRJNA325248 Human Canada 
49.  155 PRJNA325248 Human Canada 
50.  156 PRJNA325248 Human Canada 
51.  157 PRJNA325248 Human Canada 




 Isolates IDs *BioProject Host Country 
53.  159 PRJNA325248 Human Canada 
54.  161 PRJNA325248 Human Canada 
55.  162 PRJNA325248 Human Canada 
56.  163 PRJNA325248 Human Canada 
57.  164 PRJNA325248 Human Canada 
58.  166 PRJNA325248 Human Canada 
59.  167 PRJNA325248 Human Canada 
60.  168 PRJNA325248 Human Canada 
61.  169 PRJNA325248 Human Canada 
62.  170 PRJNA325248 Human Canada 
63.  171 PRJNA325248 Human Canada 
64.  172 PRJNA325248 Human Canada 
65.  173 PRJNA325248 Human Canada 
66.  174 PRJNA325248 Human Canada 
67.  175 PRJNA325248 Human Canada 
68.  176 PRJNA325248 Human Canada 
69.  177 PRJNA325248 Human Canada 
70.  178 PRJNA325248 Human Canada 
71.  179 PRJNA325248 Human Canada 
72.  180 PRJNA325248 Human Canada 
73.  181 PRJNA325248 Human Canada 
74.  182 PRJNA325248 Human Canada 
75.  183 PRJNA325248 Human Canada 
76.  184 PRJNA325248 Human Canada 
77.  185 - Human Canada 
78.  186 - Human Canada 
79.  369 PRJNA325248 Environmental Australia 
80.  532 PRJNA325248 Human Australia 
81.  534 PRJNA325248 Human Australia 
82.  664 PRJNA325248 Hospital Environment Columbia 
83.  669 PRJNA325248 Human Panama 
84.  677 PRJNA325248 Human Bulgaria 
85.  688 PRJNA325248 Human France 
86.  689 PRJNA325248 Human France 
87.  690 PRJNA325248 Human France 
88.  691 PRJNA325248 Human France 
89.  692 PRJNA325248 Human France 
90.  693 PRJNA325248 Human France 
91.  694 PRJNA325248 Human France 
92.  695 PRJNA325248 Human France 
93.  696 PRJNA325248 Animal France 
94.  698 PRJNA325248 Environmental Mexico 
95.  699 PRJNA325248 Environmental Belgium 
96.  700 PRJNA325248 Clinical isolate Canada 
97.  703 PRJNA325248 Plant  United Kingdom 
98.  705 PRJNA325248 Human Georgian Republic 
99.  706 PRJNA325248 Human Georgian Republic 
100. 710 PRJNA325248 Human Belgium 
101. 713 PRJNA325248 Human Belgium 
102. 714 PRJNA294726 Human Belgium 
103. 715 PRJNA325248 Human Canada 
104. 718 PRJNA325248 Human Colombia 
105. 720 PRJNA325248 Animal India 




 Isolates IDs *BioProject Host Country 
107. 725 PRJNA325248 Animal United Kingdom 
108. 727 PRJNA325248 Human USA 
109. 728 PRJNA325248 Human United Kingdom 
110. 729 PRJNA325248 Human United Kingdom 
111. 730 PRJNA325248 Human United Kingdom 
112. 731 PRJNA325248 Human United Kingdom 
113. 733 PRJNA325248 Human USA 
114. 734 PRJNA325248 Human United Kingdom 
115. 736 PRJNA325248 Human United Kingdom 
116. 737 PRJNA325248 Human United Kingdom 
117. 738 PRJNA325248 Human United Kingdom 
118. 740 PRJNA325248 Environmental Tunisia 
119. 742 PRJNA325248 Animal USA 
120. 744 PRJNA325248 Animal USA 
121. 747 PRJNA325248 Environmental Japan 
122. 748 PRJNA325248 Environmental Japan 
123. 749 PRJNA325248 Environmental Japan 
124. 750 PRJNA325248 Environmental Japan 
125. 751 PRJNA325248 Environmental Japan 
126. 752 PRJNA325248 Environmental Japan 
127. 754 PRJNA325248 Environmental Japan 
128. 755 PRJNA325248 Environmental Japan 
129. 756 PRJNA325248 Animal Japan 
130. 757 PRJNA325248 Environmental Japan 
131. 758 PRJNA325248 Environmental Japan 
132. 759 PRJNA325248 Environmental Japan 
133. 760 PRJNA325248 Environmental Japan 
134. 761 PRJNA325248 Environmental Japan 
135. 762 PRJNA325248 Environmental Japan 
136. 769 - Animal Purtugal  
137. 775 PRJNA325248 Animal Purtugal  
138. 776 PRJNA325248 Animal Purtugal  
139. 780 PRJNA325248 Animal Purtugal  
140. 782 PRJNA325248 Animal Purtugal  
141. 785 PRJNA325248 Animal Purtugal  
142. 786 PRJNA325248 Animal Purtugal  
143. 789 PRJNA325248 Animal Purtugal  
144. 790 PRJNA325248 Animal Purtugal  
145. 792 - Animal Purtugal  
146. 796 PRJNA325248 Animal Purtugal  
147. 797 PRJNA325248 Animal Purtugal  
148. 810 PRJNA294726 Human United Kingdom 
149. 811 PRJNA294726 Human United Kingdom 
150. 824 PRJNA325248 Environmental Belgium 
151. 825 PRJNA325248 Environmental Belgium 
152. 826 PRJNA325248 Environmental Belgium 
153. 828 PRJNA325248 Environmental Belgium 
154. 830 PRJNA325248 Environmental Belgium 
155. 831 PRJNA325248 Environmental Belgium 
156. 838 PRJNA325248 Human Belgium 
157. 852 PRJNA294726 Human United Kingdom 
158. 856 PRJNA325248 Human USA 
159. 858 PRJNA325248 Human Germany 




 Isolates IDs *BioProject Host Country 
161. 867 PRJNA325248 Human USA 
162. 871 PRJNA294726 Human Belgium 
163. 875 PRJNA325248 Environmental Benin 
164. 877 PRJNA325248 Environmental Puerto Rico 
165. 878 PRJNA325248 Environmental Puerto Rico 
166. 879 PRJNA325248 Human Congo 
167. 880 PRJNA325248 Human Philippines 
168. 881 PRJNA325248 Environmental Germany 
169. 884 PRJNA325248 Human Tunisia 
170. 885 PRJNA325248 Human Tunisia 
171. 934 PRJNA325248 Human Australia 
172. 946 PRJNA325248 Human Australia 
173. 948 PRJNA325248 Human Australia 
174. 954 PRJNA325248 Human Australia 
175. 976 PRJNA325248 Human Australia 
176. 977 PRJNA325248 Human Australia 
177. 1053 PRJNA325248 Human United Kingdom 
178. 1074 PRJNA325248 Human United Kingdom 
179. 1108 PRJNA325248 Human Thailand 
180. 1112 PRJNA325248 Human Thailand 
181. 1124 PRJNA325248 Human Thailand 
182. 1130 PRJNA325248 Human Thailand 
183. 1133 PRJNA325248 Human Thailand 
184. 1152 PRJNA325248 Human Thailand 
185. 1180 PRJNA325248 Human USA 
186. 1182 PRJNA325248 Human USA 
187. 1184 PRJNA325248 Human USA 
188. 1241 PRJNA325248 Human Brazil 
189. 1242 PRJNA325248 Human Brazil 
190. 1243 PRJNA325248 Human Brazil 
191. 1244 PRJNA325248 Human Brazil 
192. 1245 PRJNA325248 Human Brazil 
193. 1269 PRJNA325248 Human France 
194. 1296 PRJNA325248 Human United Kingdom 
195. 1506 PRJNA325248 Human Canada 
196. 1530 PRJNA326244 Human Italy 
197. 1532 PRJNA326244 Human Italy 
198. 1533 PRJNA326244 Human Italy 
199. 1534 PRJNA326244 Human Italy 
200. 1535 PRJNA326244 Human Italy 
201. 1536 PRJNA326244 Human Italy 
202. 1537 PRJNA326244 Human Italy 
203. 1538 PRJNA326244 Human Italy 
204. 1539 PRJNA326244 Human Italy 
205. 1540 PRJNA326244 Human Italy 
206. 1541 PRJNA326244 Human Italy 
207. 1542 PRJNA326244 Human Italy 
208. 1543 PRJNA326244 Human Italy 
209. 1544 PRJNA326244 Human Italy 
210. 1545 PRJNA326244 Human Italy 
211. 1546 PRJNA326244 Human Italy 
212. 1547 PRJNA326244 Human Italy 
213. 1548 PRJNA326244 Human Italy 




 Isolates IDs *BioProject Host Country 
215. 1550 PRJNA326244 Human Italy 
216. 1551 PRJNA326244 Human Italy 
217. 1553 PRJNA326244 Human Italy 
218. 1554 PRJNA326244 Human Italy 
219. 1555 PRJNA326244 Human Italy 
220. 1557 PRJNA326244 Human Italy 
221. 1558 PRJNA326244 Human Italy 
222. 1559 PRJNA326244 Human Italy 
223. 1560 PRJNA326244 Human Italy 
224. 1561 PRJNA326244 Human Italy 
225. 1562 PRJNA326244 Human Italy 
226. 1563 PRJNA326244 Human Italy 
227. 1564 PRJNA326244 Human Italy 
228. 1565 PRJNA326244 Human Italy 
229. 1576 PRJNA325248 Human - 
230. 1577 PRJNA325248 Human - 
231. 1578 PRJNA325248 Human - 
232. 1579 PRJNA325248 Human - 
233. 1580 PRJNA325248 Human - 
234. 1581 PRJNA325248 Human - 
235. 1582 PRJNA325248 Human - 
236. 1590 - Human Canada 
237. 1594 - Human Canada 
238. 1603 - Human Canada 
 
*Isolates in Bioproject PRJNA325248 are from Freschi et al. (2019), Freschi et al. (2018), 
Jeukens et al. (2019), Project PRJNA294726 are from Thrane et al. (2015) and Project 















Table 3.4: List of plasmids used and constructed in this study 
Plasmid  Description Reference  
pEX18Tc Suicidal vector with 
tetracycline resistance, oriT 
and sacB gene 
Hoang et al. (1998) 
Recombinant plasmids constructed in this study 
pEX18Tc::gyrAT83I pEX18Tc containing DNA region of 1917 bp from gyrA 
gene having point mutation that replaces amino acid T to 
I in GyrA at 83 
pEX18Tc::gyrAD87G pEX18Tc containing DNA region of 1917 bp from gyrA 
gene having point mutation that replaces amino acid D to 
G in GyrA at 87 
pEX18Tc::gyrAD87N pEX18Tc containing DNA region of 1917 bp from gyrA 
gene having point mutation that replaces amino acid D to 
N in GyrA at 87 
pEX18Tc::nfxBT39P pEX18Tc containing DNA region of 2328 bp from nfxB 
gene having point mutation that replaces amino acid T to 
P in NfxB 
pEX18Tc::PA3491H87P pEX18Tc containing DNA region of 1940 bp from 
PA3491 gene having point mutation that replaces amino 
acid H to P in PA3491 
pEX18Tc::parCS87L pEX18Tc containing DNA region of 1686 bp from parC 
gene having point mutation that replaces amino acid S to 




Plasmid  Description Reference  
pEX18Tc::parEV460G pEX18Tc containing DNA region of 4565 bp from parE 
gene having point mutation that replaces amino acid V to 
G in ParE 
pEX18Tc::pilTΔ12bp pEX18Tc containing DNA region of 1899 bp from pilT 
gene having deletion of 12 bp in PilT 
pEX18Tc::pilFΔ17bp pEX18Tc containing DNA region of 1755 bp from pilF 
gene having deletion of 17 bp in PilF 
pEX18Tc::WT PA3491 pEX18Tc containing DNA region of 1755 bp from 
PA3491 gene 


















3.2.3 Primers  
Table 3.5: Primers used for mutant construction and their properties.  
 Restriction sites in the primer sequences are shown in bold text.  
 
 *Genome coordinates for expected amplified DNA region based on reference PAO1 









































































































GTA AAA CGA CGG CCA GT 
CAG GAA ACA GCT ATG AC 







Table 3.6: Primers used for amplification of mutation-containing DNA region of 
different genes.  
 

























































































To prepare 100 mL of GYT, 10 mL of glycerol, 0.125 g of yeast extract and 0.25 g 
of tryptone (casein hydrolysate) were mixed and dissolved in double distilled water 
(Tung & Chow, 1995). GYT media were divided into 10 mL aliquots and were 
autoclaved before use.  
Luria Bertani (LB)  
To make 1 L of liquid LB, 10 g of casein hydrolysate, 5g of yeast extract and 10 g of 
sodium chloride were dissolved in ddH2O (Sambrook et al., 2001). For solid 
medium, 15 g of agar were added. Media were autoclaved before use.  
Mueller-Hinton (MH) 
To prepare MH agar, 38 g DifcoTM Mueller-Hinton agar powder were mixed in 1 L 
of ddH2O and then the media were autoclaved. 
3.2.5 Antibiotics 
Tetracycline 
A stock concentration 12.5 mg/ mL of tetracycline (Sigma) was prepared in ethanol. 
For E. coli and P. aeruginosa, 12.5 μg/mL and 24 μg/mL were used. 
Ciprofloxacin 
Infusion Cipflox bags containing 2 mg/mL ciprofloxacin were purchased from 
Mylan New Zealand Ltd. 
3.2.6 Chemicals 
PCR water 
RNase/DNase-free water (InvitrogenTM ultrapureTM distilled water) was used in 







1 mL of 1 M of Tris (pH 8) and 0.5 M of EDTA (pH 8) were mixed and the final 
volume was made up to 100 mL by adding milli-Q water. 
80% glycerol 
In 80 mL of glycerol, milli-Q water was added to make 100 mL of 80% glycerol and 
it was autoclaved.  
BCIG (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside) 
A stock concentration of BCIG (Sigma) 30 mg/mL was prepared in dimethyl 
formamide. It was used in a concentration of 120 μg/mL per LB agar plate.  
IPTG (Isopropyl β-D-thiogalactopyranoside) 
IPTG (Sigma) was prepared in ddH2O in a concentration of 24 mg/mL, and 24 
μg/mL was used in the LB agar plate.  
Aminolaevulinic acid (ALA) 
ALA (Cayman Chemicals) powder was dissolved in ddH2O at a concentration of 50 
mg/mL and stored at -20°C. After thawing, a final concentration of 50 μg/mL was 
used and stored at 4°C once thawed.  
50% Sucrose 
To prepare 50% sucrose solution, 150 g of sucrose powder was dissolved in ddH2O 
and then a final volume of the solution was made up to 300 mL by adding water. It 
was aliquoted in volumes of 25 mL and autoclaved before use. Two and a half mL of 
50% sucrose (5%) were used per LB agar plate.  
5X Sodium Borate (SB) buffer 
To prepare 5X SB buffer, sodium hydroxide (10 mM) and boric acid were dissolved 
in 1L ddH2O. A working concentration of 1X was prepared and 0.25 μg/mL ethidium 





0.85% Agarose gel  
Agarose powder (2.55 g) was added in 300mL of 1X SBE buffer to prepare 0.85% 
agarose gel and microwaved to dissolve and melt the agarose powder properly to get 
a clear solution. 
6X loading dye  
A mixture of 30% glycerol, 0.25% bromophenol blue and 0.25% xylene cyanol was 
prepared and stored at -20°C.  
Phosphate buffer saline (PBS) 
To prepare 1L of PBS (pH 7.4), 8.4 g of NaCl, 5.15 g of Na2HPO4 and 1.92 g of 
NaH2PO4 were dissolved in milli-Q water. 
 
Table 3.7: List of enzymes and compatible buffers used in this study 
Enzymes  Suppliers 
DNA polymerase Q5® high fidelity 2X 
master mix  
New England BioLabs 
Restriction enzymes (BamH1-HF, Pst1-
HF and XbaI-HF) 
CutSmart® Buffer (10X) 
New England BioLabs 
Alkaline phosphatase rSAP (M0371) 
CutSmart® Buffer (10X) 
 New England BioLabs 
T4 DNA ligase 
10X T4 DNA ligase Buffer 










Table 3.8: List of kits used in this study. 
 
3.3 Methods 
3.3.1 Analysis of experimentally-evolved ciprofloxacin resistant P. aeruginosa 
The MICs were determined for mutants using the protocol given in Section 2.4.2. 
Genomic DNA was extracted from experimentally-evolved intermediate mutants and 
were sent for genome sequencing, as described in Section 2.4.4. Genome sequences 
were analysed to find mutations as per details given in Section 2.4.5.  
3.3.1.1 Validation of mutations 
To confirm the presence of mutations, PCR was carried out using gene specific 
primers (Table 3.6), and PCR products were sent for sequencing to Otago Genetic 
Analysis Services (Dunedin, New Zealand). PCR was carried out following the 
protocol given in Table 3.9, and PCR conditions are given in Table 3.10.  
The sequencing reaction of the total volume 5 μL was prepared using 3.2 pmol of 
primer and 1 ng/100 bp of PCR product. PCR water was added to make up final 
volume to 5 μL. PCR Sequencing reaction premix for forward and reverse primers 
were prepared in two separate tubes. PCR sequences were aligned to reference 




Kits  Supplier  
Genomic DNA extraction microbial kit 
UltraClean® 
Qiagen, Germany 
NucleoSpin® Plasmid kit Macherey-Nagel, Germany 
QIAquick® gel extraction kit Qiagen, Germany 




3.3.2 Construction of isogenic mutants 
DNA cloning and the two-step allelic exchange method (Hmelo et al., 2015) were 
used to construct the mutants. A stepwise procedure of the mutant construction is 
shown in the flow chart (Figure 3.1).  
Bioinformatics tools used 
Primer 3 (v 0.4.0) was used to design primers. Multiple options of primers were 
provided from Primer 3, which were then further analysed on the Oligo IDT analyser 
(www.idtdna.com) to pick the suitable primers. 
CLC main workbench 7 (CLC bio, Aarhus, QIAGEN bioinformatics, 
www.clcbio.com) was used to visualise the PCR and plasmid sequences and for 
general DNA analysis. 
RStudio 
Multiple packages of Rstudio were used to draw the dot plots.  
The GrowthCurver version 0.2.1 (Sprouffske & Wagner, 2016) package was used to 
assess the growth of bacteria. The output of the GrowthCurver gives multiple 
metrics, including the maximum growth rate, the doubling time, the carrying 














Figure 3.1: Flowchart representing steps of isogenic mutant construction. See 
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3.3.2.1 Primer Designing and primer stock preparation 
Primers were designed to amplify ~2000 bp DNA fragment with the desired 
mutation approximately in the centre of the DNA fragment, using Primer 3 software 
(Rozen & Skaletsky, 2000). The primers designed for DNA restriction cloning are 
shown in Table 3.5. Primers were designed to amplify a region around 1000 bp on 
each side of the mutation for the high efficiency of recombination either side of the 
mutation. The different parameters of the primers included melting temperature 
(Tm), % GC content, hairpin stability and, delta G for homo- and heterodimers, 
which were analysed using the OligoAnalyzer tool (Owczarzy et al., 2008) from the 
IDT (www.idtdna.com). The length of the primers was kept between 18 to 22 bp, 
then restriction sites and 5Gs or Cs were added to the primer sequences. The 
following criteria were used to design primers: 
The difference of melting temperatures between forward and reverse primers was not 
more than 5°C. The percentage of GC content was between 50 to 65%. ΔG values for 
hairpin formation, homodimers, and heterodimers were more positive than -
9kcal/mol. A BLAST search (nucleotide BLAST) was carried out for primers against 
the PAO1 complete genome sequence from NCBI database to make sure that primers 
did not anneal non-specifically to another genomic region or if they did partially, the 
coverage was lower than 70%. Then, CLC main workbench 7 (CLC bio, Aarhus, 
QIAGEN bioinformatics, www.clcbio.com) was used to identify restriction sites 
within the DNA fragment. Restriction enzyme sites for DNA cloning were chosen, 
based on the absence of a restriction site within the fragment, and restriction sites 
were added at the 5’ end of the primers.  
Primers were purchased from Macrogen (Korea) and 100 μM stock was prepared in 
the TE buffer (Section 3.2.6) and stored at -20 °C. The working dilution of primers 
(10 μM) was prepared in PCR grade water.  
3.3.2.2 Polymerase chain reaction (PCR) 
Genomic DNA extracted (Section 2.4.4) from experimentally evolved mutants 




carried out by following the protocol given in Table 3.9 and 3.10, using Q5® high 
fidelity 2X master mix (New England BioLabs).  
For colony PCR, a boiled bacterial colony was prepared by taking a colony in a 
microcentrifuge tube containing 100 μL of double distilled water. The tube was 
incubated at 99°C for 7 minutes. 1 μL of boiled bacterial colony was used in a PCR 
reaction mixture. PCR products were run on 0.85% agarose gel to determine the size 
of the amplified DNA. 
3.3.2.3 Agarose gel electrophoresis 
Gel electrophoresis was carried out to visualise the DNA using 0.85% agarose gel 
(Section 3.2.6) in 1X sodium borate buffer (Section 3.2.6). To determine the size of 
the PCR product, 1KB Plus DNA Ladder (Invitrogen) was used. For the loading of 
the samples on the gel, PCR products were mixed with a loading dye in 6:1 ratio 
(Section 3.2.6) before loading. Gel electrophoresis was done at 180 V for 15 minutes 
in the Gel electrophoresis apparatus (Life Technologies Inc). The gel was visualised 
in UV Gel Doc XR + (Bio Rad).  
3.3.2.4 Extraction of DNA from Gel 
Amplified products of around 2000 bp were run on a 0.85% agarose gel and 
extracted from the gel using the QIAquick® gel extraction kit, (Qiagen, Germany), 
following the kit manufacturer’s instructions. One microlitre of extracted DNAs was 
run on 0.85% agarose gel to assess the quality of the DNA. 
3.3.2.5 Measurement of concentration and quality of extracted DNA 
The concentration and quality of the extracted DNA was measured using a Nano 
Drop spectrophotometer (Thermo Scientific). For the quality measurement of DNA, 
a Nanodrop spectrophotometer provides the absorption ratios at 260/280 and 260/230 
wavelengths. Values of 260/280 as 1.8-2.0 and 260/230 as 2-2.2 are considered as 






Table 3.9: Concentrations of reaction components and volumes to perform 
polymerase chain reactions.   
 
PCR ingredients Volume used (μL) Concentration 
Q5® high fidelity DNA 
polymerase master mix (2X) 
12.5 1X 
Forward primer (10μM) 1.25 0.5 μM 
Reverse primer (10μM) 1.25 0.5 μM 
DNA template 
(gDNA/boiled colony) 
variable 50 ng/25 μL reaction 
PCR water Up to 25 μL  
Final volume 25 μL  
  
Table 3.10: Temperatures and PCR cycle conditions used for amplification of 
DNA fragments. 
PCR steps Temperature (°C) Duration 
Initial DNA denaturation 98 30 seconds 
30 cycles 
98 10 seconds 
64-69* 30 seconds 
72 30 seconds/Kb 
Final extension 72 2 minutes 
 
*The annealing temperature was optimised for each primer set by gradient PCR. For 






3.3.2.6 Preparation of plasmid DNA 
An overnight culture in LB media (Section 3.2.4) containing tetracycline (24 mg/L) 
was set up from a glycerol stock of bacteria containing plasmid pEX18Tc. Plasmid 
DNA was extracted from the overnight culture using NucleoSpin® Plasmid kit, 
Macherey-Nagel, Germany. The concentration and quality of the plasmid DNA was 
measured by a NanoDrop spectrophotometer (Section 3.3.2.5).  
3.3.2.7 Restriction digestion of plasmid and purified PCR product 
A purified PCR product and a plasmid DNA were digested with restriction enzymes 
given in Table 3.5. Restriction enzymes were purchased from New England BioLabs. 
Quantities and conditions used for restriction digestion reaction are given in Table 
3.11.  
 
Table 3.11: Double digestion reaction mixture: Concentrations of reaction contents 




























DNA Up to 1 μg 
PCR grade Water 
Make up volume of the reaction 




3.3.2.8 Dephosphorylation of 5’ end of digested vector DNA  
To avoid the ligation of the cut ends of the vector with themselves, vector DNA was 
treated with shrimp alkaline phosphatase rSAP (M0371) (New England BioLabs). 
The concentrations of the reaction components and the temperature conditions are 
given in Table 3.12. 
Table 3.12: Alkaline phosphatase treatment: The reaction mixture for alkaline 







Reaction mixture was incubated at 37 °C for 30 minutes and then, at 65 °C for 5 minutes. 
3.3.2.9 Ligation of DNA insert with cloning vector 
Ligation was carried out by following the procedure given in Table 3.13 using T4 
DNA ligase enzyme, New England BioLabs. Ligation reactions were incubated 
overnight at 4 °C. Multiple controls given in Table 3.13 were included for the 
troubleshooting of ligation reaction experiments. 
3.3.2.10 Purification of DNA with butanol precipitation 
Ligation reaction mixtures were purified by butanol precipitation method to remove 
the salts from the ligation product. A ligation product (20 μL) was diluted with 30 μL 
of PCR grade water and 500 μl butanol was added to it. Precipitated DNA was 
collected down in the tube by centrifugation at 12000 rpm for 10min. After 
discarding the supernatant, the DNA pellet was dried at room temperature. The pellet 
was resuspended in 10 μL PCR water.  
 
Ingredients Volume used (μL) 
rSAP (1000 U/mL) 1 
CutSmart® buffer (10X) 2 
Cut plasmid Up to 1μg 




Table 3.13: Ligation reaction mixture: Concentrations of the buffer, DNA, and 





Ligation reaction Control reactions 
Vector: Insert 

















cut cloning vector 
pEX18Tc (6 kb) 












cut cloning vector 
pEX18Tc (6 kb) 
 
 












Up to 20 μL 
 
*to check if ligase is working. 
# to determine transformation efficiency 









3.3.2.11 Preparation of electro competent E. coli JM83 cells 
To prepare electrocompetent JM83 cells, the protocol reported by Seidman et al. 
(1997) was followed. A single colony of JM83 cells was used to set up a broth 
culture of 50 mL in LB media (Section 3.2.4) and was incubated at 37°C overnight in 
a shaking incubator. Then, 1 mL of JM83 cells broth culture was used to inoculate 
each of the 500 mL of LB media in 2 baffled flasks. The cultures were incubated at 
37°C in a shaking incubator till the OD600 of cultures reached 0.6. The cultures were 
put on ice for 30 minutes and centrifuged to collect down the cells at 5000 rpm for 15 
minutes at 4°C, in a Beckman J2-MC centrifuge. For centrifugation, 250 mL 
centrifuge bottles were used. Then, cells were resuspended in 500 mL of cold 10% 
glycerol and centrifuged at 5000 rpm for 15 minutes at 4°C. The steps of washing 
and centrifugation were repeated twice. The cells pellets were then resuspended in 5 
mL GYT media (Section 3.2.4). The resuspended cells pellets were aliquoted into 90 
μL volumes, and frozen in dry ice and an ethanol mixture. The frozen cells were then 
stored at -80°C.     
3.3.2.12 Electro transformation   
For electro transformation, 45 μL of electrocompetent cells were mixed with 5 μL of 
purified ligation product and the mixture was kept on ice. The electroporation 
cuvettes (Bio-Rad) of the 0.2 cm electrode gap were used. A 2.5 kV pulse was given 
using an electroporator (Gene Pulser, Bio-Rad). Immediately, 1mL of LB was added 
to the electroporated cells and transferred to microcentrifuge tubes; then, 
electroporated cells were incubated for 2 hours at 37°C in a shaking incubator. 
Mixtures were spread onto LB agar plates containing tetracycline (12.5 μg/mL) and 
provided with IPTG and BCIG (Section 3.2.6). Then, plates were incubated at 37°C 
for 18 hours. White colonies that were expected to contain cloned DNA were picked 
and streaked on tetracycline, containing LB agar plates provided with IPTG and 
BCIG. Blue colonies were also picked and analysed as negative controls. 
Broth cultures of white colonies were set up and incubated for 18 hours at 37 °C in a 
shaking incubator, and plasmid was extracted (3.3.2.6) and restriction digestion 
(3.3.2.7) was carried out to find if pEXTc18 has the desired DNA insert ligated in it 




(3.3.2.3) to find if the insert had been ligated into the plasmid. It was expected that 
the recombinant plasmid would show two DNA bands of desired size (one for the cut 
plasmid and one for the DNA insert) on the agarose gel, after restriction digestion. 
3.3.2.13 DNA sequencing of plasmid DNA 
Extracted plasmid DNAs were sent for sequencing (Sanger sequencing) to the Otago 
Genetic Analysis Services (Dunedin, New Zealand). Universal primers M13 and 
insert-specific primers (Table 3.5) were used to confirm the desired DNA insert was 
present containing only the intended mutation in it. A sequencing reaction of a total 
volume of 5 μL was prepared using 3.2 pmol of primer and 200 ng of plasmid. PCR 
water was added to make up the final volume to 5 μL.  
3.3.2.14 DNA sequence alignment 
Plasmid DNA sequences were aligned to reference the sequence of PAO1 using 
BLAST on NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
3.3.2.15 Preparation of electrocompetent ST18 E. coli cells 
The E. coli strain ST18 was used as donor cells for conjugation. A growth of ST18 is 
dependent on aminolaevulinic acid (ALA) (Thoma & Schobert, 2009). ST18 cells do 
not grow if ALA is not provided in LB media. 
Sucrose washing protocol (Choi et al., 2006) was used to prepare electrocompetent 
ST18 cells. For sucrose washing, a total of 6 mL of overnight grown culture of ST18 
in LB media supplemented with 50 μg/mL ALA (Section 3.2.6) was divided into 4 
microcentrifuge tubes. Cultures were centrifuged at 9000 rpm for 2 minutes and the 
supernatant was discarded. Cell pellets were resuspended in 1 mL of 300 mM 
sucrose, and centrifuged at 9000 rpm for 2 minutes, and the supernatant was 
discarded. This step of centrifugation and resuspension of the cell pellet in sucrose 
was repeated, and cell pellets in four tubes were resuspended in a total of 100 μL of 
300 mM sucrose.  
3.3.2.16 Electro transformation of donor cells with recombinant plasmid 
A mixture of 70 μL of electrocompetent ST18 cells and 400 ng of recombinant 




electric pulse of 2.5 kV was passed through the mixture using an electroporator (Bio-
Rad Gene Pulser) and 1 mL of LB was added immediately. Cells were transferred to 
a microcentrifuge tube and were incubated in a shaking incubator at 37 °C for 2 
hours. A total of 100 μL of transformed cells were spread on the LB agar plate with 
tetracycline (24 μg/mL) and ALA (50 μg/mL).  
3.3.2.17 Conjugation 
Conjugation was carried out to transfer plasmid DNA from E. coli strain ST18 cells 
to P. aeruginosa PAO1 cells using the protocol described by Thoma &  Schobert 
(2009). The broth culture of ST18 transformed with recombinant plasmid was set up 
in LB supplemented with ALA (50 μg/mL) and tetracycline (24 μg/mL) and 
incubated overnight at 37°C in a shaking incubator. The broth culture of P. 
aeruginosa PAO1 in LB supplemented with 0.4% KNO3 was set up and incubated at 
42 °C in a standing (not shaking) water bath. The dilution of overnight cultures of 
donor cells (transformed ST18) and recipient cells (PAO1) were prepared to OD600 
of 0.5. A mL of P. aeruginosa, and 3 mL of transformed ST18 were mixed and 
centrifuged. Cell pellets were resuspended in 100 μL LB media. LB agar plates with 
and without ALA (as a negative control) were prepared and inoculated with a 50 μL 
spot of suspended cell pellet of mixed cultures (donor plus recipient cells). After 
drying the spot, plates were incubated at 37°C overnight. The next day, cells were 
scraped from plates into 3 mL PBS (Section 3.2.6). 100 μL of mixed bacterial 
cultures were spread on LB agar plates with two different concentrations of 
tetracycline (Section 3.2.5) (24 and 48 μg/mL), and ALA was not provided to select 
the P. aeruginosa transconjugants and not E. coli. Plates were incubated overnight at 
37°C. Only ST18 and only PAO1 were also spread on tetracycline containing plates 
as a control to determine the background number of colonies.   
3.3.2.18 Screening for merodiploids 
Tetracycline resistant colonies were observed on LB agar plates containing 24 and 48 
μg/mL of tetracycline. Colonies were picked from a plate containing 48 μg/mL 
tetracycline and were streaked out on LB agar plates with and without tetracycline. 
To confirm that plasmid was present, colony PCR (Tables 3.9 and 3.10) was carried 




products were run on agarose gel (Section 3.3.2.3). The DNA band of 500 bp on 
agarose gel was an indication of merodiploids. After the confirmation of 
merodiploids, the LB broth culture of merodiploids was set up in the LB broth with 
24 μg/mL tetracycline and incubated at 37°C in a shaking incubator.  
3.3.2.19 Sucrose selection 
Overnight cultures of merodiploids were grown till the OD600 reached 1.5-2. Then, 
dilutions of 10-2 and 10-4 of merodiploids cultures were prepared, and 100 μl of each 
dilution was spread on LB agar plates with and without 5% sucrose (Section 3.2.6). 
Plates were incubated at room temperature. Incubation was continued till colonies 
appeared.  
Sucrose resistant colonies were streaked out on LB agar plates with and without 
tetracycline (24 μg/mL) and were incubated at room temperature overnight to 
confirm the loss of plasmid. Colonies that were susceptible to tetracycline were 
selected and for further validation, colony PCR was carried out with colE1primer. 
Colonies which did not give a colE1 PCR product were screened for introduced 
mutations.  
3.3.2.20 Identification and confirmation of engineered mutants 
Theoretically, after a second recombination, it was expected that there was a 50% 
chance of getting a mutant allele engineered into a genome of a recipient cell. The 
rest of the colonies would have a wild-type allele. To screen mutants, a total of 8 
sucrose resistant colonies (which were tetracycline susceptible) were picked and 
PCR was carried out using primers to amplify the mutation-containing DNA region 
(Table 3.6). The PCR protocol given in Tables 3.9 and 3.10 was followed. PCR 
products were enzymatically cleaned up using ExoSAP-ITTM (ThermoFisher 
Scientific). The total volume of reaction mixtures of 7 μL was prepared with 2 μL of 
ExoSA-IT and 5 μL of the PCR product. Reaction mixtures were incubated at 37°C 
for 15 minutes and then at 80°C for 15 minutes. Cleaned-up PCR products were sent 
for sequencing to Otago Genetic Analysis Services (Dunedin, New Zealand). A 




carried out to find the mutants. On average, 5 out of 8 colonies had the desired 
mutation. 
To make sure that engineered mutants had only the intended mutations, whole 
genome sequencing of engineered mutants was carried out. Genomic DNA was 
extracted from an overnight grown culture of mutants (Section 2.4.4) and sent for 
WGS to New Zealand Genomics Limited. BREseq was used to analyse the genome 
sequences. For details, see Sections 2.4.4 and 2.4.5. 
3.3.3 Analysis of genome sequences from clinical isolates to predict ciprofloxacin 
resistance 
Bioinformatics analysis on genomes of clinical and environmental isolates was 
carried out at Laval University on the Institute of Integrative and Biology System 
(IBIS) manitou server, Canada. The command line interface Git Bash was used to 
run the scripts. Scripts were written by Jean-Guillaume Emond Rheault in IBIS, 
Laval University Canada.  
3.3.3.1 Prokka (Seemann, 2014)  
Genomes were annotated using prokka (v1.10). Prokka is a command line tool to 
annotate fasta files of genome sequences and it finds coding sequences. Whole 
genome sequence annotation is a process of highlighting important features of 
sequences, for example the function of genes, and gene locus by using different 
databases. Prokka (v1.10) was run using the following command: 
prokka --setupdb 
ls | grep fasta$ | sed 's/\.fasta//' | while read file; do prokka --outdir $file --prefix $file --
locustag $file $file.fasta; done; 
 
Prokka generated multiple format files. Files with .faa and .ffn format were taken and 
concatenated by running the following script. Files with .faa are protein FASTA files 
of the translated CDS sequences and .ffn are nucleotide FASTA files of predicted 
transcripts. 





ls | grep fasta$ | sed 's/\.fasta//' | while read isolate; do cat $isolate/$isolate.ffn; done > 
all_gene.ffn 
3.3.3.2 Protein BLAST 
Sequence databases were prepared using the following command to execute the 
BLAST of reference sequence against the database of 237 Prokka-annotated 
sequences. BLAST v 2.6.0 was used to align sequences to the reference sequence.  
makeblastdb -in all_ipcd.faa -dbtype prot -parse_seqids -out ipcd_db.faa 
For the protein BLAST, a reference amino acid sequence of proteins GyrA, ParC, 
ParE and NfxB was downloaded from NCBI in fasta format. A following command 
was used to do a BLAST search. A BLAST search for GyrA is shown as an example. 
BLAST tabular output format 6 was produced. Output format was specified in the 
command line as std std qlen slen qcovs. The qlen is the query and the standard 
sequence length slen is the subject sequence length and qcovs is the query coverage 
per subject. 
 
BLAST results were filtered by setting the percentage identity at least 95% and the 
coverage of at least 90%. 
 
3.3.3.3 Retrieval of the protein sequences  
Sequences were extracted from the tabular format of BLAST results using Samtools 





3.3.3.4 Multiple Sequence Comparison by Log- Expectation (MUSCLE) 
MUSCLE 
MUSCLE (Edgar, 2004) is a program to execute multiple sequences alignments. The 
script used to run MUSCLE was: 
muscle -in gyrAblastp.fasta -out gyrAblastp.muscle 
3.3.3.5 Jalview (Waterhouse et al., 2009) 
Multiple sequence alignments were visualised using the software Jalview 
(Waterhouse et al., 2009) version 2.10.5. 
3.4 Results 
In the previous chapter, P. aeruginosa laboratory strain PAO1 was evolved to highly 
ciprofloxacin resistant mutants by a series of steps exposing bacteria to an increasing 
concentration of ciprofloxacin (Figure 2.1 in Chapter 2). An antibiotic gradient agar 
plate method was followed for experimental evolution  (Bryson & Szybalski, 1952, 
Wardell et al., 2019). From 13 independent laboratory evolved lines, mutants with 
maximum ciprofloxacin resistance were analysed. In this chapter, experimentally 





3.4.1 Trajectories of ciprofloxacin resistance in experimentally evolved P. 
aeruginosa 
The first aim of this Chapter was to monitor the resistance conferred by mutations 
which occurred in experimentally evolved mutants. To achieve this aim, whole 
genome sequence analysis and MIC testing of intermediate experimentally evolved 
mutants were carried out. Mutants were evolved through multiple steps of 
experimental evolution (Figure 2.1) till the bacteria achieved the maximum 
resistance. Mutants evolved before attaining the maximum resistance are termed as 
“intermediate mutants” in this chapter. Mutations in the experimentally evolved 
resistant mutants were identified through comparison to PAO1-Otago using BRESeq 
version 0.30.0 (Deatherage & Barrick, 2014) (Section 2.4.5). The MIC testing was 
carried out for almost all the intermediate mutants by following the protocol 
described by Wiegand and colleagues (Schurek et al., 2008), as described in Chapter 
2 (Section 2.4.2). The MICs of experimentally evolved intermediate mutants are 
given in Appendix B1. Figure 3.2 represents the mutational pathways of 
experimentally evolved mutants from low ciprofloxacin resistance to high resistance. 
3.4.1.1 Stepwise increase in ciprofloxacin resistance with accumulation of 
mutations 
MIC testing of experimentally evolved intermediate mutants showed that MICs were 
enhanced at almost all steps (Appendix B1). However, there were a few intermediate 
mutants that had same MICs as their ancestral mutant (Appendix B1). For example, 
CF4 had same MIC as CF3 (4 mg/L) and CF6 had same MIC as CF5 (128 mg/L). 
Analysis of genome sequences showed that new mutations were acquired in most of 
the analysed intermediate mutants, leading to an increase in ciprofloxacin resistance 












Figure 3.2: Evolutionary pathways of experimentally evolved ciprofloxacin 
resistant P. aeruginosa in thirteen independent lines showed a step-wise increase 
in resistance with the acquisition of mutations (from left to right). Each arrow 
represents an experimentally-evolved P. aeruginosa line (CA, CB, CC, and so on). C in 
names of mutants represents ciprofloxacin, lines are labelled alphabetically, and numbers 
represent the cycle number of the experimental evolution. All the intermediate mutants 
were analysed only for CK line, while for other lines, selected intermediate mutants were 
analysed. The dots on arrow denote mutants collected during the experimental evolution 
from each line. Mutants were whole genome sequenced and variants were found by 
comparing genomes with the reference PAO1 genome. Genes listed in green have acquired 
mutations from the strain at the previous step. MICs are shown above each dot. Mutated 
genes are listed under each dot. Genes containing two different mutations in a gene were 
listed twice (sdhA and gyrA). Mutants with equivalent MICs and mutated genes are shown in 
bold text. The functions of genes are given in Appendix B3, and mutations are given in 




In ten out of thirteen experimentally evolved lines (Figure 3.2), mutations in genes 
gyrA and nfxB and/or PA3491 were acquired in the early steps of the experimental 
evolution (first 3-4 steps of the experimental evolution). These combinations of 
mutations increased resistance by 32-64-fold above the resistance of PAO1. 
Mutations in genes parC/parE and pil occurred in the later steps of the experimental 
evolution and further enhanced the ciprofloxacin resistance by 8-fold. Mutations in a 
similar gene in most of the independently evolved lines occurring in a similar step-
wise manner indicated that there are probably limited possible evolutionary paths to 
attain a higher level of ciprofloxacin resistance. This suggests epistasis between 
ciprofloxacin resistance associated mutations. Mutational paths to a higher level of 
ciprofloxacin resistance were not random which suggested that mutations were likely 
dependent on each other to get selected through the experimental evolution.  
However, the CM did not follow the trend observed in other lines. In the CM line, 
mutation in gyrA gene was selected in a later step of the experimental evolution. In 
contrast to other lines, an earlier step mutant from the CM line CM3 was resistant to 
ciprofloxacin without gyrA mutation. However, it had a mutation in the tpiA gene in 
combination with three more mutations. The gene tpiA encodes triosephosphate 
isomerase. Resistance in the CM3 mutant could be attributed to the mutation in gene 
tpiA because, in another line (CO), the mutation in tpiA was the only mutation which 
was present in CO5 and not in CO3, and rest of the mutations in CO5 and CO3 were 
identical. The MIC of CO5 was 16-fold higher than the MIC of CO3. The gene tpiA 
has been associated with antibiotic resistance (Cabot et al., 2016). However, in 
previous studies, there is no evidence of the association of tpiA mutation with 
ciprofloxacin resistance and how mutation in tpiA leads to antibiotic resistance, is not 
known yet. 
One exceptional mutant was CI4 (Figure 3.2) which only had a mutation in nfxB 
gene and had a MIC of 4 mg/L, while all other intermediate mutants with a MIC of 4 
mg/L had multiple mutations. This result suggests that exclusively efflux mediated 
ciprofloxacin resistance (without target site modification) is also possible. Efflux 
associated resistance without mutation in gyrA has been reported in clinical isolates 




sourced solely from the overexpression of the efflux pump mechanism in P. 
aeruginosa.  
In the experimental evolution, it was expected that mutations acquired in the earlier 
steps were passed to subsequent progeny. However, some mutations did not persist 
along the subsequent steps of the evolution (Figure 3.2), as observed in previous 
studies (Feng et al., 2016, Melnyk et al., 2017). For example, a mutation in gene 
nalC occurred in the first mutant CK1 from the CK line. However, nalC was not 
mutated in mutants from CK2 to CK7. Most frequently missing mutations were in 
genes sdhA, nalD, PA1740, PA1291 and PA2613. Gene descriptions are given in 
Appendix B3. PCR sequencing of nalD and sdhA was carried out for further 
confirmation of the presence of mutations in a parent mutant and the absence in a 
subsequent mutant. PCR sequencing results were consistent with results from 
BREseq analysis. For example, PCR sequence analysis also showed that nalC was 
mutated in CK1 and not in CK2.  
3.4.1.2 Additional genes associated with ciprofloxacin resistance 
In Chapter 2, it was found that experimentally evolved mutants had mutation in several 
genes, which have not been strongly associated with resistance in previous studies, i.e., 
ssg, pil and tpiA. Analysis of experimentally evolved intermediate mutants showed 
that resistance was enhanced as a result of mutations in ssg, pilT, and tpiA. Mutation 
in ssg in CG6 mutant and pilT in CK5 mutant increased resistance by 2- and 4-fold 
relative to CG4 and CK4 respectively (Figure 3.2). The ssg and pilT genes encode the 
cell surface sugar biosynthetic glycosyltransferase ssg and the twitching motility 
protein PilT, respectively.  
3.4.1.3 Quantification of resistance conferred by combination of mutations in 
experimentally evolved mutants 
An analysis of experimentally evolved intermediate mutants did not provide 
information on how much mutations individually contribute to resistance; however, it 
provided quantification of ciprofloxacin resistance conferred by a few combinations 
of mutations. MICs were consistent in independently evolved mutants which had the 




collectively resulted in a 64-fold increase in MIC relative to PAO1 in experimentally 
evolved intermediate mutants CK3, CF3 and CF4. CO3 had the same mutations as 
these mutants but MIC was different; however, it was only a 2-fold difference in 
MIC of CO3 than that of CK3, CF3 and CF4. A combination of mutations in gyrA, 
nfxB, PA3491 and parC further increased the MIC by 8-fold in mutants CK4, CH5, 
CI5 and CC6 (shown in bold text in Figure 3.2). Overall, Section 3.4.1 showed that a 
high level of ciprofloxacin resistance in P. aeruginosa was developed by the 
stepwise accumulation of mutations.  
3.4.2 Construction of isogenic mutants 
To thoroughly investigate the contribution of individual and combinations of 
mutations in ciprofloxacin resistance, isogenic mutants were constructed using DNA 
cloning and a two-step allelic exchange method (Hmelo et al., 2015), and MICs were 
determined using a double dilution method (Wiegand et al., 2008). The ciprofloxacin 
resistance-associated alleles found in Chapter 2 (Table 2.1) gyrAT83I, nfxB T39P, 
parC S87L, parE V460G, and small deletions in pilT and pilF were introduced in the 
P. aeruginosa wild-type strain PAO1 singly and in different combinations.  
3.4.2.1 DNA cloning 
For the cloning of DNA fragments, cloning vector pEX18Tc (Hoang et al., 1998) 
was used (Figure 3.3). The pEX18Tc is a suicide vector and has genes for screening 
and selection required after conjugation. DNA restriction cloning was used to clone 
DNA fragments containing resistance alleles into vector pEX18Tc. 
The strategy used to perform DNA cloning is shown in Figure 3.4. Primers were 
designed following the criteria given in Section 3.3.2.1. The annealing temperature 
of primers to amplify the DNA fragments was optimised with the gradient PCR. An 
example of the gradient PCR results are shown in Figure 3.5. PCRs using optimized 
annealing temperatures were carried out using primers given in Table 3.5. The 
genomic DNA of experimentally evolved mutants containing the desired mutation 
was used as a PCR template. For all the genes, a ~ 2 kb DNA fragment was 
amplified for cloning, except for parE. A 4.5 kb DNA fragment of parE gene was 




Section 3.3.2. Restriction digestion of all recombinant plasmid was performed to 
confirm the DNA fragment had been ligated in pEX18Tc. Two expected size DNA 
bands (one of a DNA insert and the other of a cut pEX18Tc) in the gel picture of 
restriction digestion product (Figure 3.6 a) indicated that the DNA insert was 
successfully ligated into plasmid. This was further confirmed with a Sanger 
sequencing of the DNA fragment in the recombinant plasmid. Sequence alignment 
with reference sequence confirmed that the DNA fragment had only intended 
mutation in it (Figure 3.6). Analysis of recombinant plasmid containing the DNA 




Figure 3.3: Cloning vector pEX18Tc Hoang et al., (1998) used for mutant 
construction. Tet represents tetracycline resistance marker, lacZ alpha encodes the α 
peptide of β-galactosidase and lacZ alpha contains multiple cloning sites, oriT represents 







Figure 3.4: Schematic representation of cloning mutation-containing DNA 
fragment into the allelic exchange vector. Genomic DNA from experimentally 
evolved mutant with desired mutation (red vertical line) was used as a PCR template. 
Restriction digestion of purified PCR product and allelic exchange vector (pEX18Tc) was 
carried out. The DNA fragment and linearized cloning vector were then ligated together 
using T4 DNA ligase. Cloning of mutation-containing DNA region of the gyrA gene (orange 








Figure 3.5: Gradient PCR products ran on an agarose gel. To optimize the 
annealing temperatures (Ta) of primers, a range of annealing temperatures 59-64°C was 
used to perform gradient PCR. In this example, PCR at annealing temperature 59 to 61°C 
gave multiple non-specific amplifications. At 64°C single desired size band (~2 kb) was 
found therefore, 64°C was chosen as optimized annealing temperature to carry out PCR 
for downstream experiments. Optimization of primers (given in Table 3.5) used for 













Figure 3.6: Analysis of recombinant plasmid with restriction digestion and 
Sanger sequencing.  (A) Representative gel picture of restriction digestion of plasmids 
extracted from the blue colony and white colonies. The first lane from left has 1kb plus 
DNA ladder. Methods for plasmid extraction and restriction digestion are given in Section 
3.3.2.6 and 3.3.2.7 (B) Sequencing chromatogram of the recombinant plasmid containing 
DNA insert is shown. Sequencing was carried out using universal primers set M13 and 
gene-specific primers. The red arrow represents the position of mutation (C) Nucleotide 
BLAST search of the sequence against PAO1 was carried out to confirm the presence of a 
desired mutation in the DNA insert (shown in the red box) and absence of non-intended 
mutations (99% identities in the red box). Analysis of recombinant plasmid, with gyrA DNA 




3.4.2.2 Two-step allelic exchange  
A two-step allelic exchange method was used to replace the wild-type allele in PAO1 
genome with the resistance allele in selected genes. A graphical representation of the 
two-step allelic exchange method is shown in Figure 3.7.  
For an allelic replacement (Figure 3.7), DNA from the gene of interest containing the 
desired mutation, flanked by the homologous DNA region to the recipient genome, is 
engineered into the allelic exchange vector (pEX18Tc). These recombinant plasmids 
are introduced into the recipient cells (PAO1) through conjugation. The first 
homologous recombination leads to the integration of the plasmid into the genome at 
the desired site, and because of the antibiotic resistance marker in the plasmid, 
colonies become antibiotic-resistant, termed as merodiploids. The second 
homologous recombination results in the excision of plasmid from the genome. 
Bacteria in which the second homologous recombination occurred are selected by 
sucrose selection.  Plasmid pEX18Tc has a sacB gene which is a counter selectable 
marker. Gene sacB encodes levansucrase, which converts sucrose into levans (high 
molecular-weight polymers of fructose) that are toxic to bacteria. In the presence of 
sucrose, only those colonies grow, in which plasmid has been excised and thus do 
not have a sacB gene. The second homologous recombination results either in the 
replacement of the wild-type allele to a mutant in the genome or retains the wild-type 
allele.  
Screening for merodiploids was carried out by colony PCR (Section 3.3.2.2) using 
the vector-specific primer colE1 (Table 3.5). PCR results are shown in Figure 3.8. 
The PCR product of 500 bp indicated the presence of plasmid, which indicated that 
colonies had undergone the first homologous recombination and plasmid had been 
integrated into the genome. Colonies that gave the PCR product of 500 bp were 
merodiploids.  
A sucrose selection was performed to find the colonies which lost the plasmid and 
were sucrose resistant (Section 3.3.2.19). The number of colonies on LB agar 
containing sucrose was less than LB agar plates without sucrose (Figure 3.9), as LB 
agar plates containing sucrose had only sucrose resistant colonies. In sucrose-




any cells which had plasmid containing the conditional lethal gene sacB were not 
able to grow. On average, for diluted culture (10-4), 25-35 colonies were observed on 
the LB agar plate with 5% sucrose in comparison to the LB agar plate without 
sucrose on which hundreds of colonies were grown. Sucrose-resistant and antibiotic 













Figure 3.7: Schematic representation of the two-step allelic exchange method 
adapted from Hmelo et al. (2015). Allelic replacement in gyrA is shown as an example. 
DNA region of interest (green rectangle) containing desired mutation (red line inside the 
green rectangle) and homologous DNA region to recipient genome, was engineered into 
the pEX18Tc allelic exchange vector (shown on the top of the figure). Two homologous 
recombination events occur in this process. The plasmid gets integrated into the genome of 
P. aeruginosa at the desired site with first homologous recombination. To select for bacteria 
that had undergone the first homologous recombination (merodiploids), the tetracycline 
resistance marker in the plasmid was used. With second homologous recombination, the 
plasmid was excised from the genome. Sucrose selection was carried to select the colonies 
in which plasmid had been excised. As, sacB is a conditional lethal gene, in the presence of 
sucrose, only those colonies grow in which plasmid has been excised and does not have a 
sacB gene. Theoretically, after second homologous recombination, there is a 50% chance to 
replace wild-type allele with a resistant allele. Sequencing of PCR products was performed 





Figure 3.8: Representative gel picture of colE1 PCR for the screening of 
merodiploids of gyrA. PCR with pEX-specific primer set colE1 (Table 3.5) was carried 
out to screen for merodiploids. PCR product size of 500bp indicated that colonies had 
plasmid integrated into their genome and thus are merodiploids. 
 
Figure 3.9 (A): Sucrose selection: Merodiploids of gyrA were grown in LB broth, 
diluted (10-4), and spread onto LB agar plate with and without 5% sucrose to select sucrose 
resistant colonies. (B) Sucrose resistant colonies were picked and grown on LB agar plates 
with and without antibiotic (tetracycline) to confirm that they had lost the plasmid and thus 







3.4.2.3 Mutant screening 
Colony PCR was carried out on sucrose resistant and tetracycline sensitive colonies 
with primers (Table 3.6) which amplified the mutation-containing the DNA region, 
and the PCR products were sent for sequencing and DNA sequences were aligned 
with PAO1 using BLAST on NCBI, to find out if PCR products had the desired 
mutations. On average, 5 out of 8 PCR products from the sucrose-resistant and 
antibiotic sensitive colonies had a mutation, and the rest of the colonies were wild-
type revertants. PCR sequencing and sequence alignment of mutants gyrA T83I, gyrA 
D87G, gyrA D87N, nfxB T39P, PA3491 H87P, parC S87L, parE V460G, pilT small 




Figures 3.10 (a): The gyrA T83I mutant: Sequencing chromatogram with an arrow 
pointing at the position of mutation and sequence alignment with mutation (C to T at 
position 3558951) is shown in a red box. DNA region of interest was amplified using 
primers given in Table 3.6 from sucrose resistant and tetracycline sensitive colonies and 





















































3.4.3 Quantification of resistance conferred by mutations  
In the previous Section, results from the mutant construction were shown. After the 
mutant construction, ciprofloxacin MICs were determined by a double dilution 
method for each engineered mutant three times. Some of the mutants were 
constructed twice to evaluate the reproducibility of the results. The summarized 
results are shown in Table 3.14. 
3.4.3.1 Effects of mutations in gyrA on ciprofloxacin resistance 
Three different gyrA mutations found in experimentally evolved mutants were 
engineered into PAO1 and the MICs were determined (Figure 3.11). The MIC of 
gyrA T83I mutant was 16-fold higher than PAO1. The gyrA T83I confers the clinical 
level of ciprofloxacin resistance that is 1 mg/L (EUCAST breakpoint for 
ciprofloxacin resistance is above 0.5 mg/L). The MIC of gyrA D87G and gyrA D87N 
was 8 and 4-fold higher than PAO1, respectively. The higher MIC of gyrA T83I 
mutant explains the higher frequency of the gyrA T83I variant than gyrA D87G and 
D87N in our laboratory-evolved ciprofloxacin resistant mutants (Wardell et al., 
2019), other experimental evolution studies and in clinical isolates (Higgins et al., 
2003, Lee et al., 2005, Wydmuch et al., 2005, Pasca et al., 2012, Bruchmann et al., 
2013).  
3.4.3.2 Effects of individual mutations in genes other than gyrA on ciprofloxacin 
resistance  
Previous studies on clinical isolates reported the presence of ciprofloxacin resistance-
associated genetic variations in genes parE, parC and gyrB in fluoroquinolone 
susceptible and resistant isolates (Kos et al., 2015), which led to the question of 
whether individual mutations contribute to ciprofloxacin resistance. To investigate 
the contribution of mutations in ciprofloxacin resistance, mutations were engineered 
into PAO1, and MICs were determined. The engineered mutants with other 
mutations: nfxB T39P, PA3491H87P, parC S87L, parE V460G, pilT, and pilF small 
deletion, all had MICs same as the parent strain PAO1 (0.0625 mg/L) (Figure 3.12). 
This result showed that these mutations do not confer ciprofloxacin resistance by 







Figure 3.11:  Ciprofloxacin resistance of gyrA mutants: Ciprofloxacin MICs of 
laboratory control strain PAO1 and gyrA engineered mutants are shown. Mutants were 
constructed using two-step allelic exchange method (Section 3.4.2.2) and MICs were 
determined by the double dilution method (Section 2.4.2). MICs were recorded in mg/L. 
Each dot represents a biological replicate of MICs. MIC replicates of gyrA T83I are shown in 
yellow (resistant), and MICs of other gyrA mutants are shown in blue dots (susceptible). 















Figure 3.12: Effects of other mutations on ciprofloxacin resistance: Resistance 
alleles nfxB T39P, PA3491 H87P, parC S87L, parE V460G, small deletions in pilT and pilF 
found through experimental evolution were engineered to PAO1 using two-step allelic 
exchange method (Section 3.4.2.2) and MICs were determined by double dilution method 
(Section 2.4.2). MICs were recorded in mg/L. Each dot represents one replicate of MIC 
testing. MICs in the range of clinical resistance are shown in yellow dots and blue dots 













3.4.3.3 Effects of the combination of mutations in genes other than gyrA on 
ciprofloxacin resistance  
Based on the results from the previous section, it was hypothesised that mutations 
nfxB T39P, PA3491H87P, parC S87L, parE V460G, and small deletions in pilT and 
pilF likely confer resistance when combinations of mutations are present. To find out 
if these mutations confer resistance when they are present together, triple mutants 
were constructed using a two-step allelic exchange method, containing mutations 
PA3491 H87P, nfxB T39P and parC S87L/parE V460G. It was found that both triple 
mutants had MIC of 0.0625 mg/L (Fig 3.13), which was the same as MIC of PAO1. 
This result confirmed that when gyrA wild-type allele is present, none of the other 
mutations tested confer a clinical level of resistance either individually or in 




Figure 3.13: Effects of the combinations of mutations on ciprofloxacin 
resistance: Combinations of mutated alleles were engineered into PAO1 genome by two-
step allelic exchange method (Section 3.4.2.2) and MICs were determined by double 
dilution method (Section 2.4.2). Each dot represents one replicate of MIC testing. Yellow 
dots represent ciprofloxacin MICs in range of clinical level of resistance and blue dots 





Another approach (Figure 3.14) was used to further validate the result that mutations 
other than gyrA T83I do not confer resistance in combination. The resistant allele 
gyrA T83I was replaced with wild-type allele in the experimentally evolved mutants 
CK4 and CH5, which lead to reduction in resistance by 128-fold relative to parent 
mutant (Figure 3.15). Despite the genome sequences being identical, the MIC of 
these mutants were 4-fold higher than those of bacteria engineered to contain the 












Figure 3.14: Replacement of mutant gyrA allele T83I to wild-type allele in 
experimentally evolved mutants using two-step allelic exchange method (Section 3.4.2.2). 
The pEX18Tc::WT gyrA was prepared (Table 3.4) using DNA cloning (Section 3.4.2.1) and 
used to replace the mutated gyrA T83I in experimentally evolved mutants CH5 and CK4 





 Experimentally evolved mutant CK4 
gyrA T83I, nfxB T39P, PA3491 H87P, parC S87L 
Knock-in WT gyrA in CH5 
WT gyrA, nfxB T39P, PA3491 H87P, parC S87L 
  
Experimentally evolved mutant CH5 
gyrA T83I, nfxB T39P, PA3491 H87P, parC S87L 
 
Knock-in WT gyrA in CK4 
WT gyrA, nfxB T39P, PA3491 H87P, parC S87L 
Replacement of mutant allele gyrA 







Figure 3.15: Validation of the effects of combinations of other mutations on 
ciprofloxacin resistance: MICs in mg/L are shown on the y-axis and genotypes of 
engineered mutants are given on the x-axis. Mutants constructed from the replacement of 
resistance allele gyrA T83I with wild-type allele in highly resistant experimentally evolved 
mutants are named as “Knock-in WT gyrA in CK4 and CH5” and their MICs are shown as 
blue dots. MICs of CK4 and CH5 are shown as red dots. Each dot represents one replicate 
of MIC testing. MICs indicating different levels of resistance are represented by different 
colour dots i.e., blue, yellow and red dots denote a susceptible range of MICs, MICs that 
just crossed the EUCAST resistance breakpoint (0.5 mg/L) and high level of resistance 
(MICs of 4 mg/L and above) respectively. MICs data of engineered triple mutants and gyrA 






The summarised results from Section 3.4.3 are gyrA T83I which were prerequisite to 
develop ciprofloxacin resistance. Mutations other than gyrA T83I do not confer 




Figure 3.16: Map of mutants with single and combinations of mutations constructed in this study. Arrows represent order of mutations 
engineered in PAO1 using two step allelic exchange method. Each box represents an engineered mutant with genotypes given inside the box. 
 
PAO1 
gyrA T83I, parC S87L 
gyrA D87N gyrA T83I nfxB T39P pilT del gyrA D87G parC S87L PA3491 H8P pilF del parE V460G 
gyrA T83I, parEV 460G gyrA T83I, PA3491 H87P gyrA T83I, nfxB T39P 
PA3491 H87P, nfxB T39P, 
parC S87L 
PA3491 H87P, nfxB T39P, 
parE V460G 
gyrA T83I, PA3491 H87P, 
nfxB T39P 
gyrA T83I, PA3491 H87P, 
parC S87L 
gyrA T83I, nfxB T39P, 
parC S87L 
gyrA T83I, PA3491 H87, nfxB T39P, parE V460G gyrA T83I, PA3491 H87P, nfxB T39P, parC S87L 




3.4.4 Effects of the combinations of mutations with gyrA mutation on 
ciprofloxacin resistance 
DNA cloning and a two-step allelic exchange method (Figure 3.7) were used to 
construct the mutants with combinations of mutations. To construct double mutants, 
a protocol of conjugation was used as described in Section 3.3.2.17, except gyrA 
T83I mutant cells were used as the recipient (Figure 3.16). To construct triple 
mutants, double mutants were taken as recipient cells and so on (Figure 3.16). MICs 
were determined using a double dilution method (Section 2.4.2). Ciprofloxacin MIC 
testing of all mutants was carried out in triplicate.  
3.4.4.1 Double mutants  
The previous Section showed that mutation gyrA T83I conferred the ciprofloxacin 
resistance when present individually. Other mutations parC S87L, parE V460G, 
nfxB T39P and PA3491 H87P did not confer resistance individually or in 
combination when gyrA was not mutated. Therefore, it was hypothesised that a 
combination of mutations in other genes parC, parE, nfxB and PA3491 with mutated 
gyrA would increase the resistance. To test the hypothesis, double mutants were 
constructed. The MICs of double mutants are shown in Figure 3.17. Consistent with 
the hypothesis, mutations parC S87L and parE V460G increased the ciprofloxacin 
MIC by 4- and 2-fold, respectively, above the MIC of gyrA T83I mutant. Genes parC 
and parE encode the secondary target of ciprofloxacin that is DNA topoisomerase IV 
subunits A and B. An increase in ciprofloxacin resistance by parC S87L and parE 
V460G above the resistance of the gyrA T83I mutant indicated that gene-gene 
interactions between ciprofloxacin resistance associated mutations led to an increase 
in ciprofloxacin resistance. 
Mutations nfxB T39P and PA3491 H87P did not increase the resistance in engineered 
double mutants above the resistance conferred by gyrA T83I (Figure 3.17). Gene 
nfxB encodes the negative regulator NfxB of the efflux pump MexCD-oprJ-encoding 
genes. Mutations in nfxB are generally thought to inactivate the protein NfxB, that 
results in an overexpression of the efflux pump, and thus increases ciprofloxacin 
resistance (Poole et al., 1996, Wong & Kassen, 2011). The gene PA3491 encodes 






Figure 3.17: Effects of combinations of other mutations with gyrA T83I on 
ciprofloxacin resistance. Resistance alleles were engineered into gyrA T83I mutant by 
two-step allelic exchange method (Section 3.4.2.2) and MICs were determined by double 
dilution method (Section 2.4.2). Genotypes of engineered mutants are shown along the x-
axis and MICs are shown on the y-axis. Each dot represents one replicate of MIC testing. 
Yellow dots represent ciprofloxacin MICs in range of clinical level of resistance and blue 
dots represent MICs in susceptible range. Red dots represent a high level of resistance.  
 
3.4.4.2 Contribution of PA3491 H87P and NfxB T39P in ciprofloxacin resistance 
Double mutants which had mutations in nfxB or PA3491 in combination with a 
mutated gyrA did not show an increase in resistance above the resistance conferred 
by the gyrA T83I mutant (Figure 3.17). However, nfxB T39P and PA3491 H87P 
mutations were present in a high number of maximally resistant experimentally 
evolved mutants (Chapter 2, Table 2.1), indicating that these are associated with 
resistance. In an early step, laboratory evolved mutants CK3, CF3 and CF4, 
mutations gyrA T83I, nfxB T39P and PA3491 H87P (Figure 3.2, shown in bold text) 




only gyrA T83I and PA3491 H87P. Co-occurrence of mutations in experimentally 
evolved mutants led to the hypothesis that nfxB T39P and PA3491 H87P mutations 
may be dependent on each other to enhance ciprofloxacin resistance. To test this 
hypothesis, a mutant containing resistance alleles gyrA T83I, nfxB T39P and PA3491 
H87P was constructed. This engineered triple mutant had a MIC of 4 mg/L (Figure 
3.18), that was 4-fold higher than the MIC of double mutants gyrA T83I, nfxB T39P 
and gyrA T83I, PA3491 H87P (Figure 3.17). A higher MIC of the triple mutant than 
the mutant containing gyrA T83I and nfxB T39P showed for the first time that the 
variant PA3491 H87P enhanced ciprofloxacin resistance in P. aeruginosa. In 
addition, it was found that nfxB T39P mutation increased resistance only when it was 
present in combination with PA3491 H87P and gyrA T83I. 
As variant PA3491 has not been associated with antibiotic resistance previously, the 
involvement of PA3491 H87P in resistance was further tested. Resistance allele 
PA3491 H87P in experimentally evolved mutant CK3 which also had mutant alleles 
gyrA T83I and nfxB T39P, was replaced with a wild-type allele in gene PA3491 
(Experimental strategy is shown in Figure 3.19). The resulting mutant was named as 
Knock in WT PA3491 in CK3. Ciprofloxacin MIC was determined to investigate the 
effect on the resistance of a wild-type allele in PA3491. The replacement of the 
mutant allele to a wild-type allele in gene PA3491 decreased the ciprofloxacin 
resistance by 2-fold relative to MIC of CK3. The MIC of the resulting strain was 2-
fold higher than that of the engineered mutant in which the gyrA and nfxB mutations 
were introduced separately, despite the bacteria having the same genotype, and the 
reason for this difference is not clear  (Figure 3.20). This is may be because of non-
genetic factors such as altered DNA-methylation (Motta et al., 2015, Yugendran & Harish, 
2016). 
MIC results were reproducible when mutant construction and MIC testing were 
repeated (Figure 3.20). A Possible role of the variant PA3491 in ciprofloxacin 






Figure 3.18: Effects of PA3491 H87P on ciprofloxacin resistance: Mutants (along 
the x-axis) were constructed by a two-step allelic exchange method (Section 3.4.2.2) and 
MICs (along the y-axis) were determined by double dilution method (Section 2.4.2). Each 
dot represents one replicate of MIC testing. Yellow dots represent ciprofloxacin MICs in 
range of clinical level of resistance and blue dots represent MICs in susceptible range. Red 







Figure 3.19: Replacement of mutant PA3491 allele H87P to wild-type allele in 
experimentally evolved mutants using a two-step allelic exchange method (Section 3.4.2.2). 
The pEX18Tc :: WT PA3491 was prepared (Table 3.4) using DNA cloning (Section 3.4.2.1) 
and used to replace the mutated PA3491 H87P in an experimentally-evolved mutant CK3 
(Appendix B2). MICs of these mutants are given in Figure 3.20.  
 Experimentally evolved mutant (CK3) 
gyrA T83I, nfxB T39P, PA3491 H87P 
WT PA3491 in experimentally evolved mutant  






Figure 3.20: Validations of the effects of PA3491 H87P variant on ciprofloxacin 
resistance. MICs in mg/L are shown on the y-axis and genotypes of engineered mutants 
are shown on the x-axis. Resistance allele in gene PA3491 was replaced with wild-type 
allele in experimentally evolved mutant CK3 and the resulted-mutant named Knock in WT 
PA3491 and its MICs are shown as orange dots. Each dot represents a replicate of MIC 
testing. MICs of mutants other than Knock in WT PA3491 are from Figure 3.12 and 3.18. 
Construction of triple engineered mutant and Knock in WT PA3491 in CK3 mutant was 











3.4.4.3 Higher level of antibiotic resistance caused by combinations of mutations 
To find out whether a combination of all the mutations have an additive effect on 
ciprofloxacin resistance, quadruple mutants were constructed, and then MIC was 
determined (Figure 3.21). To construct the quadruple mutants, resistance alleles parC 
S87L and parE V460G were engineered into a mutant, that already had variants gyrA 
T83I, nfxB T39P and PA3491 H87P (Figure 3.16). An increase in resistance by 8-
fold above the MIC of the triple mutant (MIC of 4 mg/L) was found in quadruple 
mutants (MIC of 32 mg/L), which indicated that a higher level of resistance is gained 
by a specific combination of mutations. Quadruple mutants had a MIC of 32 mg/L 
(Figure 3.21), which was consistent with equivalent laboratory evolved mutants 
CK4, CH5, CI5 and CC6 (Figure 3.2), indicating the reproducibility of the results. 
The MICs of engineered mutants, indicating combinatorial effects of mutations on 
ciprofloxacin resistance, are summarised in Figure 3.21 and Table 3.14. A graphical 
representation of the overall results is given in Figure 3.22. 
Overall, results from Section 3.4.4 showed that a higher level of ciprofloxacin 
resistance (MIC >1 mg/L) in P. aeruginosa was attained through a combination of 
mutations, suggesting that mutations were dependent on each other to increase the 
resistance. Gene-gene interactions were found as an important contributing factor in 
the enhancement of ciprofloxacin resistance in P. aeruginosa. In addition, the MICs 
of engineered mutants were consistent with the equivalent experimentally evolved 
mutants, indicating the reproducibility of the quantification of resistance associated 












Figure 3.21: Effects of combinations of mutations on ciprofloxacin resistance. 
MICs in mg/L are shown along the y-axis and genotypes of engineered mutants are shown 
on the x-axis. Mutants with combinations of mutations were constructed by two-step allelic 
exchange method (Section 3.4.2.2) and MICs were determined by double dilution method 
(Section 2.4.2). Each dot represents a replicate of MIC testing. MICs of mutants other than 









Table 3.14: MICs of engineered mutants and main findings. 






PAO1 0.06265 Parent strain 
1.  gyrAT83I 1 
gyrA T83I confers clinical level of ciprofloxacin 
resistance 
2.  gyrAD87G 0.5 
3.  gyrAD87N 0.25 
4.  nfxBT39P 
0.0625 
Mutation in gyrA is necessary for ciprofloxacin 
resistance development. 
5.  PA3491H87P 
6.  parCS87L 
7.  parEV460G 
8.  pilTΔ 
9.  pilFΔ 
10.  PA3491 H87P + nfxBT39P + parCS87L 
11.  PA3491 H87P + nfxBT39P + parEV460G 
12.  
Knock in WT gyrA in CK4ƚ (gyrAT83I + nfxBT39P 
+ PA3491 H87P + parCS87L) 
0.25 
13.  
Knock in WTgyrA in CH5ƚ (gyrAT83I + nfxBT39P 
+ PA3491 H87P +parCS87L) 
0.25 
14.  gyrAT83I + parCS87L 4 
parC and parE increase resistance above gyrA mutation. 
15.  gyrAT83I + parEV460G 2 
16.  gyrAT83I + PA3491H87P 1 
nfxB T39P or PA3491 H87P do not increase the 
resistance in double mutants 
17.  gyrAT83I + nfxBT39P 1 
18.  gyrA T83I + nfxBT39P + PA3491 H87P X2 4 
Combination of mutations in nfxB and PA3491 increased 
the ciprofloxacin resistance, and are probably dependent 
on each other 
19.  gyrAT83I + parCS87L + PA3491 H87P 4 
20.  gyrAT83I + nfxBT39P + parCS87L 4 
21.  gyrAT83I + nfxBT39P + parEV460G 4 
22.  
Knock in WT PA3491 in CK3 (gyrAT83I + 
nfxBT39P + PA3491 H87P) X2 
2 
Further confirmed the involvement of PA3491H87P in 
ciprofloxacin resistance development 
23.  
Knock in WT PA3491 in gyrA + nfxB + 
PA3491 X2 
2 
24.  gyrAT83I + nfxBT39P + PA3491H87P + parCS87L X2 32 
The mutations in genes parC and parE are associated 
with high level of ciprofloxacin resistance  







Figure 3.22: Mutational pathways that lead to higher ciprofloxacin resistance in 
engineered mutants. Lines represent the mutational pathways that increase resistance 
from the top to the bottom of the figure. Each circle represents a mutant with mutated 
genes inside it and MICs are shown under the mutated genes. The map of mutants with 










3.4.5 Growth analysis  
The growth of resistant mutants in the absence of an antibiotic is an important factor 
to assess how well the resistant bacterial populations would be maintained when 
antibiotic exposure is interrupted (Andersson & Hughes, 2010). To investigate the 
effects of mutations on the growth of mutants, an area under the growth curve was 
calculated for the mutants from one experimentally evolved P. aeruginosa line CK 
(Figure 3.24 a and c) and the equivalent engineered mutants (Figure 3.24 b and d). 
Growth analysis of the mutants in this chapter was carried out following the method 
given in Section 2.4.3 in Chapter 2. Mutants were grown for 18 hours in LB without 
an antibiotic and OD600 was measured to assess the growth every 30 minutes. The 
OD600 data was used to calculate the area under the growth curve (AUC) using the 
GrowthCurver package version 0.2.1 (Sprouffske & Wagner, 2016) of software 
Rstudio.  
3.4.5.1 Growth analysis of experimentally evolved mutants 
Line CK was chosen to analyse the growth of experimentally evolved mutants 
because all the mutants from this line (CK1 to CK7) had been whole genome 
sequenced, and mutations were identified. Generally, resistance-associated mutations 
result in amino acid changes in proteins that are involved in important biological 
functions (Andersson & Hughes, 2010). Therefore, the acquisition of mutations was 
hypothesised to affect the growth of mutants in the absence an of antibiotic. 
The area under the curve values of all three biological replicates for experimentally 
evolved mutants are shown in Figure 3.24 a. Growth curves are shown in Figure 3.23 
a and b. Consistent with this hypothesis, a reduction in growth compared to the 
parent strain PAO1 was observed in mutants that had accumulated mutations that 
lead to a high level of ciprofloxacin resistance (Figure 3.24 a and c). The growth of 
CK1 and CK2 were similar to the parent strain PAO1. Mutant CK3 had reduced 
growth with an AUC of 989.3, compared to PAO1 that had an AUC of 1150. 
Reduced growth in CK3 could be attributed to the presence of the resistance allele 
nfxB T39P. This result suggested a fitness cost of nfxB mutation, consistent with 
previous studies (Sanchez et al., 2002, Andersson & Hughes, 2010, Melnyk et al., 




environment. Generally, the overexpression of efflux pumps has been thought to 
reduce the growth of bacteria (Stickland et al., 2010). Further reduction in growth 
was observed with the acquisition of a mutation in parC gene in CK4. From mutants 
CK5 to CK7, growth did not decrease substantially compared to CK4 even though additional 
mutations were present, indicating that mutations acquired in mutants CK5 to CK7 are not 
fitness-costly mutations. Previously, it has been observed that the evolution of 
antibiotic resistance that occurs through resistance-associated mutations are usually 
accompanied by compensatory mutations (Andersson & Hughes, 2010, Melnyk et 
al., 2017).  
3.4.5.2 Growth analysis of engineered mutants 
The growth of engineered mutants with equivalent mutations to the experimentally 
evolved mutants from the CK line, were analysed (Figure 3.24 b). The area under the 
growth curve was comparable between laboratory-evolved and the equivalent 
engineered mutants (Figures 3.24 a and b). The experimentally evolved mutant CK2 
and the engineered double mutant had an average area under the curve of 1114.18 
and 1041, respectively, and CK3 and the equivalent engineered triple mutants had 
989 and 784.3, respectively. The CK4 and engineered quadruple mutant had an area 
under the curve of 766.5 and 820, respectively. The acquisition of the parC mutation 
in the experimentally evolved mutant CK4 reduced growth relative to CK3; however, 
in the engineered mutant, there was no difference in growth between triple and 
quadruple mutants. Difference in growth of genetically identical mutants could be 
because the experimentally-evolved mutants were exposed to ciprofloxacin through 
many passages. Exposure to ciprofloxacin could alter the expression of genes 
involved in cellular metabolism which could make bacteria to grow slow. The 
average values of the area under the curve are given in Appendix D1.  
Overall, Section 3.4.5 shows that resistance mutations reduced the growth of mutants 
in LB without an antibiotic, indicating that the ciprofloxacin resistance-associated 








Figure 3.23 (a): Growth of mutants from an experimentally evolved P. 
aeruginosa line CK. Bacteria were grown in L-broth and optical density at 600 nm (shown 
on the y-axis) was measured every 30 minutes (time shown on the x-axis) for 18 hours. 
Means of 3 biological replicates are shown. Average OD600 readings of 3 biological 
replicates for each mutant were calculated to generate the growth curves. The colour key 









Figure 3.23 (b): Growth of engineered mutants. Bacteria were grown in L-broth and 
optical density at 600 nm (shown on the y-axis) was measured every 30 minutes (time 
shown on the x-axis) for 18 hours. Means of 3 biological replicates are shown. Average 
OD600 readings of 3 biological replicates for each mutant were calculated to generate the 








Figure 3.24 (a) 
 
Figure 3.24 (b) 
Figure 3.24 a and b: Effects of mutations on the growth of experimentally evolved 
mutants (a) and engineered mutants (b). The area under the curve calculated from OD600 
measurements from three biological replicates of growth. The area under the growth curve 
was calculated for comparison of growth between mutants and reference strain PAO1. 
Each dot represents a biological replicate of the experiments. Average values are 
represented by black bars. The mean values of the area under the curve are given in 




Figure 3.24 (c)  
 
Figure 3.24 (d) 
Figure 3.24 c and d: Growth and minimum inhibitory concentrations of mutants 
from experimentally evolved resistance in line CK (c) and of engineered 
mutants (d). The bar graph represents the MICs of mutants. The orange line shows the 
average AUC of mutants (given in Appendix D1) with standard deviation error bars on it. 
Mutated genes in mutants starting with the parent strain PAO1 (on left) are listed on the x-





3.4.6 Prediction of ciprofloxacin resistance in clinical isolates  
In the previous Sections 3.4.3 and 3.4.4, the contribution of mutations in 
ciprofloxacin resistance was quantified in engineered mutants. It was hypothesised 
that the clinical isolates of P. aeruginosa containing equivalent ciprofloxacin 
resistance-associated genetic variations would have the same MICs as engineered 
mutants. To test the hypothesis, ciprofloxacin resistance was predicted for the 
isolates of P. aeruginosa, based on the presence of resistance alleles in selected 
genes, for which resistance had been quantified. The MIC data of engineered and 
experimentally evolved mutants was used to predict the ciprofloxacin resistance in 
clinical isolates from genome sequences. Predicted and actual MICs were then 
compared. MICs determined by a culture-based technique and MICs predicted from 
genotypes are termed as actual MICs and predicted MICs, respectively.  
3.4.6.1 Genotypes of clinical isolates of P. aeruginosa  
The International Pseudomonas Consortium Database (IPCD) is a consortium of 
thousands of genomes sequences and glycerol stocks of cultures of P. 
aeruginosa isolates from human, animal infections and the general environment. 
Genome sequences of 237 P. aeruginosa isolates were downloaded from IPCD 
(Freschi et al., 2015). Out of these, 200 had MIC data available in IPCD. For the 
remaining 37 isolates, MIC testing was carried out using a double dilution method 
(Section 2.4.2). MICs of isolates are shown in Appendix E. The strategy used to 
analyse genomes of P. aeruginosa isolates is shown in flowchart (Figure 3.24). The 
methodology for bioinformatics analysis is given in Section 3.3.3. Amino acid 
variations searched in clinical isolates were GyrA T83I, NfxB T39P, ParC S87L and 
ParE V460G. The gene PA3491 was not analysed for antibiotic resistance 
predictions because the involvement of the PA3491 H87P mutant allele in clinical 
isolates is not known yet, and further investigations are needed before it is 
considered for antibiotic resistance predictions. Protein variants found in 
experimentally evolved mutants were also present in clinical isolates i.e., GyrA T83I 
and ParC S87L, while in proteins ParE and NfxB, clinical isolates did not have 






















Figure 3.26: Schematic representation of methodology used to find amino acid 
variations associated with ciprofloxacin resistance from WGS of clinical and 
environmental samples sourced from IPCD. To annotate the genomes, software 
Prokka v1.10 was used and a database of annotated genomes was prepared. Protein BLAST 
of four proteins was carried out, to find the amino acid variations in comparison to 
proteins from reference sequence PAO1 from NCBI. Sequences were retrieved from 
BLAST results and MUSCLE (Edgar, 2004) was used to align the protein sequences. After 
that, alignments were visualized in Jalview (version 2) (Waterhouse et al., 2009) to search 
the amino acid changes in GyrA, NfxB, ParC, and ParE. 
Ran Prokka and made 
database 
Ran protein BLAST and 
filtered the table using awk 
commands   
Retrieved the sequences of 
GyrA, NfxB, ParC and ParE 
Ran MUSCLE 
Alignments were viewed in 
Jalview and analysed 




ParE variations that were present in CARD A473V, M437I and other changes close 
to a 460 position, S457C and P438S were taken into consideration to predict the 
ciprofloxacin resistance. ParE S457C (López-Causapé et al., 2018) and P438S 
(López-Causapé et al., 2017) have been associated with ciprofloxacin resistance in P. 
aeruginosa. However, ciprofloxacin resistance has not been quantified for ParE 
A473V, M437I, S457C and P438S. Thus, resistance was considered equivalent to 
resistance conferred by ParE V460G in combination with the mutated gyrA.  
The NfxB variant T39P, which was identified through analysis of experimentally 
evolved mutants, was not found in clinical isolates analysed in this study. The protein 
variant NfxB T39P did not increase resistance above the resistance conferred by 
GyrA T83I in an engineered double mutant. Thus, any amino acid variations in NfxB 
in comparison to PAO1 were thought not to increase the resistance. However, 
variants were recorded to find those which are present in isolates with an actual MIC 
higher than predicted. NfxB amino acid variations R82L and R42C were found in 
isolates with an actual MIC higher than the predicted MICs. The NfxB variants R82L 
and R42C are associated with ciprofloxacin resistance in other studies on clinical 
isolates (Jalal et al., 2000, Esquisabel et al., 2011). 
The isolates of P. aeruginosa showed six different genotypes (Table 3.15); 117/237 
isolates had no analysed amino acid variations i.e., GyrA T83I, NfxB, ParC S87L or 
ParE A473V, M437I, S457C and P438S. Thirteen out of 237 had a combination of a 
wild type GyrA with amino acid variations in other analysed proteins, 28 had only 
GyrA T83I, 22 had a combination of GyrA T83I with ParC S87L and ParE 
variations, and 7 had a combination of GyrA T83I, NfxB and a ParE variant.  
3.4.6.2 Criteria used to predict ciprofloxacin resistance in isolates of P. 
aeruginosa 
Ciprofloxacin resistance was predicted in two ways: predicted antibiotic 
susceptibility profiling and predicting MICs. Antibiotic susceptibility profiling was 
categorised isolates in two categories as resistant and susceptible. Another approach 
was the prediction of MIC values which was applied for resistant isolates. Criteria 
used to predict antibiotic susceptibility profiling and MICs in P. aeruginosa isolates 




presence of specific amino acid changes, for which resistance had been quantified by 
making engineered mutants and performing MIC testing. To predict the resistance, 
criteria were decided, in which the presence of specific amino acid changes and most 
importantly, the effects of the combinations of variants were taken into account that 
have been omitted in previously designed tools to predict antibiotic resistance (Su et 
al., 2018). Actual MICs and predicted antibiotic susceptibility profiles of clinical 
isolates were compared with predicted MICs and antibiotic susceptibility profiles. 
Isolates were categorised as actual MIC equal to, higher than, and less than 
predicted. For susceptible isolates, antibiotic susceptibility profiles were predicted 


















Table 3.15: Criteria used to designate ciprofloxacin MICs and ciprofloxacin 
susceptibility profiles for clinical isolates.  
 
Criteria to predict resistance was based on MICs of equivalent engineered mutants. S represents 














No amino acid variation at gyrA83, parC87, nfxB39 
or parE 437, 438,473,457, 460 
- 
Less than 1 
(S) 
Wild type gyrA and variant parC87 or parE437, 
438,473,457 and 460 or nfxB 
parC S87L 




gyrAT83I gyrA T83I 
1 
(R)  
gyrAT83I + parCS87L gyrAT83I + parCS87L 
4 
(R) 
gyrAT83I + parE473/457/460/438 gyrAT83I + parEV460G 
2 
(R) 
gyrAT83I + nfxB and  
gyrAT83I + nfxB + parE473/457/460/438 











3.4.6.3 Ciprofloxacin resistance was predicted correctly in the majority of P. 
aeruginosa isolates 
A total of 237 genomes from P. aeruginosa isolates were analysed to predict 
ciprofloxacin resistance, out of which 180 were phenotypically susceptible and 57 
were resistant to ciprofloxacin (Table 3.16), based on the EUCAST breakpoint for 
ciprofloxacin resistance (MIC > 0.5 mg/L). A comparison of actual and predicted 
ciprofloxacin MICs showed that MICs were predicted correctly for 69% (164/237) of 
isolates (Table 3.16) and the predicted ciprofloxacin susceptibility profiles were 
correct in 71% (168/237) of the analysed clinical isolates (Appendix E).  
Out of 180 susceptible isolates, 126 were predicted correctly (Table 3.16). Out of 
these 126 isolates, 117 did not have any analysed amino acid variations in proteins 
GyrA, ParC, ParE and NfxB and had actual MICs in the range of 0.125-0.5 mg/L. 
These isolates were predicted correctly as ciprofloxacin susceptible (MIC was 
predicted less than 1 mg/L) (Table 3.17). Nine isolates with only a ParE variant 
and/or a NfxB variant in combination with a wild type GyrA83 were correctly 
predicted as susceptible. Correct predictions for the majority of ciprofloxacin-
susceptible P. aeruginosa isolates (126/180) showed that these analysed 
ciprofloxacin resistance-associated variants are specific ciprofloxacin resistance 
determinants. 
Among the 57 resistant isolates, the MIC predictions for 21 out of 22 isolates with 
GyrA T83I plus ParC S87L variants and 12/28 with only a GyrA T83I variant were 
correct (Table 3.17). Antibiotic susceptibility profiles were predicted correctly in the 
rest of the 16 out of 28 isolates, with only a GyrA T83I variant. A few isolates (7) 
had a combination of GyrA T83I, ParE and NfxB variants and 5/7 had the predicted 
MICs and a phenotype the same as the actual MIC. Total, 38/57 resistant isolates had 
a predicted MIC the same as the actual MIC. This result demonstrated that 
quantification of resistance associated with mutations in engineered mutants was 
consistent with that in the clinical isolates of P. aeruginosa. Out of 57 isolates, 42 
had a predicted susceptibility profile same as the actual MIC. 
Overall, ciprofloxacin MICs for most of the isolates were predicted correctly. This 




resistance identified through experimental evolution, and the quantification of 
resistance associated with mutations assessed by determining the MICs of engineered 
mutants. Clinical isolates usually have many genetic variations, despite the fact that 
clinical isolates showed consistent results with engineered mutants. However, the 
reproducibility of the actual MIC was not assessed. The MIC testing will be repeated 
for these isolates in future. A caveat for an approach to predicting antibiotic 
resistance is that actual MICs might vary if determined by variable methods, and thus 
would impact the consistency between predicted and actual MICs.  
 
Table 3.16: Summarised results of predicted ciprofloxacin 

















 WT gyrA + mutant 
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3.4.6.4 Isolates with actual MICs higher than predicted 
Around 24% (58/237) of the isolates had actual MICs higher than predicted MICs 
(Table 3.17, Appendix E6-E8).  
Out of 58 isolates with actual MIC higher than predicted, 50 isolates which did not 
have any analysed resistance-associated variants, were wrongly predicted as 
susceptible. While, actual MICs showed that these isolates were resistant to 
ciprofloxacin based on EUCAST breakpoints and had MICs in the range of 1-4mg/L. 
Resistant isolates (50/58) with no analysed amino acid variations indicated that 
probably additional genes or mutations in the analysed genes are associated with 
ciprofloxacin resistance, which needs to be explored. Different possibilities of non-
classical ciprofloxacin resistance are elaborated in discussion Section 3.5. Among 
rest of the 8 out of 58 isolates, 4 had only NfxB R82L or only ParE A473V and 
D533E variants (Appendix E7) and were ciprofloxacin resistant, while predicted as 
susceptible. It was hypothesized, that NfxB R82L and combination of ParE A473V 
and D533E confer resistance without GyrA variant. NfxB variant R82L has been 
reported in resistant clinical isolates and did not have GyrA variant (Jalal et al., 
2000). However, there is no direct evidence of the resistance conferred by NfxB 
R82L and ParE variants without GyrA variant. Other 4 out of 8 isolates had only 
GyrA variant and were predicted correctly as resistant while, actual MICs were 4-
fold higher than predicted MICs (Appendix E8). Further analysis is required to find 
causal variants of resistance in resistant P. aeruginosa isolates.  
Isolates which were predicted as susceptible but were resistant and isolates which 
had higher actual MICs than predicted, highlighted the significance of criteria 
designed in this study to predict the resistance. These criteria were based on certain 
combinations of variants contrast to the criteria used in other studies. Unique criteria 
used in this study facilitated to screen out isolates that likely have additional 
resistance-associated genes or variants. In addition, approach used in this study to 
predict the antibiotic resistance in clinical isolates based on MICs of equivalent 
engineered mutants had an advantage that predictions are more likely based on 




predictions, it remained a question if genetic variations which were considered as 
resistance determinants were the source of resistance.  
3.4.6.5 Isolates with actual MICs less than predicted 
About 6% (15/237) isolates had actual MICs (<1 mg/L) less than predicted (1 mg/L) 
(Table 3.17). Of these 15, 12 isolates had only GyrA variant T83I. The MIC testing 








 Table 3.17: Antibiotic resistance prediction in isolates of P. aeruginosa using genomes. Predictions were based on the presence of 














Isolates with MICactual > 
MICpredicted 
 
Isolates with MICactual < 
MICpredicted 
 
No. of isolates 
MIC range 
mg/L 
No. of isolates 
MIC range 
mg/L 
Clinical samples with wild type gyrA83 





MIC < 1 
167 117 50 1-4 0 N. A 
WT gyrA in combination with 




MIC is < 1 
13 9 4 1-2  0 N. A 
Clinical isolates with variant gyrAT83I 
Only gyrAT83I 
Resistant 
MIC = 1 
28 12 4 4-8 12 0.05-0.5 
Both gyrAT83I and parCS87L 
Resistant 
MIC ≥ 4 
22 21 0 N. A 1 0.125 
gyrAT83I and parE473/457/460/438 
gyrAT83I+nfxB+parE473/457/460/438 
Resistant 
MIC ≥ 2 
7 5 0 N. A 2 0.5 





3.5.1 Overview  
This chapter aimed to quantify the ciprofloxacin resistance associated with mutations 
and to predict the resistance in clinical isolates from genotypes. Minimum inhibitory 
concentrations and a whole-genome sequence analysis of experimentally-evolved 
intermediate mutants showed that the mutations were acquired sequentially/stepwise, 
which enhanced resistance through the experimental evolution towards a high level 
of ciprofloxacin resistance (Figure 3.2, Appendix B1 and B2). Then, for further 
understanding of the contribution of variants in resistance, isogenic mutants with 
individual and combinations of mutations were constructed, and their MICs were 
determined. The MICs of engineered mutants showed that gyrA T83I mutation was a 
majorly responsible and a prerequisite for the development of ciprofloxacin 
resistance (Figure 3.15). Mutations other than gyrA T83I did not increase resistance 
above the MIC of PAO1 individually or in combination when gyrA was a wild type 
(Figure 3.12 and 3.15). A higher level of ciprofloxacin resistance resulted with a 
combination of other mutations with gyrA mutation T83I in P. aeruginosa (Figure 
3.21). MICs of engineered mutants are summarised in Table 3.14. The quantification 
of resistance conferred by mutations showed that mutations were dependent on each 
other to confer and increase the resistance, which indicated the involvement of 
epistatic interactions between the mutations in ciprofloxacin resistance. 
Ciprofloxacin resistance was predicted in clinical isolates based on MICs of isogenic 
and experimentally-evolved mutants using genome sequence analysis. A high 
proportion of clinical isolates showed the predicted MICs equal to the actual MICs 
(Tables 3.16 and 3.17).  
3.5.2 Analysis of experimentally evolved intermediate mutants 
To understand the genetic basis of the evolutionary trajectories of ciprofloxacin 
resistance in experimentally evolved mutants, whole genome sequence analysis was 
carried out and MICs were determined. The genome analysis of experimentally-
evolved lines showed that P. aeruginosa acquired mutations in a stepwise manner, 




B2). Three key findings from an analysis of experimentally-evolved intermediate 
mutants were the involvement of gene-gene interactions in ciprofloxacin resistance 
evolution, the quantification of resistance associated with different combinations of 
mutations, and association of genes with ciprofloxacin resistance which have not 
been strongly associated with resistance previously.  
However, some mutations did not persist through the experimental evolution (Figure 
3.2). A possible explanation of unstable mutations could be the method of 
experimental evolution used in this study. Bacteria were grown in an alternating 
environment with and without ciprofloxacin. Mutations leading to resistance could 
be selected when an antibiotic was present. If resistance-conferring mutations are 
high in fitness cost, it is more likely that in the absence of an antibiotics, bacteria 
could evolve to get rid of costly mutations. Generally, antibiotic resistance-
associated mutations have a high fitness cost (Schulz zur Wiesch et al., 2010). It has 
been observed in other studies that ciprofloxacin-resistant mutants re-sensitized to 
ciprofloxacin when grown in LB (Yen & Papin, 2017). 
3.5.2.1 Gene-gene interactions between gyrA and parC / parE in ciprofloxacin 
resistance  
In ten out of thirteen experimentally evolved P. aeruginosa lines (Figure 3.2), the 
mutation in gyrA and nfxB or PA3491 were acquired in the early steps of the 
experimental evolution. Consistent with other studies, mutations in genes parC and 
parE were found in the later steps of evolution (Jørgensen et al., 2013). Mutations in 
gyrA, PA3491, and nfxB increased the resistance level by 16-32-fold relative to 
PAO1, and a further 8-fold enhancement of resistance was observed with the 
acquirement of mutations in parC and parE. This indicated an association of 
mutations in parC and parE with a higher level of ciprofloxacin resistance, 
consistent with other studies on clinical isolates of P. aeruginosa (reviewed in 
Rehman et al., 2018) and in other bacterial species (Belland et al., 1994, Georgiou et 
al., 1996). Gyrase A is the primary target of ciprofloxacin and mutations in gyrA 
occur earlier in evolution. Topoisomerase IV is a secondary target for ciprofloxacin, 
and parC mutations result in an increase in resistance only in later steps of evolution 




speculated for a long time that a mutation in gyrA occurs first and then other 
mutations accumulate in fluoroquinolone-resistance experimental evolution studies 
(Akasaka et al., 2001, Jørgensen et al., 2013). However, in clinical isolates, 
fluoroquinolone resistance has not been tracked in detail to explore what mutations 
would be selected in what order. In one study, multiple clinical isolates collected 
from a patient at different time points showed that isolates collected in the years 
1988 and 1991 were susceptible to fluoroquinolones. The gyrA variations were 
selected in isolates taken in 1992, and samples collected post-1992 also had parC 
S87L amino acid variation (Treepong et al., 2018). A study by Treepong et al., 2018, 
also showed that parC mutation was selected only when a gyrA mutation was present 
in the background. This indicated that parC mutation is dependent on gyrA mutation 
to increase the ciprofloxacin resistance, suggesting that gyrA T83I and parC S87L 
have epistatic interactions between them. This was consistent with previous studies 
on other bacterial species (Almahmoud et al., 2009, Sutera et al., 2013, Zhang et al., 
2015).  
3.5.2.2 Additional genes associated with ciprofloxacin resistance 
The MICs of experimentally evolved intermediate mutants (Figure 3.2) showed that 
mutations in genes pil, tpiA, and ssg increased resistance to ciprofloxacin, although 
the role of mutated pil, tpiA and ssg genes in ciprofloxacin resistance is not known 
yet. 
In a few other studies, the mutation in ssg has been associated with antibiotics 
resistance including ciprofloxacin (Dötsch et al., 2009, Alvarez-Ortega et al., 2010, 
Fernández et al., 2013) however, ssg mutation has been observed in low frequency. 
The gene ssg encodes cell surface sugar biosynthetic glycosyltransferase, and the 
mutation in ssg probably leads to a disruption in the biosynthesis of the 
lipopolysaccharide core of the cell membrane. A study by Wiegand et al. (2008) 
tested a hypothesis that a mutation in gene ssg could result in an increased mutation 
frequency in P. aeruginosa, and found that mutation frequency was not increased in 
the ssg mutant. One possible explanation for an increase in ciprofloxacin resistance 
with mutations in genes that are involved in the synthesis of the lipopolysaccharide 




decreased entry into the cell (Chamberland et al., 1989). Mutations in pil genes have 
been recently associated with ciprofloxacin resistance (Ahmed et al., 2018). 
Mutations in pil genes have been shown to increase the ability of bacteria to make 
biofilm (Ahmeda et al., 2018). Increased biofilm production could limit the exposure 
of bacterial cells to ciprofloxacin and consequently increase the resistance. The gene 
tpiA has been reported in association with antibiotic resistance (Cabot et al., 2016, 
Hwang et al., 2016). The tpiA mutation has been speculated to be involved in efflux 
pump mediated fluoroquinolone resistance (Su et al., 2010). The gene tpiA encodes a 
key enzyme triose phosphate isomerase that is involved in cellular metabolism. 
Mutation in the tpiA increases carbon metabolism and cellular respiration (Xia et al., 
2020) that could increase the proton motive force because the efflux of antibiotics 
through efflux pumps is dependent on the proton motive force (PMF). Mutation in 
tpiA might facilitate PMF production in mutants.  
3.5.2.3 Quantification of resistance associated with combinations of mutations in 
experimentally evolved mutants 
The quantification of resistance was partially explored from the analysis of 
experimentally evolved intermediate mutants (shown in bold in Figure 3.2). Mutants 
CK3 and CK4 had the same three mutations (gyrA T83I, nfxB T39P, PA3491 H87P) 
and had the same MIC of 4 mg/L. Likewise, mutants CK4, CH5, CI5, CC6 all had 
the same four mutations gyrA T83I, nfxB T39P, PA3491 H87P, and parC S87L and 
had the same MIC of 32 mg/L. These results indicated the reproducibility of a 
genotype to a phenotype correlation and showed that a high level of ciprofloxacin is 
gained by a combination of both resistance mechanisms i.e., target site modifications 
and overexpression of efflux pumps, similar to previous studies on the clinical 
isolates of P. aeruginosa (Bruchmann et al., 2013, Hamed et al., 2018).  
3.5.3 Quantification of an increase in ciprofloxacin resistance conferred by 
mutations 
To quantify the level of resistance conferred by single and different combinations of 




PAO1, and MIC testing was performed. The summarised results of isogenic mutants 
constructed in this study are shown in Table 3.14. 
3.5.3.1 Quantification of ciprofloxacin resistance conferred by individual 
mutations 
The gyrA T83I increased the ciprofloxacin resistance by 16-fold relative to the MIC 
of the reference strain PAO1 (Figure 3.11). The ciprofloxacin MIC of the mutant 
gyrA T83I was 1 mg/L in our study which was comparable to the MIC for an 
engineered mutant gyrA T83I reported by Melnyk et al., 2016 and Bruchmann et al., 
2013. In our study, the MICs of three different variants of gyrA showed that gyrA 
T83I resulted in a clinical level of ciprofloxacin resistance based on the EUCAST 
breakpoint for ciprofloxacin resistance that is above 0.5 mg/L (www.eucast.org). The 
MICs of gyrA D87N and D87G were in a susceptible range, though MICs were 
higher than PAO1. In contrast, other studies (Bruchmann et al., 2013, Melnyk et al., 
2017) reported that gyrA D87G and D87N confer a clinical level of resistance to 
ciprofloxacin. This difference in results between studies was likely because other 
studies engineered mutations in the reference strain PA14 which has higher MIC (0.5 
mg/L) than the MIC of PAO1 (0.0625 mg/L) used in this study.  
Higher resistance conferred by gyrA T83I compared to other gyrA variants was 
consistent with findings in other studies on engineered mutants (Bruchmann et al., 
2013, Melnyk et al., 2017), clinical isolates of P. aeruginosa and other bacteria (Lee 
et al., 2005, Almahmoud et al., 2009, Pasca et al., 2012, Sutera et al., 2014). Higher 
resistance conferred by gyrA T83I than gyrA D87G and gyrA D87N elucidated a 
stronger selection of gyrA T83I than other gyrA variants in experimentally evolved 
mutants (Wong & Kassen, 2011, Feng et al., 2016) and clinical isolates of P. 
aeruginosa (Akasaka et al., 2001, Higgins et al., 2003, Lee et al., 2005, Llanes et al., 
2011, Pasca et al., 2012, Bruchmann et al., 2013, Yang et al., 2015). In addition, a 
higher MIC of the gyrA T83I mutant compared to the MIC of gyrA D87G and D87N 
suggest that ciprofloxacin likely interacts directly with amino acid T in Gyrase at 83 




Mutations in genes other than gyrA did not confer ciprofloxacin resistance in the 
absence of gyrA T83I mutation (Figure 3.12 and Table 3.14). This finding was 
consistent with other studies on clinical isolates (Kos et al., 2015) and engineered 
mutants (Bruchmann et al., 2013). The MIC of engineered mutant parC S87L in 
Bruchmann et al., 2013 was not higher than the reference strain PA14 and was in a 
susceptible range. A study by Kos et al., 2015 reported isolates of P. aeruginosa 
which had genetic variations in genes parE, parC, and gyrB and were susceptible to 
ciprofloxacin. The susceptibility of mutants to ciprofloxacin could be explained by 
the fact that mutants with mutations in PA3491, nfxB, parC, parE, and pil genes have 
wild type GyrA which has a higher affinity to ciprofloxacin binding as compared to 
mutated GyrA (Jacoby, 2005). No resistance conferred by mutations other than gyrA 
T83I explained the selection of gyrA mutation in the earlier step and the selection of 
parC mutation in the later steps of experimental evolution.  
In our study, the MIC of engineered mutant nfxB T39P was contrary to results in a 
study by Melnyk et al., 2017. They reported that the MIC of nfxB T39P was 4-fold 
higher than PA14 and was in the resistance range. This could be because in a study 
by Melnyk et al., 2017, mutations were engineered in PA14, which had a MIC of 0.5 
mg/L, while in our study, mutations were engineered in PAO1 (MIC 0.0625 mg/L). 
Different genetic backgrounds of PAO1 and PA14 could affect the MICs. 
3.5.3.2 Effects of the combinations of mutations in genes other than gyrA 
Engineered mutants with mutations in genes PA3491, nfxB, parC, and parE did not 
increase ciprofloxacin resistance when present individually; however, these genes 
were frequently mutated in experimentally evolved mutants (Table 2.2, Chapter 2). 
Therefore, it was hypothesised that combinations of mutations in these genes may 
alter resistance. To investigate the effect of the combination of mutations on 
ciprofloxacin resistance, triple mutants were constructed which had mutations in 
genes PA3491, nfxB, and parC / parE. Mutations in genes PA3491, nfxB, parC, and 
parE do not confer resistance in combination when gyrA is a wild type (Figure 3.13 
and 3.15). The effects of the combinations of mutations in genes other than gyrA was 




To validate the finding further, that a combination of mutations in genes other than 
gyrA do not confer resistance, the resistance allele gyrA T83I was replaced with a 
gyrA wild-type allele in laboratory-evolved mutants which had a MIC of 32 mg/L. A 
reduction in ciprofloxacin MIC by 128-fold was found with the replacement of the 
resistance allele with a wild-type allele in gyrA (Figure 3.15). This result indicated 
that gyrA mutation T83I was a prerequisite for the development of ciprofloxacin 
resistance. In addition, it could be hypothesized that any fluoroquinolone which 
interacts with amino acids other than T at 83 position of gyrase will be effective 
against highly ciprofloxacin-resistant P. aeruginosa. Moxifloxacin and gatifloxacin 
have shown different molecular binding sites on target enzymes DNA gyrases than 
ciprofloxacin and levofloxacin in different bacterial species (Pestova et al., 2000), 
although it has not been investigated fully in P. aeruginosa. An engineered triple 
mutant with the same mutations in the same genes (MIC = 0.0625 mg/L) as in the 
Knock-in WT gyrA in CK4 and CH5 mutants (MIC = 0.25 mg/L) had 4 to 8-fold 
lower MICs than that of the Knock-in WT gyrA mutant. However, the MICs of a 
triple engineered mutant and the Knock-in WT gyrA in CK4 and CH5 mutants were 
in a susceptible range.  
To make sure that the mutant Knock-in WT gyrA in CK4 had the same mutations as 
the engineered triple mutant, the mutant Knock-in WT gyrA in CK4 was whole-
genome sequenced which showed that both mutants had the same mutations. Further 
investigations are required to explain the difference in the MICs of mutants with the 
same combinations of mutations, which were constructed using different strategies. 
For example, proteomic analysis or an investigation of non-genetic factors might 
give further insights into it (Yugendran & Harish, 2016, Jedrey et al., 2018).  
3.5.3.3 Effect of the combinations of other mutations with gyrA T83I on 
ciprofloxacin resistance 
3.5.3.3.1 Mutation in parC and parE enhanced the ciprofloxacin resistance  
To investigate the effects of the combinations of mutations on ciprofloxacin 
resistance, double mutants with a combinations of gyrA T83I and other mutations 




of gyrA T83I and other mutations, resistance alleles parC S87L and parE V460G 
increased the resistance by 8-fold above the MIC of the gyrA T83I mutant (Figure 
3.17). Previously, a mutation in parC has been shown to increase the resistance by 8-
fold above the resistance conferred by gyrA in an isogenic mutant of P. aeruginosa 
(Bruchmann et al., 2013) and other bacteria (Almahmoud et al., 2009). The 
quantification of resistance associated with the ParE variant has not been investigated 
before.  
3.5.3.3.2 NfxBT39P did not increase ciprofloxacin resistance by itself 
The nfxB gene encodes the negative regulator NfxB of the efflux pump (MexCD-
OprJ)-encoding genes (Poole et al., 1996). Mutations in the nfxB gene are generally 
associated with an overexpression of the efflux pump MexCD-OprJ and 
ciprofloxacin resistance (Purssell & Poole, 2013). The nfxB mutation leading to the 
NfxB variant T39P in a double mutant did not increase ciprofloxacin resistance 
above the resistance conferred by gyrA T83I (Figure 3.17). This result did not follow 
the generalisations made in previous studies on clinical isolates that have shown that 
a combination of target site mutations and efflux regulator gene mutations increase 
fluoroquinolone resistance (Higgins et al., 2003, Dunham et al., 2010, Esquisabel et 
al., 2011, Wong & Kassen, 2011, Bruchmann et al., 2013). However, the NfxB 
variant T39P has not been reported in clinical isolates. Previously, the association of 
nfxB mutations with resistance has been mostly investigated by deleting the nfxB 
gene (Bruchmann et al., 2013) or analysing clinical samples (Higgins et al., 2003). 
The deletion of nfxB in combination with gyrA T83I in a study by Bruchmann et al. 
(2013) led to a 16-fold increase in resistance above the MIC of gyrA T83I. Different 
mutations in the nfxB gene lead to a different level of expression of the efflux pump-
encoding gene mexD (Purssell & Poole, 2013). The deletion of the nfxB gene leads to 
inactivation of the protein NfxB that results in an overexpression of the efflux pump 
(Purssell & Poole, 2013), while point mutation in nfxB probably does not inactivate 
the protein fully. The effects of point mutations depend on where in gene it occurred 
and the nature of the mutation. Clinical isolates usually have many genetic variations 
and it is complicated to pinpoint causal genetic variations, for antibiotic resistance. 




S36N probably increase resistance by themselves; however, the frequency of such 
changes was not as high as of NfxB T39P in the experimentally-evolved mutants 
(Table 2.2). Low frequency of NfxB amino acid changes other than T39P was 
probably because the efflux pump genes are expressed more in these mutants than in 
the nfxB T39P mutant. Increased expression of efflux pumps has been associated 
with a high fitness cost (Melnyk et al., 2017).  
It was speculated that nfxB T39P probably leads to an increase in the expression of 
efflux pump genes mexCD-oprJ genes, but not sufficiently enough to enhance the 
resistance. The nfxB T39P did not increase resistance above the resistance conferred 
by gyrA T83I. However, not many studies have investigated the direct effect of 
single nucleotide mutations in nfxB on the expression of efflux pump encoding genes 
and ciprofloxacin resistance, which are common in clinical samples (Jalal et al., 
2000, Kugelberg et al., 2005). The investigation of the effect of point mutations in 
gene nfxB on the expression of efflux pump genes and ciprofloxacin resistance has 
significance for the prediction of antibiotic resistance using genome analysis of the 
clinical isolates of P. aeruginosa.  
3.5.3.3.3 Genes nfxB and PA3491 interact to increase ciprofloxacin resistance  
No increase in resistance with mutations nfxB T39P and PA3491 H87P individually, 
and the co-occurrence of nfxB T39P and PA3491 H87P in experimentally evolved 
mutants led to the hypothesis that nfxB T39P and PA3491 H87P are dependent on 
each other to increase ciprofloxacin resistance. The engineered mutant with 
mutations gyrA T83I, nfxB T39P, and PA3491 H87P had a 4-fold higher resistance 
than mutants, which had gyrA T83I plus nfxB T39P or gyrA T83 plus PA3491 H87P 
mutations (Figure 3.18). This result showed for the first time that the PA3491 variant 
H87P is involved in ciprofloxacin resistance. The function of PA3491 is not known 
yet. It has been proposed previously that PA3491 encodes probable ferredoxin, based 
on the presence of conserved amino acid motifs, and structural features; however, the 
PA3491 function has not been experimentally characterised yet. The PA3491 
mutation might be involved in efflux-mediated ciprofloxacin resistance, as PA3491 
and nfxB mutations were dependent on each other to increase the resistance. Energy-




resistance (Su et al., 2010). The role of mutation in gene PA3491 in ciprofloxacin 
resistance is discussed in the next chapter (Chapter 4). 
In addition, a higher MIC of the triple mutant than the double mutant showed that 
specific combinations of mutations are required to enhance ciprofloxacin resistance. 
Mutations are dependent on each other to increase the resistance. An increase in 
resistance with combinations of mutations suggested epistatic interactions between 
ciprofloxacin resistance-associated mutations.  
3.5.3.3.4 Gene-gene interactions in the high level of ciprofloxacin resistance  
To understand the genetic basis of the high level of ciprofloxacin resistance (MIC > 
4 mg/L) in P. aeruginosa, the mutations parC S87L and parE V460G were 
engineered into the triple mutant which had mutations in gyrA, nfxB, and PA3491, 
and MICs were determined. The MICs of quadruple mutants were 32 mg/L which 
was 8-fold higher than the MIC of the triple mutant (Figure 3.21). This result 
indicated that genes interact with each other to increase the resistance. Ciprofloxacin 
resistance associated mutations are dependent on each other to gain a high level of 
resistance. The MICs were found to be consistent between experimentally evolved 
mutants and equivalent engineered mutants. The consistent MICs between 
laboratory-evolved and engineered mutants highlighted the reproducibility of the 
results. 
3.5.4 Growth analysis of ciprofloxacin-resistant mutants  
In addition to the level of resistance associated with mutations, fitness cost is also an 
important factor that plays a significant role in the evolution of resistance in the 
bacterial population (Andersson & Hughes, 2011, Melnyk et al., 2017). In the 
presence of an antibiotic, a mutation could be beneficial to the bacteria because of 
the higher level of resistance associated with it. The same mutation in the absence of 
an antibiotics could be disadvantageous for the bacteria (Andersson & Hughes, 
2010). Resistance-associated mutations are usually associated with a high fitness 




relative growth of bacteria with different genotypes. However, all resistance-
associated mutations would not have a high fitness cost.  
Reduction in growth was observed in some mutants compared to the parent strain 
(Figure 3.24 a to d). Mutations in gyrA did not lead to a reduction in growth 
consistent with earlier studies (Melnyk et al., 2017, Jedrey et al., 2018) and thus, 
were thought to be fitness-cost free in P. aeruginosa (Melnyk et al., 2017) and other 
bacteria (Baker et al., 2013). Supercoiling and doubling time did not alter with gyrA 
mutation in E. coli (Bagel et al., 1999). A mutation in nfxB gene occurred in mutant 
CK3 which showed reduced growth compared to CK2. An overexpression of efflux 
pumps results in an energetic burden on the cells (Stickland et al., 2010), which 
could result in reduced growth. CK4 showed further reduced growth than CK3 with 
the acquirement of a mutation in parC. Previously, a combination of a mutations in 
gyrA and parC in clinical isolates has been associated with the reduced fitness of P. 
aeruginosa (Kugelberg et al., 2005), and of other bacteria (Kunz et al., 2012). A 
combination of mutations in gyrA and parC showed altered supercoiling and 
doubling time in E. coli (Bagel et al., 1999). Mutations occurred in CK5 and CK6 
did not affect growth in the absence of antibiotic.  
3.5.5 Prediction of ciprofloxacin resistance in clinical isolates using genome 
sequences  
It was hypothesised that if clinical isolates have ciprofloxacin resistance associated 
mutations the same as engineered mutants, then the MICs of clinical isolates should 
also be equal to engineered mutants. The MICs of engineered and experimentally 
evolved mutants were used to predict the resistance in clinical isolates based on the 
presence or absence of those genetic variations, for which resistance had been 
quantified. Amino acid variations GyrAT83I, NfxB T39P, ParC S87L, and ParE 
V460G, A473V, S457C, P438S were searched in the protein sequences of 237 
clinical isolates, and ciprofloxacin resistance was predicted, based on the criteria 
given in Table 3.15. In susceptible isolates, antibiotic susceptibility profiling was 
predicted and for resistant isolates, MICs and antibiotic susceptibility profiling were 




3.5.5.1 Prediction of ciprofloxacin resistance in isolates with no analysed 
variants  
The majority of isolates that did not have any analysed variants were predicted 
correctly as susceptible. Out of 237 isolates, 167 did not have any analysed amino 
acid variations (Tables 3.16 and 3.17) and 117/167 isolates had the same predicted 
ciprofloxacin susceptibility profile as the actual phenotype. Similarly, in a study by 
Kos et al., 2015, out of 190 susceptible samples, 174 had no QRDR mutations in 
genes gyrA, gyrB, parC, and parE (Kos et al., 2015, Nouri et al., 2016).  
On the other hand, 50 out of 167 isolates in our study, which did not have any 
analysed genetic variations (gyrA T83I, nfxB T39P, parC S87L, and parE V460G, 
A473V, S457C, P438S) were ciprofloxacin-resistant with a MIC of 1–4 mg/L. This 
result was contradictory to the MICs of engineered mutants which showed that gyrA 
T83I is required for ciprofloxacin resistance. This result indicated that non-classical 
resistance associated mutations are possibly the source of resistance in these isolates. 
There are several other examples of resistant clinical isolates of P. aeruginosa which 
did not have mutations in gyrA (Bruchmann et al., 2013, Salma et al., 2013, Wang et 
al., 2014, Kos et al., 2015, Yang et al., 2015, Nguyen et al., 2018, Telling et al., 
2018). Resistance in isolates which did not have mutated gyrA 83 or 87 could be 
attributed either to resistance alleles in gyrA other than gyrA T83I and D87G/N 
(Cabot et al., 2016, López-Causapé et al., 2017, Nguyen et al., 2018) or have 
plasmid-mediated resistance (Jiang et al., 2014). Resistance alleles other than T83I in 
gyrA have been found in other experimental evolution studies and clinical isolates 
G81C, G81D, Y86N, Q106L, T133M, E153K, S612L which will be searched in the 
genomes of clinical isolates. Multiple gyrA resistance alleles highlight the diversity 
of ciprofloxacin resistance-determinants that suggests the need for advancements in 
antibiotic resistance prediction tools. None of these gyrA resistance alleles are 
present in CARD. Investigations on direct evidence of these alleles in resistance and 
their incorporation in antibiotic resistance genes database might increase the 
accuracy of antibiotic resistance prediction. In addition, diverse resistance alleles in 
gyrA emphasise the need for detailed investigations on gyrase-ciprofloxacin 




3.5.5.2 Prediction of ciprofloxacin resistance in isolates with mutations in genes 
other than gyrA  
Thirteen out of 237 isolates had amino acid variations in ciprofloxacin resistance-
associated proteins other than GyrA. Based on the MICs of mutants with individual 
mutations in genes other than gyrA, isolates with amino acid variations in NfxB, 
ParC and ParE were predicted as susceptible, and 9/13 had actual MIC in a 
susceptible range (Table 3.17). This finding was consistent with another study on 
levofloxacin resistance-prediction in P. aeruginosa (Kos et al., 2015). It has been 
reported that clinical isolates with only parE or parC or a combination of gyrB and 
parE mutations were phenotypically susceptible, which further backed our findings 
that other mutations in combination with a wild-type gyrA 83 allele do not lead to 
ciprofloxacin resistance.  
3.5.5.3 Prediction of ciprofloxacin resistance in isolates with a mutation in only 
gyrA and combination with other mutations 
Clinical isolates with combinations of ciprofloxacin resistance-associated mutations 
were predicted to have higher MICs than those of clinical isolates with individual 
resistance alleles (Table 3.15). However, in previous studies on antibiotic resistance 
predictions, the presence of resistance alleles and genes were considered and gene-
gene interactions between resistance-associated mutated genes were overlooked (Su 
et al., 2019). In addition, other studies designated isolates as resistant or susceptible 
using genomic sequences, while resistance was predicted quantitatively in addition to 
phenotypic profiling for ciprofloxacin-resistant clinical isolates in this study.  
The MIC of engineered mutants showed that gyrA T83I led to a clinical level of 
ciprofloxacin resistance (MIC of 1 mg/L) in P. aeruginosa PAO1. This finding was 
used to set the criteria for the prediction of ciprofloxacin MIC in isolates (Table 
3.15). Isolates that had GyrA T83I and no other amino acid variations in analysed 
proteins were predicted to be resistant and to have the MIC of 1 mg/L (Table 3.15). 
Twelve out of 28 isolates with GyrA T83I and no other analysed variants had 
predicted MIC the same as the actual MICs. However, 4 isolates with only gyrA T83I 




A higher actual MIC than predicted for isolates with only GyrA T83I indicated that 
these isolates probably have additional genetic variations associated with 
ciprofloxacin resistance (Bruchmann et al., 2013) and needs further analysis to find 
the causal genetic variations of resistance. In Bruchmann et al., 2013, 27/100 clinical 
isolates with only gyrA mutation had a range of MIC from 1-8 mg/L.  
In contrast to the isolates which had actual MICs higher than predicted, 12/28 
isolates containing only gyrA T83I had actual MICs less than predicted. These 12 
isolates were predicted as resistant and the predicted MIC was 1 mg/L, while the 
actual MICs were in the susceptible range (0.05-0.5 mg/L). However, 6/12 had an 
MIC of 0.5 which is borderline resistance (Appendix E9). Isolates with borderline 
resistance are difficult to predict accurately. In another study, 31/139 isolates which 
showed the predicted phenotypes as different than the actual phenotype had MICs in 
the range of 0.5 to 8 mg/L (Khaledi et al., 2019), which is a borderline resistance.  
The MIC of an engineered double mutant with gyrA T83I and parC S87L mutations 
had a MIC of 4 mg/mL; therefore clinical isolates had a combination of gyrA T83I 
and parC S87L were predicted to have a MIC of 4 mg/L. Twenty-one out of 22 
isolates with a combination of GyrA T83I and ParC S87L had an actual MIC equal to 
the predicted MIC (Table 3.16). Previously, the combination of gyrA and parC has 
been associated with a higher resistance than the resistance associated with mutations 
only in gyrA gene (Jalal et al., 2000, Bruchmann et al., 2013, Redgrave et al., 2014, 
Yang et al., 2015, Nouri et al., 2016, Nguyen et al., 2018). Very few isolates had 
analysed ParE variants in isolates analysed in this study. Future studies include an 
analysis of more isolates containing parE genetic variations to investigate the 
contribution of clinically relevant parE genetic variations in resistance.  
3.5.5.4 The prediction of efflux-mediated ciprofloxacin resistance is complex 
The combination of amino acid variations in proteins GyrA and NfxB was found in 
5/237 P. aeruginosa isolates. In an engineered double mutant, nfxB T39P did not 
increase ciprofloxacin resistance above the resistance conferred by gyrA T83I. This 
finding did not follow the generalisations made in previous studies on clinical 




the regulator genes of efflux pump genes increased fluoroquinolone resistance 
(Higgins et al., 2003, Kugelberg et al., 2005, Dunham et al., 2010, Esquisabel et al., 
2011, Wong & Kassen, 2011, Bruchmann et al., 2013). It was shown in a study by 
Purssell et al.,2013 that different point mutations in nfxB could lead to a different 
level of increase in the expression of efflux pump-encoding genes.  
Therefore, it could not be concluded that all point mutations in nfxB are always a 
good determinant of ciprofloxacin resistance because of the possibility of the 
variable effects of different point mutations in nfxB gene on ciprofloxacin resistance. 
In addition, a number of isolates that contained genetic variations in nfxB was small 
in the data set we analysed.  
Isolates containing a combination of GyrA and NfxB variants were predicted to have 
a MIC of 1 mg/L. Resistance alleles nfxB R82L and R42C were reported in other 
studies on clinical isolates (Reinhardt et al., 2007) and also observed in clinical 
isolates in our study which had MIC higher than predicted. It is hypothesised that 
R82L and R42C probably increase the resistance. Further investigations are required 
to quantify the resistance associated with the NfxB variant R82L and R42C.  
3.6 Conclusion 
The quantification of resistance associated with individual mutations and 
combinations of mutations gave insight into the contribution of mutations in 
ciprofloxacin resistance, which enhanced the understanding of ciprofloxacin 
resistance evolution in P. aeruginosa. It was found that the gyrA T83I variant 
conferred ciprofloxacin resistance in engineered mutants. Other resistance alleles 
parC S87L, parE V460G, nfxB T39P, and PA3491 H87P did not confer 
ciprofloxacin resistance when present individually or in combination when a wild 
type gyrA was present. Combinations of other mutations with gyrA T83I increased 
ciprofloxacin resistance. Ciprofloxacin resistances predicted using genome 
sequences were correct in the majority of isolates. However, analysis of clinical 
isolates showed that 50/237 isolates were ciprofloxacin resistant which did not have 
the variant GyrA T83I. A unique approach used in this study to predict MICs, in 




breakpoints, showed that some isolates had predicted MICs less than the actual 
MICs. This finding indicates that additional ciprofloxacin resistance-associated genes 
and mutations are probably present, which need further investigations. The findings 
of this study will facilitate the advancement of models and approaches used for 
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The gene nfxB encodes a negative regulator NfxB which represses transcription of 
the genes encoding efflux pump MexCD-OprJ (Poole et al., 1996). The efflux pump 
MexCD-OprJ is comprised of three proteins that make a channel embedded in the 
outer membrane of a bacterial cell. This channel effluxes the substrates, including 
antibiotics out of the cytoplasm. The efflux of substrates through efflux pumps is an 
energy-dependent process. The genes which encode MexCD-OprJ exist in the form 
of an operon (Figure 4.1). MexC is encoded by the first gene in the operon, mexC. 
MexC is a membrane fusion protein in the cytoplasmic membrane. MexD encoded 
by mexD, is a transporter, which transfers the substrates through the inner membrane. 
The outer membrane protein OprJ is encoded by oprJ which enables the transport of 
the substrate through the outer membrane (Nikaido, 1998). Mutations in the gene 
nfxB lead to the inactivation of the protein NfxB, resulting in the overexpression of 
MexCD-OprJ (Poole et al., 1996, Wong & Kassen, 2011), which increases the 
antibiotic resistance. 
In Chapter 3, it was found that a mutation in nfxB, which replaces amino acid T with 
P at position 39, did not increase ciprofloxacin resistance by itself or in combination 
with gyrA T83I (Chapter 3, Figure 3.12 and 3.17). Variant NfxB T39P increased 
resistance by 4-fold but only when gyrA T83I and PA3491 H87P were both present 
(Figure 3.18). Two questions arose from these results. Firstly, does nfxB T39P lead to 
overexpression of efflux pump genes? Secondly, are mutations in genes nfxB and 
PA3491 dependent on each other to increase ciprofloxacin resistance through 














Figure 4.1: Graphical representation of the operon that encodes the MexCD-
OprJ efflux pump. The white boxes indicate the intergenic region.  
4.1.1 The role of the mutated nfxB gene in efflux pump overexpression and 
fluoroquinolone resistance in P. aeruginosa 
The overexpression of efflux pumps MexEF-OprN and MexCD-OprJ through 
mutations in the efflux pump-regulatory genes mexS and nfxB, respectively, has been 
associated with fluoroquinolone resistance in clinical isolates and laboratory-evolved 
P. aeruginosa (Llanes et al., 2011, Monti et al., 2013, Purssell & Poole, 2013), 
although the mutation identified in nfxB T39P did not increase resistance in 
engineered mutants (Chapter 3, Figure 3.17). Variant NfxB T39P has not been 
reported in clinical isolates of P. aeruginosa and its effect on the expression of efflux 
pump genes has not been investigated so far. Previous studies have investigated the 
effect of the inactivation of NfxB on the expression of efflux pump-encoding genes 
by deleting the nfxB gene from the genome (Bruchmann et al., 2013). An increase in 
the expression of efflux pump genes and an increase in ciprofloxacin MIC was 
observed in bacteria with the nfxB deletion. Common mutations in clinical isolates of 
P. aeruginosa that lead to varying degrees of inactivation of NfxB are frameshift 
mutations (Poole et al., 1996, Chuanchuen et al., 2001), insertion sequences (Dean et 
al., 2003) and substitution mutations (Jalal et al., 2000, Kugelberg et al., 2005). To 
our knowledge, there is no thorough study on screening of substitution mutations in 
the nfxB gene to find the strongly NfxB-inactivating mutations which result in 
overexpression of efflux pump genes, above a threshold where bacteria become 
resistant. In a study by Jalal et al., 2000, the correlation between variant NfxB R82L, 
nfxB 




expression of the efflux pump-encoding gene oprJ and the ciprofloxacin MIC was 
investigated in clinical isolates of P. aeruginosa. It was found that 16 isolates with 
ciprofloxacin MICs in the range of 0.5-8 mg/L had the NfxB R82L variant, while 8 
of these isolates did not express OprJ. This indicated that the effect of NfxB R82L is 
not fully known, and the correlation of mutations in the nfxB, the expression of 
efflux, and ciprofloxacin MIC is complex. Similarly, a study by Kugelburg et al., 
(2005) reported that 6 out of 12 norfloxacin (quinolone) resistant isolates which had 
variant NfxB, showed overexpression of mexD.  
In addition, the threshold level of MexCD-OprJ efflux overexpression which confers 
ciprofloxacin resistance and evolves antibiotic susceptible bacteria to resistant is not 
known yet. Different substitution mutations likely disrupt the function of NfxB to 
different intensities and thus lead to varying levels of overexpression of the MexCD-
OprJ efflux pump. Investigating the effect of point mutations or small deletions in 
nfxB, which are common in clinical fluoroquinolone-resistant isolates, on the 
expression of efflux pump genes and MICs will improve the predictions of antibiotic 
resistance using genome sequences. Studies on antibiotic prediction using genome 
sequences have highlighted the lack of a complete picture of an efflux pump 
mediated resistance which is hampering the progress in the development of antibiotic 
resistance prediction models (Jeukens et al., 2017). The frequency of clinical isolates 
with nfxB mutations is relatively low, which could be attributed to the high fitness 
cost of nfxB mutations (Stickland et al., 2010, Melnyk et al., 2017) and also less 
virulence (Sanchez et al., 2002). In contrast, in experimental evolution studies 
(Köhler et al., 1997, Morero et al., 2011, Wardell et al., 2019), fluoroquinolones 
frequently select nfxB mutants. Over a long period, a single antibiotic treatment 
selects nfxB mutants (Jeannot et al., 2008), indicating that the selection of nfxB 
mutants is dependent on therapy.  
4.1.2 Role of mutant PA3491 in ciprofloxacin resistance 
The high frequency of experimentally evolved mutants (11/13) had a mutation in 
gene PA3491, which has not previously been associated with antibiotic resistance 
(Chapter 2, Table 2.1). Only one mutation in PA3491, leading to H87P, was found in 




The involvement of variant PA3491 H87P in ciprofloxacin resistance was shown by 
making isogenic mutants and determining the MIC (Chapter 3). It was found that the 
resistance allele nfxB T39P and PA3491 H87P increased resistance 4-fold when 
engineered together in the gyrA T83I mutant (Figure 3.18). It was hypothesised that 
mutations in genes nfxB and PA3491 are possibly dependent on each other to 
increase ciprofloxacin resistance. 
PA3491 is reported as a probable ferredoxin in the Pseudomonas database and as an 
electron transport complex C in the NCBI database, which is involved in energy 
metabolism. PA3491 gene has a homology with rnfC from E. coli (Jouanneau et al., 
1998), which is involved in the electron transport system. However, the exact 
function of the protein encoded by PA3491 has not been experimentally 
characterised yet. The upregulation of energy metabolism-related genes has been 
shown in experimentally evolved ciprofloxacin-resistant P. aeruginosa (Su et al., 
2010) and has been hypothesised to be associated with efflux pump-related 
resistance. However, the exact role of energy-related genes in antibiotic resistance is 
not known. Previous studies have not found a direct correlation between genetic 
variations in nfxB and the overexpression of efflux pump genes and MICs (Jeannot et 
al., 2008, Dunham et al., 2010), which indicates that additional genes or regulators 
are likely involved in efflux pump-mediated resistance and need to be explored 
further.  
4.1.3 Aims of the chapter 
• To test the hypothesis that PA3491 H87P is a gain of function mutation.  
• To find the effects of resistance alleles nfxB T39P and PA3491 H87P on the 








Materials and Methods 
4.2 Materials 
4.2.1 Bacterial strains  
Table 4.1: E. coli strain used in this study  
Strain Reference 
JM83 Yanisch-Perron et al. (1985) 
ST18 Thoma &  Schobert (2009) 
 
Table 4.2: List of P. aeruginosa strains used and created in this chapter.  
Strain 
P. aeruginosa strain used in this chapter 
PAO1  Holloway (1955) 
Wardell et al. (2019) 
P. aeruginosa mutants created in this chapter  
Mutants Features 
PA3491KO In frame deletion of PA3491 gene in PAO1 
gyrA T83I + PA3491KO In frame deletion of PA3491 gene in gyrA T83I 
mutant 
gyrA T83I + PA3491KO + nfxB T39P Substitution mutation in nfxB gene to replace T to 
P, engineered in double mutant gyrA T83I + 
PA3491KO 
 
PA3491 H87P + nfxB T39P Substitution mutation in nfxB gene to replace T to 







Table 4.3: Primers used to amplify flanking DNA regions of gene PA3491 to 
delete gene PA3491 from the PAO1 genome.  
 
Table 4.4: List of primers used to carry out RT-qPCR for expression analysis of 
genes mexC and mexD. 


























56.2 This study 
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Table 4.5: Kits used for expression analysis  
Kits Suppliers 
RNA extraction RNeasy® mini kit QIAGEN 
DNase I kit  Quanta bio PerfeCTa ® 
qScript XLT cDNA SuperMix  Quanta bio 
 
Materials used for mutant construction are given in the previous chapter (Sections 
3.2.4 to 3.2.6, Tables 3.7 and 3.8)  
4.3 Methods 
4.3.1 Deletion of gene PA3491 in PAO1 strain 
Two sets of primers were designed to amplify ~1000 bp DNA region upstream from 
the start and downstream from the end of the gene PA3491, using Primer3 software 
(Rozen & Skaletsky, 2000). Primers used to delete the gene PA3491 from the wild-
type strain PAO1 and primers used to amplify the junction of the two DNA 
fragments in the cloning vector pEX18Tc are listed in Table 4.3. Usually DNA 
fragments of around 800-1000 bp are used for a high efficiency of recombination on 
either side of the gene to be deleted. The parameters of the primers used were: the 
melting temperature (Tm), the GC content, the hairpin stability, and the ΔG for 
homo- and heterodimers were analysed using the OligoAnalyzer tool from Integrated 
DNA Technologies (IDT). Criteria used to design primers are given in Section 
3.3.2.1, Chapter 3. The properties of the two sets of primers used to construct a 
mutant are outlined in Table 4.3. Screening primers PA3491KOmutFR (Table 4.3) 
were designed to give approximately 2.5 Kb PCR product if PA3491 was not 
deleted, and a 400 bp PCR if gene PA3491 was deleted. The Snapgene® software 
was used to visualise the DNA cloning.  
DNA cloning and a two-step allelic exchange method were carried out, as described 




combination with multiple mutations. See Section 3.3.2 for the methodology used for 
mutant construction.  
4.3.2 Expression analysis of genes mexC and mexD  
4.3.2.1 Primer efficiency calculations 
Primers used for RT-qPCR are listed in Table 4.4. Primers for genes clpX and oprL 
have been validated to be used as reference gene primers (Konings et al., 2013). 
Primer efficiencies were determined to ensure that all reference gene primers and 
target gene primers had similar primer efficiencies, ideally between 1.8 and 2. 
Genomic DNA (gDNA) was used to perform PCR for the calculation of primer 
efficiencies. Different dilutions of gDNA were prepared from a stock of 160 ng/μL in 
PCR water: 1 in 50, 100, 200, 500, 1000, and 5000. Reaction mixtures were prepared 
with 0.1 pmol of each of the forward and reverse primers, 5 μL of SYBR green 
master mix (LightCycler 480 SYBR green I master kit, Roche), and PCR water was 
added to make the final volume up to 7 μL. To each reaction, 3 μL of gDNA dilution 
was added. The reaction mixture was prepared on ice. Conditions for PCR used are 
given in Table 4.9 and 4.10. PCR reaction mixtures were set up using CAS 1200 
PCR Robot (Corbett Life Science). RT-qPCR was carried out in LightCycler 480 
(Roche). 
4.3.2.2 RNA extraction 
To extract the RNA from the bacterial culture, the QIAGEN RNeasy® mini kit was 
used following the manufacturer's instructions and as described below. Bacterial 
cultures were grown in LB to the logarithmic growth phase OD600 of 0.6 to 0.9.  
In one volume of bacterial culture (500 μL), 1mL of the RNA protect reagent 
provided in the QIAGEN RNeasy® mini kit was added to stabilise the RNA. The 
mixture was vortexed for 5 seconds and incubated at room temperature for 5 
minutes. This mixture was then centrifuged for 10 minutes at 8000 rpm at 4°C and 
the supernatant was discarded. In a separate tube, a mixture of TE buffer and 
lysozyme was prepared (1 mg/mL). The bacterial cell pellet was resuspended in 200 




for 5 minutes at room temperature. During the incubation, the mixture was vortexed 
every two minutes for 10 seconds. After that, 10 μL of beta-mercaptoethanol was 
added to 1 mL of the RLT buffer (the RLT contains guanidine thiocyanate for lysis), 
and the 700 μL mixture of the RLT buffer and beta-mercaptoethanol was added to 
the lysate and centrifuged at maximum speed for 2 minutes.  
The supernatant was transferred to a new 1.5 mL tube. To provide suitable binding 
conditions, 500 μL of 100% ethanol was added to the lysate and mixed by pipetting. 
Samples of volume 700 μL were loaded on the RNeasy column. RNA binds to the 
column membrane. Centrifuged for 15 seconds at a speed of 10,000 rpm, the flow-
through was discarded. This step was repeated to apply all the samples on the 
column. 
To wash the membrane of the column, the buffer RW1 (350 μL) was added to the 
column and centrifuged for 15 seconds at 10,000 rpm. The flow-through was 
discarded. In a separate tube, 70 μL of the RDD buffer was added to 10 μL aliquot of 
Qiagen DNaseI and mixed gently and spun down the mixture. Mixing was done 
gently at this step because DNaseI is sensitive to mechanical denaturation. The 
mixture of DNase I and RDD buffer was loaded directly to the column and incubated 
at room temperature for 15 minutes. Then, 350 μL of RW1 was added to the column, 
incubated at room temperature for 5 minutes, and centrifuged for 15 seconds at 
10,000 rpm. The flow-through was discarded and the collection tube and the column 
was placed in the new collection tube. Ethanol was added to the RPE buffer 
according to the manufacturer's instruction. The Buffer RPE of a volume up to 500 
μL was added to the column and centrifuged for 15 seconds at 10,000 rpm. The flow-
through was then discarded. A further 500 μL of buffer RPE was added to the 
column and centrifuged for 15 seconds at 10000 rpm, and the flow through was 
discarded.  
The column was centrifuged again for 2 minutes at 10,000 rpm to remove all the 
ethanol and the column was placed in a new tube. Then, 40 μL of RNase-free water 
was added to the column and centrifuged for 1 minute at 10000 rpm. The quality and 




values of the absorbance ratios 260/280 and 260/230. A value of 2.0 for 260/280 and 
18-2.2 for 260/230 indicates that extracted RNA is pure.  
Precautions for the handling of RNA 
Special precautions were taken to handle RNA because RNA is sensitive to 
degradation and RNases are ubiquitous. RNA work was done on a special bench 
which was designated for RNA work only. The bench was frequently sterilized with 
ethanol and RNase-inactivating agents. Disposable and RNase-free plasticware was 
used.  
4.3.2.3 Treatment of RNA with DNAase I to remove DNA contamination 
To remove any genomic DNA contaminations in extracted RNA, a DNase I Quanta 
bio PerfeCTa® DNase I kit was used. Each reaction was set up by following the 
manufacturer's instructions given below in Table 4.6. The reaction mixtures were 
prepared on ice. 
Table 4.6: DNase I treatment of RNA: Volumes and stock concentrations of reaction 







Reaction contents were mixed briefly and spun down. The reaction mixture was 
incubated at 37°C for 30 minutes. Then, 2 μL of 10X stop buffer was added and 
mixed. The mixture was incubated at 65°C for 10 minutes. Half of the DNaseI 
treated RNA (11 μL) was taken to prepare cDNA and the rest of the half was used to 
prepare RT- control.  
Reaction contents (Stock 
concentrations) 
Volumes 
RNA 2 μg 
DNase I (2U/ μL) 2 μL 
10X buffer 2 μL 




4.3.2.4 cDNA preparation 
A reverse transcription of DNase I treated RNA was carried out using qScript XLT 
cDNA SuperMix (Quantabio). Reaction mixtures were prepared by following the 
instructions provided with the kit. Concentrations and volumes of total reaction for 
cDNA preparation are given in Table 4.7. Table 4.8 shows the thermoprofile used for 
the cDNA synthesis in Bio-Rad Thermocycler. A reaction mixture without reverse 
transcriptase (RT-) was also included as a negative control. 
 
Table 4.7: cDNA synthesis: Reaction mixture to synthesize cDNA and reaction 
conditions are shown in Table 4.5. 








qScript XLT cDNA SuperMix 
(5X) 
4 - 
Water 5 9 
DNaseI treated RNA 11 11 
Total reaction volume 20 20 
 




















The cDNA was stored at -20°C.  
4.3.2.5 RT-qPCR 
LightCycler 480 SYBR green I master kit (Roche) was used to carry out RT-qPCR 
using LightCycler 480 (Roche). PCR reaction mixtures were set up in 96 well plate 
(Corning® Costar®) using CAS 1200 PCR Robot (Corbett Life Science). In each 
RT-qPCR run, one reaction mixture without cDNA was included as a negative 
control. Reaction mixture of RT- was also included to make sure that there was no 
genomic DNA contamination. The concentrations of the reagents required for RT-
qPCR reaction mixture are outlined in Table 4.9. The temperatures and duration of 
incubations for RT-qPCR are given in Table 4.10. RT-qPCR reactions were carried 

















Table 4.9: Reaction mixtures prepared to carry out RT-qPCR including negative 
controls.  
 
*Target genes were mexC and mexD  
#Reference genes were clpX and oprL  
Primers used for RT-qPCR are given in Table 4.3 
** The cDNA synthesis reaction mixture without reverse transcriptase (RT-) was prepared 
as a negative control. Amplification was not expected in PCR reaction with RT- control, if 




















0.1 μL 0.1 μL 0.1 μL 0.1 μL 
Reverse Primer 
(100 pmol/μL) 
0.1 μL 0.1 μL 0.1 μL 0.1 μL 
SYBR Green master 
mix (2X) 
5 μL 5 μL 5 μL 5 μL 
1 in 5 diluted cDNA 3 3 - - 
PCR water 1.8 μL 1.8 μL 1.8 μL 4.8 
**RT- - - 3 - 




Table 4.10: RT-qPCR reaction conditions: Temperatures and duration used to carry 
out RTqPCR on LightCycler 480. 
 
RT-qPCR Steps Temperature (°C) Time 









3.  Cycles 44 cycles to repeat from step 2 
4.  






5.  Hold 40  
 
4.3.2.6 Analysis of RT-qPCR data 
Calculations of crossing points, primer efficiencies, melting temperatures, and 
absolute and relative quantification were carried out using LightCycler 480 
thermocycler software (Roche).  
4.3.3 Potential function-altering genetic variations in gene PA3491 in clinical 
isolates of P. aeruginosa 
Genetic variations found in clinical isolates were compared with the ones found in 
environmental isolates from Wardell et al., 2019. To find function-altering genetic 
variations in the PA3491 gene in clinical isolates, the online tool 
Protein Variation Effect Analyzer (PROVEAN) (Choi & Chan, 2015) was used to 
analyse the genetic variations which were present only in clinical isolates. 
PROVEAN is a software which predicts whether an amino acid substitution or indel 
alter the function of the protein. The PROVEAN default threshold value (-2.5) was 
used to describe mutations as deleterious or neutral. Genetic variations with 
PROVEAN score less than or equal to -2.5 were considered likely to alter the protein 





4.4.1 Mutants construction 
In Chapter 2, 11 out of 13 laboratory-evolved mutants had an identical mutation in 
the PA3491 gene, leading to an amino acid change H87P (Table 2.1). This was the 
only mutation in PA3491 in independently evolved mutants, indicating that PA3491 
H87P is potentially a gain of function mutation. To test the hypothesis that PA3491 
H87P was a gain of function mutation, the PA3491 gene was deleted in PAO1 and 
the MIC of the mutant was determined. It was expected that if PA3491 H87P was a 
loss of function mutation, then the deletion of the gene would increase ciprofloxacin 
resistance. DNA cloning and a two-step allelic exchange method were used to delete 
the gene (Section 3.3.2). The schematic representation of DNA amplification (Figure 
4.2), DNA cloning (Figure 4.4) and a two-step allelic exchange are shown in Figure 
4.6.  
4.4.1.1 Amplification of DNA fragments 
To delete the gene, approximately 1000 bp flanking regions upstream and 
downstream of PA3491 gene were amplified (DNA fragments 1 and 2 respectively) 
(Figure 4.2). PCR was carried out to amplify the DNA fragments 1 and 2, using the 
method given in Section 3.3.2.2. Genomic DNA from PAO1 was used as a PCR 
template. Gradient PCR was performed to determine the annealing temperature at 
which only the expected sized DNA was amplified. Then, PCR was carried out using 
an optimised annealing temperature, and PCR products were visualized on agarose 
gel (Figure 4.3). The expected size DNA bands (1 Kb) showed that primers annealed 











Figure 4.2: Graphical representation of the genomic location of gene PA3491 
and annealing positions of primers on operon used to amplify upstream and 





Figure 4.3: Amplification of DNA fragments 1 and 2 (1kb): PCR was carried out 
using primers given in Table 4.3. PAO1 genomic DNA was used as a PCR template. PCR 
products were visualized on an agarose gel. The first lane of each gel is 1Kb plus DNA 






4.4.1.2 Cloning of DNA fragments 1 and 2 into plasmid pEX18Tc 
To clone the DNA fragment 1 in pEX18Tc, the methods in Sections 3.3.2.4 to 
3.3.2.14 were followed. Colony PCR showed an amplification of 1 Kb DNA, 
indicating that DNA fragment 1 has been ligated in the plasmid (Figure 4.5 A). After 
confirming the ligation of DNA fragment 1 into the plasmid, Sections 3.3.2.6 to 
3.3.2.14 were carried out to clone DNA fragment 2 in the recombinant plasmid 
pEX18Tc::DNA fragment 1. Colony PCR was carried out, using DNA insert 2-
specific primers (PA3491KO2FR) given in Table 4.3, to screen the colonies which 
had plasmid carrying successfully ligated DNA fragments 1 and 2. Colony PCR 
results are shown in Figure 4.5 B. The 1Kb DNA band indicated that DNA fragment 
2 was ligated in plasmid. The primer set PA3491KOmutFR amplified the DNA 
region (400bp) where the two DNA inserts joined, and confirmed that the plasmid 
has both DNA fragments 1 and 2 ligated in it (Figure 4.5 B). Colony PCR showed 
that out of 7 colonies, 5 had successfully ligated a recombinant plasmid 
(pEX18Tc::ΔPA3491) (Figure 4.5 B). 
 
Figure 4.4: Schematic representation of cloning DNA fragments 1 and 2 into 
pEX18Tc: Flanking DNA regions of PA3491 gene were ligated into vector pEX18Tc 
consecutively by restriction cloning using methods given in Section. DNA insert 1 cut with 
restriction enzymes HindIII and PstI is shown as a red bar and DNA insert 2 cut with 
restriction enzymes PstI and BamHI as a green bar. For DNA cloning pEX18Tc was used 







Figure 4.5: Analysis of recombinant plasmid (A) Gel picture of colony PCR with 
white colonies to find the colonies with the plasmid containing DNA fragment 1 (the 
approach used is shown in Figure 4.4). The first lane from the left of each gel is 1Kb plus 
DNA ladder. Colony PCR was carried out using insert-specific primers (Table 4.3) (B) Gel 
picture of colony PCR to find the colony with the recombinant plasmid containing DNA 
fragments 1 and 2 (Figure 4.4). Colony PCR with DNA fragment 2-specific primers (Table 
4.3) amplified the DNA fragments 2 (1.1kb). Screening primers amplified the junction of 
two DNA fragments (~430bp). Amplification of DNA fragment 2 and fragments junction is 
shown as 2 DNA bands (from left) lanes 3-5, 7, and 8. Plasmids carrying both DNA 
fragments 1 and 2 were sent for Sanger sequencing with DNA fragment-specific primers 













4.4.1.3 Two-step allelic exchange 
Recombinant plasmids carrying both DNA fragments 1 and 2 (shown at the end of 
Figure 4.4) were used for a two-step allelic exchange. A schematic representation of 
a two-step allelic exchange method to delete a gene is shown in Figure 4.6. To delete 
the PA3491 gene from the PAO1 genome, Sections 3.3.2.15 to 3.3.2.20 were 
followed. Colony PCR on sucrose resistant colonies with screening primers 
PA3491KOmutF and R (Table 4.3) was carried out to distinguish mutants from the 
wild type revertants (last step in Figure 4.6). The size of the PCR product using the 
screening primer set was expected to be approximately 430 bp if the PA3491 gene 
had been deleted. Wild type revertants were expected to give a PCR product of ~2.5 
kb. Sequences of an amplified product (400 bp) were aligned to PAO1 from NCBI to 
further confirm if PA3491 had been deleted. Colony PCR of two out of 9 colonies 
showed 400 bp PCR products which indicated that PA3491 gene had been deleted 
(Figure 4.7). PCR products were sent for Sanger sequencing, and sequences were 
aligned to reference the PAO1 genome sequence to further confirm the gene deletion. 
The sequence of DNA fragments from recombinant plasmids and PCR sequences 
from mutants using a screening primer (PA3491KOmutFR) were mapped on the 











Figure 4.6: Schematic representation of the two-step allelic exchange method 
(Hmelo et al., 2015) used to delete a gene. Two homologous recombination events 
occur in this process. The recombinant plasmid is integrated into the genome of P. 
aeruginosa after the first homologous recombination. To select the antibiotic resistant 
bacteria which had undergone the first homologous recombination (merodiploids), the 
antibiotic resistance marker (tetracycline) in the plasmid (pEX18Tc) was used and PCR with 
colE1 primers (Table 3.5) was carried out. Sucrose selection was carried out to select 
clones that had undergone the second recombination, and therefore were sucrose 
resistant. Colony PCR (Figure 4.7), Sanger sequencing of PCR products, and alignment to 










Figure 4.7: Screening of sucrose resistant colonies to find mutants: A two-step 
allelic exchange method was used to delete the gene (Figure 4.6). Shown is a gel picture of 
colony PCR of 12 sucrose resistant colonies using primer set PA3491KOmutFR (Table 4.3). 
Primer set PA3491KOmutFR amplified the DNA region where two DNA fragments joined. 
Lane 1 has 1Kb plus DNA ladder. The rest of the lanes have PCR products from sucrose 
resistant colonies. Lane 2-6, 9, and 12 showed PCR products of 2.5 kb size (wild type 
revertants). Lane 7 and 10 showed PCR products of ~400 bp (mutants). 400 bp PCR 


















Figure 4.8 (A). The map of sequences of pEX18Tc::DNA insert 1, 
pEX18Tc::DNA insert 2 and pEX18Tc ΔPA3491 aligned to the reference 
sequence of PAO1 from NCBI. Map was generated with Snapgene®. Red and green 
arrows represent the DNA sequences of fragments 1 and 2 in recombinant pEX18Tc on 
left and right sides, respectively. Red arrows in the centre represent the ~400 bp PCR 
product using screening primers. Filled parts of centre arrow represent the alignment to 
reference sequence PAO1 at two regions, at the start and end of the PA3491 gene. Unfilled 
arrow portions indicate the deletion of the PA3491 gene (yellow arrow in reference 
sequence). B. In-frame deletion of PA3491.  
4.4.2 Engineered mutants with combinations of mutations 
In Chapter 3, it was found that gyrA T83I was a prerequisite for the development of 
resistance. Therefore, to investigate the effect of ΔPA3491 on ciprofloxacin 
resistance, PA3491 was deleted in the gyrA T83I mutant (Figure 4.9). To construct 
the mutant with the deleted PA3491 gene and the variant gyrA T83I, 
electrocompetent E. coli ST18 were electro-transformed with a recombinant plasmid 
which had DNA fragments 1 and 2 ligated in it (pEX18Tc::ΔPA3491), and ST18 






gyrA T83I was used as a recipient. Methods given in Sections 3.3.2.15 to 3.3.2.20 
were followed to perform a two-step allelic exchange.  
Chapter 3 showed that PA3491 H87P increased resistance only in combination with 
variants gyrA T83I and nfxB T39P. Therefore, it was hypothesised that deletion of 
PA3491 (ΔPA3491) would show its effect on resistance, only in combination with 
gyrA T83I and nfxB T39P. To test the hypothesis, a mutant with a combination of the 
deleted PA3491 gene, variant gyrA T83I and nfxB T39P was constructed (Figure 
4.9), and its MIC was determined. To test the hypothesis that nfxB and PA3491 are 
dependent on each other, another double mutant was constructed which had 
mutations nfxB T39P and PA3491 H87P. PCR sequencing was carried out using 
primers given in Table 3.6 and sequences were aligned to reference sequence to 









Figure 4.9: Engineered mutants with combinations of mutations. A two-step 
allelic exchange method was used to construct the mutants. For triple mutant construction 
(left side), pEX18Tc::ΔPA3491 was prepared by DNA cloning, and the mutant gyrA T83I 
from Chapter 3 was used as a recipient. For double mutant construction (right side), 
pEX18Tc::PA3491 H87P was used to introduce PA3491 H87P  in mutant nfxB T39P (from 
Chapter 3). To identify the mutants, PCR sequencing was carried out using primers given in 




gyrA T83I + ΔPA3491 
gyrA T83I + ΔPA3491 + nfxB T39P 
nfxB T39P 




4.4.3 Effects of deleting PA3491 on ciprofloxacin resistance  
To determine the effect of deleting the PA3491 gene on ciprofloxacin resistance, the 
MIC of the ΔPA3491 mutant was measured. Deletion of the PA3491 gene did not 
increase or decrease the resistance to ciprofloxacin (Figure 4.10). The MIC of the 
double mutant with the deleted PA3491 and gyrA T83I was 1 mg/mL, which was 
equal to the MIC of the gyrA T83I mutant and the MIC of the double mutant 
containing gyrA T83I and PA3491 H87P mutations (Figure 4.10). 
PA3491 H87P increased ciprofloxacin resistance by 4-fold above the resistance 
conferred by the combination of gyrA T83I and nfxB T39P mutations (Figures 3.18 
and 4.10). In contrast, the deletion of the PA3491 gene in combination with point 
mutations gyrA T83I and nfxB T39P did not increase nor decrease the resistance 
(Figure 4.10). This result showed that a mutation which replaced the amino acid 
histidine to proline at the codon position 87 in the PA3491 gene was likely a gain of 














Figure 4.10: Comparison between the effect of the point mutation in PA3491 
gene H87P and deletion of PA3491 on ciprofloxacin resistance in P. aeruginosa: 
Ciprofloxacin MICs were determined in mg/L (shown on the y-axis) for engineered mutants 
with single and combinations of mutations (shown on the x-axis). MICs were determined by 
the double dilution method. Mutants were constructed using a two-step allelic exchange 
method. Each dot represents a biological replicate of MIC testing. An increase in resistance 
is represented with different colours of dots. Data for mutants other than those with 












4.4.4 Effects of the combination of nfxB T39P and PA3491 H87P on 
ciprofloxacin MIC 
In Chapter 3, the MIC of the engineered mutant with mutations in the genes gyrA, 
nfxB, and PA3491 was higher than the MICs of the mutants that had mutations in 
gyrA and nfxB or gyrA and PA3491 (Figure 3.18). Therefore, it was hypothesised 
that the nfxB mutation and PA3491 mutation are dependent on each other to increase 
the ciprofloxacin resistance level. 
To investigate whether combinations of mutations in genes nfxB and PA3491 
increase ciprofloxacin resistance in the gyrA wild type, nfxB T39P, and PA3491 
H87P mutations were engineered together into PAO1, and ciprofloxacin MIC was 
determined. The combination of nfxB T83I and PA3491 H87P did not increase 
resistance above that of PAO1 and single mutants nfxB T39P or PA3491 H87P 
(Figure 4.10). This was likely because of the presence of the wild type gyrA in this 
mutant (Figure 4.10).  
4.4.5 Expression analysis of efflux pump genes mexC and mexD 
RT-qPCR was carried out to investigate the effect of nfxB T39P and PA3491 H87P 
mutations individually and in combination on the expression of efflux pump genes 
mexC and mexD. RT-qPCR quantifies the transcripts of the target gene. For RT-
qPCR, RNA was reverse transcribed to cDNA, and then cDNA was used as a 
template to perform PCR using fluorescent DNA-binding dye to quantify the 
product. Relative quantification was carried out, which included amplification of 
internal control genes and target genes at the same time. Internal control or reference 
genes were used to normalise the data from different samples. The expression level 
of internal control should be the same in all the samples (mutants and the wild type). 
Relative quantification analysis was represented as ratios of the target to a reference 
signal. Ratios were compared between mutants and the wild type. The expression of 
mexCD was evaluated in seven different mutants in comparison to PAO1. The 
strategy used to perform RT-qPCR is given in Figure 4.11 and Figure 4.12. The 




PA3491 H87P. RT-qPCR was performed on RNA samples (Figure 4.11) extracted 





Figure 4.11: Experimental approach followed to carry out RT-qPCR. Different 
































Figure 4.12: Workflow for RTqPCR to analyse expression analysis of genes in different 
mutants in comparison to PAO1. 
* Data are valid if RT-qPCR crossing points for negative controls are 6 cycles higher than 
that of reactions with cDNA, one specific melting temperature (Tm) of RT-qPCR product 
per primer reaction, single band of RT-qPCR product on an agarose gel, PCR efficiencies of 
1.8 to 2. 
Extraction of RNA 
DNAaseI treatment to remove 
genomic DNA contamination 
cDNA synthesis and negative 
controls (RNA without reverse 
transcriptase) 
Preparation of cDNA dilutions  
 
Quantification of crossing points and 
normalization of data using reference 
genes clpX and oprL 
Validation of data* 
 
Relative quantification and calculation of 






4.4.5.1 Normalisation and validation of RT qPCR data 
Primer efficiencies were calculated using a range of genomic DNA dilutions by 
following the method given in Section 4.3.2.1. Primer efficiencies were between 1.8-
2 (Appendix G1-G3). PCR efficiencies were calculated using Linreg software using 
fluorescence data, and efficiencies were between 1.8-2. After ensuring that all the 
primers had similar efficiency values, RT-qPCR was carried out. RT-qPCR crossing 
points (shown in Appendix G4) were analysed for cDNA from mutants, wild type 
PAO1 and negative controls. Negative controls included RNA samples which had 
not been reverse transcribed (RT-) and water (Figure 4.11). Genes clpX and oprL 
were used as reference genes. Previously, 23 transcriptomic studies on P. aeruginosa 
showed that the expression of clpX and oprL was constant, indicating that clpX and 
oprL are good reference genes (Balasubramanian & Mathee, 2009). For almost all 
the samples, RT-qPCR crossing points for negative control were higher than for 
cDNAs by 6 cycles and above, except the crossing points for mexC in PAO1 and 
mutants without nfxB mutation. Crossing points using negative control RT- were 
higher than the cDNAs that showed there was no gDNA contamination in the 
extracted RNA (Appendix G4). To make sure that there was no non-specific or 
multiple PCR products, Tm values were calculated, and PCR products were also run 
on agarose gels (Appendix G7).  
4.4.5.2 Relative gene expression 
Consistent with previous studies (Poole et al., 2013), expressions of mexC and mexD 
were weaker in PAO1 and mutants without nfxB mutations than in nfxB mutants. 
Target to reference signal ratios are given in Appendix G5 and G6 and Figures 4.13 
and 4.14. In all mutants, the unexpected expression of mexD was higher than mexC. 
As expected, the expression of mexC and mexD in gyrA mutant or PA3491 H87P/ 
KO was similar to the expression of mexC and mexD in PAO1. The fold changes in 
the expression of mexCD in all mutants compared to PAO1 are given in Table 4.12. 
One-way ANOVA and Tukey’s HSD test was carried out and p-values were 








Figure 4.13: Effects of mutations in gyrA, nfxB, and PA3491 on the expression of 
mexC: RT-qPCR was carried out as described in Section 4.3.2.5. Expression levels (target 
to reference ratios) are shown on the y-axis. Bars represent the average value of Target: 
Reference ratios of three biological replicates, which are shown as blue dots. Each blue dot 
is an average of 2 technical replicates. Plus and minus signs denote the presence and 
absence of mutations, respectively. Gene deletion is denoted by KO. MICs for ciprofloxacin 










Figure 4.14: Effects of mutations in gyrA, nfxB and PA3491 on expression of 
mexD: RT-qPCR was carried out as described in Section 4.3.2.5. Expression levels (target 
to reference ratios) are shown on the y-axis. Bars represent the average value of 
Target/Reference ratios of three biological replicates, which are shown in blue dots. Each 
blue dot is an average of 2 technical replicates. Plus and minus signs denote the presence 
and absence of mutations, respectively. Gene deletion is denoted by KO. MICs for 
ciprofloxacin are from Figure 4.10. p-values were calculated from one-way ANOVA 
followed by Tukey’s test (post-hoc t-test) and were significant (p<0.05) between PAO1 and 







Table 4.11: Statistical analysis: Tukey’s HSD (Honestly significant difference) test p-
values for multiple comparisons of mexD gene expression between mutants and PAO1. 
Multiple comparisons between mutants 
*mexD expression p-values 
nfxB - PAO1 0.004 
gyrA, nfxB - PAO1 0.0066 
nfxB - gyrA 0.004 
gyrA, nfxB - gyrA 0.006 
nfxB - PA3491 0.005 
gyrA, nfxB - PA3491 0.008 
*Only significant p-values are given, all other comparisons were non-significant. 
 
Table 4.12: Fold difference in expression of mexCD in nfxB and PA3491 mutants compared 
to PAO1 and ciprofloxacin MICs.  





Fold change in expression of 
mexC 
relative to PAO1  
 
Fold change in expression of mexD 

























gyrAT83I 1 4 1.25 3 
2.5 
(0.080) 
1 1.3 1.28 
1.18 
(0.097) 
PA3491H87P 0.0625 1.6 - 1.8 
1.7 
(0.1) 
0.9 1.9 1.5 
1.4 
(0.29) 
nfxBT39P 0.0625 300 500 200 
333 
(88.1) 
31 66.6 42.8 
46.8 
(10.5) 
gyrA T83I + nfxB T39P 1 500 625 300 
475 
(94.6) 
28 63.3 42.8 
44.7 
(10.2) 
PA3491 H87P + nfxB 
T39P 
0.0625 469 496 894 
619.7 
(137.4) 
7 24  20 
17 
(5.1) 
gyrA T83I + nfxB T39P + 
PA3491H87P 
4 900 1250 600 
916.7 
(187.8) 
184.2 266.6 303.5 
251.4 
(35.3) 
gyrA T83I + nfxB T39P + 
PA3491KO 
1 252 583 521 
452 
(101.6) 






4.4.5.3 Effect of nfxB T39P on expression of efflux pump genes mexCD 
As expected, the mutation nfxB T39P led to an increase in the expression of mexC 
and mexD. The mexC expression was higher in mutants with only the nfxB mutation 
T39P by 333-fold, and in the mutant containing gyrA T83I plus nfxB T39P by 475-
fold, compared to both the wild-type strain PAO1 and mutants with only gyrA T83I 
or PA3491 H87P (Figure 4.13, Table 4.12 and Appendix G5). Similarly, the 
expression of mexD was higher in single and double mutants, with nfxB mutation by 
17-47-fold relative to PAO1 (Figure 4.14 and Appendix G6). A higher expression of 
efflux pump genes was thought to enhance the ciprofloxacin resistance. However, 
mutants that had only nfxB T39P and had a higher expression of mexCD did not have 
a higher ciprofloxacin resistance than PAO1, and mutants with only PA3491 H87P 
or gyrA T83I. This result suggested that to increase the resistance the expression of 
mexC and mexD is required to be even higher than that in mutants with only nfxB 
T39P. Further investigation is required to explain the lack of a phenotypic correlation 
between the increased expression of mexCD and ciprofloxacin MICs. 
4.4.5.4 Effects of a combination of nfxB T39P and PA3491 H87P on the 
expression of efflux pump genes 
To investigate the role of PA3491 H87P in ciprofloxacin resistance, expression 
analysis of mexCD in mutants with PA3491 H87P was carried out. A double mutant 
with PA3491 H87P and nfxB T39P mutations had a higher expression of mexC by 
619-fold relative to PAO1 (Figure 4.13 and Table 4.11) and by 2-fold relative to a 
mutant with only an nfxB mutation (Table 4.15). However, a mutant with a 
combination of nfxB T39P and PA3491 H87P mutations unexpectedly had 
expression of mexD less than that of a mutant with only a nfxB mutation. This 
discrepancy in results needs further investigation. In future, the expression of mexD 
in all the mutants will be assessed in more biological replicates. In addition, another 
primer set will be used to assess the expression of mexCD. The mutant with a 
combination of mutations gyrA T83I, nfxB T39P and PA3491 H87P had 
approximately 2.7 and 5- fold higher expression of mexC and mexD, respectively, 
compared with the mutant with only nfxB T39P mutation. A four-fold higher MIC of 




the mutant with only a nfxB T39P (1 mg/L) or a mutant with a combination of nfxB 
T39P and gyrA T83I could be attributed to the higher expression of the efflux pump 
genes mexC and mexD. This finding indicated that PA3491 H87P, in combination 
with nfxB T39P and gyrA T83I, increased ciprofloxacin resistance likely through the 
overexpression of the efflux pump. Another explanation of the higher expression 
levels of mexCD in the triple mutant is may be the gyrA mutation T83I. This 
mutation alters the supercoiling of DNA in bacteria (Han et al., 2012. Kugelberg et 
al, 2005). These changes in supercoiling could possibly affect the regulatory region 
of mexCD which could lead to the overexpression of mexCD. 
Variability was higher in the expression of mexC gene between different replicates 
than the expression of the gene mexD (Figure 4.13 and 4.14). Thus, to make data 
more conclusive, RT-qPCR on more replicates will be carried out in the future. 
4.4.6 Genetic variations in the PA3491 gene in clinical and environmental 
isolates of P. aeruginosa 
Expression analysis of mexC and mexD in a triple mutant has indicated the role of 
PA3491 H87P in the overexpression of efflux pump genes. However, the clinical 
relevance of genetic variations in gene PA3491 remains a question.  
Genetic variations identified in the PA3491 gene in clinical genomes (Wardell et al., 
2019) were compared with genetic variations in environmental samples. Genetic 
variations which were present only in clinical isolates were selected and their 
PROVEAN values were calculated using the web-based PROVEAN software (Choi 
& Chan, 2015) to identify variations which likely alter the function of protein. In 
total, 71 genetic variations were found in P. aeruginosa isolates in comparison to 
PAO1. Out of 71 genetic variations, 19 were present only in clinical isolates given in 
Table 4.13. Three out of 19 showed significant PROVEAN values below the 
threshold value -2.5, indicating that I42M, Q60D and A63T probably alter the 
function of PA3491. Variant PA3491 H87P had the PROVEAN value -3.907. 
Further investigations are required to find the effect of genetic variation in the 





Table 4.13: Genetic variations in PA3491 found in clinical isolates, and their 
PROVEAN values. 
Variant PROVEAN score Prediction (Cut-off= -2.5) 
A15G -0.863 Neutral 
R33H -2.029 Neutral 
I42M -2.797 Function-altering 
Q60D -3.848 Function-altering 
A63T -2.826 Function-altering 
A112D -1.514 Neutral 
R120H -1.88 Neutral 
V302I -0.032 Neutral 
A317T -2.485 Neutral 
A457E -0.818 Neutral 
R466D -2.178 Neutral 
A485T -1.266 Neutral 
D586G -0.612 Neutral 
M600I 0.004 Neutral 
 
4.4.7 PA3491 homology model  
To predict the function of PA3491 and to evaluate the effect of mutations on the 
structure, a homology model was made using Phyre2 (Kelley et al., 2015). The 
PA3491 sequence was matched to an oxidoreductase which was a Na+ translocating 
NADH-quinone 2 reductase subunit A from Vibrio cholerae with 56% coverage and 
100% confidence over the first approximately 430 residues (Table 4.14). These N-
terminal residues matched to subunit A of a Na+ translocating NADH-quinone 2 
reductase (Figure 4.15) and the predicted structure is shown in Figure 4.16. The 
remainder of the sequence did not have a strong match and was not modelled, 







Table 4.14: Intensive search on Phyre2 for PA3491 homology model: Parts of 


















Amino acid Coverage Confidence Modelled to Organism 
4-438 56 100 
Na+ translocating NADH: 
Ubiquinone 2 oxidoreductase 
Vibrio cholerae  
119-442 41 100 




113-447 43 100 
NADH dehydrogenase 
(ubiquinone) flavoprotein 
mammalian respiratory complex I 
- 
522-731 27 97.2 Essential protein pcsb  
Streptococcus 
pneumoniae  
523-757 30 96.8 
DNA binding protein 
chromosome partition protein 






Figure 4.15: Prediction of the secondary-structural elements of PA3491. The known 
secondary structure of Na+ translocating NADH: Ubiquinone 2 oxidoreductase of Vibrio 













Figure 4.16: Homology model of PA3491 protein in P. aeruginosa using Phyre2. 
The amino acid sequence of PA3491 (4-438) modelled to Na+ translocating NADH-quinone 
reductase subunit A oxidoreductase of Vibrio cholerae, with 100% confidence and 56% 














In Chapter 3, it was found that PA3491 H87P increased ciprofloxacin resistance in 
combination with nfxB T39P and gyrA T83I. To further investigate the role of PA3491 
H87P in ciprofloxacin resistance, the PA3491 gene was deleted and MIC was 
determined. The deletion of PA3491 did not alter ciprofloxacin resistance, indicating 
that PA3491 H87P is probably a gain of function mutation (Figure 4.10).  
The effects of nfxB T39P and PA3491 H87P mutations on the expression of efflux 
pump genes mexC and mexD were evaluated. The gene nfxB encodes the negative 
regulator NfxB of the efflux pump-encoding genes. nfxB T39P led to an increase in 
the expression of mexC and mexD, but did not increase the resistance to ciprofloxacin 
when present individually or in combination with gyrA T83I (Figure 4.13 and 4.14). 
The PA3491 H87P in combination with nfxB T39P and gyrA T83I further increased 
the expression of mexC and mexD (Figure 4.13 and 4.14), which is likely the reason 
that the mutant with PA3491 H87P, nfxB T39P, and gyrA T83I had a higher resistance 
than the mutant with only nfxB T39P and gyrA T83I.  
4.5.2 The nfxB T39 mutation increased the expression of efflux pump genes but 
not ciprofloxacin resistance  
To find the effects of mutations in gene nfxB on the expression of efflux pump genes 
mexC and mexD, RT-qPCR was carried out. The RT-qPCR results showed that nfxB 
T39P led to an increase in the expression of mexC and mexD (Figures 4.13 and 4.14). 
However, nfxB T39P did not increase the resistance when present individually or in 
combination with gyrA T83I. This result was contrary to previous studies. An 
overexpression of the efflux pump MexCD-OprJ genes is attributed to mutations in 
the regulatory gene nfxB (Shiba et al., 1995, Poole et al., 1996). An overexpression of 
the efflux pumps MexCD-OprJ and MexEF-OprN has been associated with 
fluoroquinolone resistance in P. aeruginosa (Reinhardt et al., 2007, Jeannot et al., 
2008, Morita et al., 2015), in contrast to this study. However, a mutation that leads to 
the replacement of T to P at the 39 codon position has not been reported in clinical 




mutations nfxB T39P and PA3491 H87P in the triple mutant than in the nfxB T39P 
mutant correlated with the increase in the MIC. 
The lack of a phenotypic correlation between the expression of mexCD and MICs 
could be attributed to three possibilities. Firstly, translation efficiency has not been 
investigated, and it is not known if the same amount of protein has been made as the 
number of transcripts. Secondly, efflux pumps are overexpressed, but probably not 
active enough to efflux the antibiotic out from the P. aeruginosa cells to avoid the 
effect of the antibiotic and increase the resistance. Thirdly, it is not known how much 
overexpression of mexCD is required to increase the resistance to ciprofloxacin. 
The expression of mexD was higher than mexC in all mutants. Possible explanations 
for the increased mexD expression are that the region of the gene assessed in this study 
possibly transcribed more efficiently than the rest of the gene. A 160 bp region of the 
mexD gene was reverse transcribed and quantified by RT-qPCR, assuming that the 
transcription occurs uniformly throughout the entire gene. However, the accuracy of 
this assumption is unknown. To investigate this ambiguity, another primer set could 
be designed to amplify some other region of mexCD genes to reverse transcribe and 
quantify. Another possible explanation is that the number of transcripts of mexC and 
mexD are different, but possibly equal amounts of both proteins MexC and MexD were 
produced.  
4.5.3 Different mutations lead to variable levels of increased expression of efflux 
pump genes 
A wide range of nfxB point mutations have been reported, and it has been highlighted 
that it is complicated to correlate different nfxB point mutations with an overexpression 
of MexCD-OprJ-encoding genes and MICs (Jeukens et al., 2017). Different mutations 
in nfxB lead to different levels of overexpression of efflux pump genes (Purssell & 
Poole, 2013). However, how much overexpression is required for the development of 
resistance in bacteria remains a question.  
The effect of a T39P amino acid change in NfxB on ciprofloxacin resistance was 
investigated by engineering a mutation in PA14 (Melnyk et al., 2017), and it was found 




This difference could be attributed to the difference in the genetic background of PA14 
and PAO1. Ciprofloxacin MIC of PA14 used in a study by Melnyk et al., 2017 was 
0.5 mg/L which is 8-fold higher than the MIC of PAO1. The MIC differences between 
PAO1 and PA14 indicate underlying genotypic differences. Different genetic 
backgrounds of mutant nfxB T39P could result in different MICs. 
In previous studies, mutants were constructed to find the effect of the inactivation of 
NfxB on ciprofloxacin resistance, by deleting the nfxB gene (Bruchmann et al., 2013), 
which led to an increase in resistance. Deleting the nfxB gene led to the overexpression 
of efflux pump genes higher than that of a point mutation in the nfxB gene, depending 
on the position of the point mutation in the gene. The mexC expression in the clinical 
strain with genetic variation in the nfxB gene leading to amino acid replacement at the 
codon position 38 Ala to Val was lower by 1.5- to 3.5-fold than that in strains with 
disrupted nfxB genes (gene with insertions). This indicates that NfxB A38V only 
moderately affects the ability of NfxB to bind to the promoter region of mexCD-oprJ 
and repress its expression (Jeannot et al., 2008). Antibiotic resistance was lower in the 
clinical strain with NfxB A38V than other strains that had a disruption in the nfxB gene 
with insertion sequences. 
The amino acid change T39P analysed in this Chapter lies in the proposed DNA 
binding motif region where NfxB interacts with DNA (Monti et al., 2013, Purssell & 
Poole, 2013). The N-terminal region from residues R21 to F43 is likely the DNA-
binding region in the NfxB dimer (Monti et al., 2013) (Appendix H). Since proline 
acts as a structural disruptor of regular secondary structure elements such as α-helices 
(O'Neil & DeGrado, 1990), these changes could alter protein folding or structure 
which, in turn, could alter how the channel interacts with DNA and hinder DNA 
binding (figure adapted from (Purssell & Poole, 2013).  
A study by Purssell & Poole (2013), aimed to find mutations in nfxB that affect the 
function of NfxB. The nfxB mutants were spontaneously selected after exposure to 
erythromycin. NfxB mutations that were selected under the exposure of treatment also 
showed an overexpression of mexD and multidrug resistance. The nfxB mutants were 
then reconstructed and introduced in the P. aeruginosa strain K1542. It was shown 




fold), and the deletion of nfxB had the highest level of the overexpression of mexD 
(400-fold compared to wild type).  
4.5.4 Correlations of genotype to efflux-mediated resistance are complex  
Studies on clinical isolates have shown that a combination of target site mutations and 
efflux regulator gene mutations are associated with high ciprofloxacin resistance 
(Higgins et al., 2003, Dunham et al., 2010, Esquisabel et al., 2011, Wong & Kassen, 
2011, Bruchmann et al., 2013). An analysis of multiple isolates of P. aeruginosa from 
two mechanically ventilated patients at different time points was carried out during the 
course of treatment with ciprofloxacin (Reinhardt et al., 2007) and identified 
molecular determinants of antibiotic resistance selected in patients through whole-
genome sequence analysis. Ciprofloxacin resistance emerged after 10 days and nfxB 
mutants were evolved. With the occurrence of nfxB mutations, bacteria evolved from 
being susceptible to intermediate and then intermediate to resistant, based on 
breakpoints defined by the Clinical Laboratory Standards Institute (CLSI) (Reinhardt 
et al., 2007). Fluoroquinolone intermediate and fluoroquinolone-resistant isolates had 
a 20-fold higher expression of efflux pump genes than fluoroquinolone susceptible 
isolates (Reinhardt et al., 2007). In another study, the overexpression threshold 
required to change an antibiotic-susceptible to a resistant P. aeruginosa was reported 
as a 70-fold increase in the expression of mexC (Dumas et al., 2006). However, our 
study showed an increase in MIC with a 900-fold and 250-fold increase in mexC and 
mexD expressions, respectively, relative to that in PAO1 (Figures 4.13 and 4.14). One 
possible explanation of the variability in fold increase in the expression of efflux pump 
genes required to effect MIC, could be because across the literature, most of the 
expression analysis was carried out on the clinical isolates (Dumas et al., 2006, 
Reinhardt et al., 2007). In clinical isolates, it is hard to pinpoint if antibiotic resistance 
was because of the overexpression of efflux MexCD-OprJ or additional genes were 
involved in resistance. The relative contribution of efflux-mediated resistance to target 
modification-associated resistance is complex and strain-specific (Dunham et al., 
2010). Expression levels of efflux pump genes and resistance were not consistent with 




A one-to-one correlation between different nfxB point mutations in engineered 
mutants, the overexpression of efflux pump genes, and ciprofloxacin MICs have not 
been investigated in detail. Genotype-to-phenotype correlations in clinical isolates 
have been considered complex in the past (Wolter et al., 2009, Li & Plésiat, 2016). In 
particular, studies on antibiotic resistance prediction using genome sequences have 
highlighted the complexities of efflux-mediated resistance as one of the factors 
limiting the accuracy of predictions (Bruchmann et al., 2013, Suzuki et al., 2014, Kos 
et al., 2015, Jeukens et al., 2017).  
4.5.5 PA3491 H87P increased resistance probably through an overexpression of 
efflux pump genes in combination with nfxB T39P 
The triple mutant with mutations in gyrA, nfxB, and PA3491 had a higher MIC than 
the mutant with mutations in only gyrA and nfxB (Figure 3.18). The triple mutant with 
gyrA T83I, nfxB T39P, and PA3491 H87P had a higher expression of efflux pump 
genes mexCD than single and double mutants (Figure 4.13 and 4.14), indicating that 
PA3491 H87P is involved in the increase in expression of efflux pump genes and 
increases ciprofloxacin resistance. The gene PA3491 has been reported as a probable 
ferredoxin in the Pseudomonas database (www.Pseudomonas.com). A homology 
model of PA3491 generated by Phyre2 is shown in Figure 4.16, and sequence and the 
secondary structure alignment is shown in Figure 4.15. The amino acid sequence of 
PA3491 was modelled to the Na+ translocating NADH-quinone reductase subunit A 
oxidoreductase of Vibrio cholerae. The involvement of energy-related genes 
putatively encoding succinate-semialdehyde dehydrogenase and methylmalonate-
semialdehyde dehydrogenase in antibiotic resistance has been reported previously (Su 
et al., 2010). However, the role of PA3491 H87P in ciprofloxacin resistance is not 
fully known, and the mechanism by which PA3491 H87P leads to an increase in the 
expression of efflux pump genes remains a question. It is also possible that the 
increased production of other efflux pumps, such as MexEF-OprN or non-genetic 






4.6 Conclusions and future perspective  
In conclusion, nfxB T39P resulted in the enhanced expression of mexCD but did not 
increase ciprofloxacin resistance, suggesting that an increase in the efflux pump 
expression did not sufficiently reduce the concentration of ciprofloxacin inside the cell 
to affect the MIC. There is a need to screen the different genetic variations in the nfxB 
gene to identify the ones which lead to the overexpression of efflux pump genes to the 
level where bacteria become resistant, and increase resistance to the antibiotic. The 
involvement of PA3491 H87P in the overexpression of efflux pump genes mexCD and 
its association with ciprofloxacin resistance has been shown for the first time. In the 
future, it will be important to find the role of this gene in clinical isolates and further 
investigations are needed to find out how PA3491 H87 leads to the enhanced 
expression of efflux pump genes. The deletion of mexCD genes in double and triple 
mutants and the determination of MIC will provide further information on the role of 





































P. aeruginosa causes a wide range of infections and with the rapid emergence of 
antibiotic resistance in P. aeruginosa, it has become a serious problem clinically. 
Ciprofloxacin is a routinely prescribed antibiotic for the treatment of P. aeruginosa 
infections. P. aeruginosa becomes resistant by acquiring mutations (López-Causapé 
et al., 2018). This study aimed to investigate the spectrum of mutations associated with 
ciprofloxacin resistance in P. aeruginosa, to investigate the effects of individual and 
combinations of mutations on ciprofloxacin resistance, and to predict ciprofloxacin 
resistance in the clinical isolates of P. aeruginosa, using genome sequences. The role 
of the mutation PA3491 H87P that has not previously been associated with 
ciprofloxacin resistance was also investigated.  
P. aeruginosa laboratory reference strain PAO1 was evolved independently to 13 
highly ciprofloxacin-resistant mutants, using the antibiotic gradient agar plate method 
(Figure 2.1). To find the mutations associated with ciprofloxacin resistance, whole-
genome sequence analysis, and MIC testing of experimentally evolved mutants were 
carried out. Mutants with maximum ciprofloxacin resistance from each of the 13 
evolved lines had acquired mutations in the ciprofloxacin-target encoding genes gyrA, 
parC, and parE, in the negative regulator gene of MexCD-OprJ efflux pump nfxB, in 
the unknown function protein-encoding gene PA3491, and in any one of the pil genes 
(Table 2.1). Analysis of the intermediate ciprofloxacin-resistant mutants showed that 
mutations were acquired stepwise, which resulted in the evolution towards a high level 
of ciprofloxacin resistance in P. aeruginosa (Figure 3.2 and Appendix B2).  
The effects of individual and combinations of mutations on ciprofloxacin resistance 
were assessed by engineering mutations into PAO1 genome. The MICs of engineered 
mutants revealed that not all the tested ciprofloxacin resistance-associated mutations 
confer resistance individually (Figure 3.12). Only gyrA T83I conferred resistance 
individually, indicating that the gyrA T83I mutation was a prerequisite for the 
development of ciprofloxacin resistance. The MICs of mutants with combinations of 
other mutations with gyrA T83I showed that other mutations further increase 
ciprofloxacin resistance (Figures 3.17 and 3.21, Table 3.14). Increased resistance with 




in the development of a high level of ciprofloxacin resistance. The MIC data of 
engineered mutants was used to set the criteria to predict the ciprofloxacin resistance 
profiles (predicting isolates as sensitive or resistant) and MICs in the isolates of P. 
aeruginosa, based on the presence of analysed mutations in their genomes (Table 
3.15). Predicted MICs (MICs based on genotypes) and actual MICs (MICs determined 
by a double dilution method) of clinical P. aeruginosa isolates were compared. 
Ciprofloxacin resistance profiles and MICs were predicted correctly for a high 
proportion (71%) of clinical isolates (Tables 3.16 and 3.17). Furthermore, the 
expression of efflux pump genes mexCD was assessed in engineered mutants 
containing nfxB and PA3491 mutations individually and in combination (Figures 4.13 
and 4.14). The mutation nfxB T39P increased the expression of mexCD but did not 
increase ciprofloxacin resistance by itself. The PA3491 mutation in combination with 
mutations in gyrA and nfxB increased the expression of mexCD, and increased 
ciprofloxacin resistance. Overall, the findings of this study increased insight into the 
genetic basis of ciprofloxacin resistance development in P. aeruginosa. 
5.2 Ciprofloxacin resistance-associated genetic variations 
Whole-genome sequence analysis showed that gyrA was the most frequently mutated 
gene in experimentally evolved mutants (13/13) (Table 2.1). A higher frequency of 
gyrA T83I than other mutations in experimentally evolved mutants was consistent with 
previous studies on fluoroquinolone-resistant isolates of P. aeruginosa from CF and 
non-CF infections (Lee et al., 2005, Pasca et al., 2012, Bruchmann et al., 2013, Yang 
et al., 2015) and with other experimental evolution-based studies (Wong et al., 2012, 
Jorgensen et al., 2013, Cabot et al., 2016, Feng et al., 2016, Melnyk et al., 2017). In 
addition to gyrA, the genes nfxB (12/13) and parC (6/13) were frequently mutated in 
experimentally-evolved mutants. The nfxB encodes a negative regulator of the efflux 
pump MexCD-OprJ, and parC encodes the secondary target protein topoisomerase IV 
subunit. These genes have been associated with ciprofloxacin resistance in clinical 
isolates and other experimental evolution-based studies (Rehman et al., 2018). 
Consistency between frequencies of mutations in multiple genes gyrA, nfxB, parC, and 




other studies, indicated that the method used for experimental evolution has parallels 
with the evolution of ciprofloxacin resistant P. aeruginosa clinical isolates. 
However, experimentally-evolved mutants in this study did not have mutations in 
genes gyrB, CPA2 (Feng et al., 2016), pmrB (Cabot et al., 2016) and orfN (Wong et 
al., 2012) that were reported in experimentally-evolved mutants in previous studies 
reviewed in Rehman et al. (2018). Out of these, the roles and clinical relevance of 
mutations in CPA2, pmrB, and orfN are not yet known, while gyrB is frequently found 
in fluoroquinolone-resistant clinical isolates (Bruchmann et al., 2013, Wang et al., 
2014, Yang et al., 2015). This result indicated that the analysis of only experimentally-
evolved mutants was not enough to identify the complete set of ciprofloxacin 
resistance-associated genes. The role and clinical relevance of ciprofloxacin 
resistance-associated genes which were found through an analysis of experimentally-
evolved mutants were assessed using the PROVEAN analysis (Wardell et al., 2019). 
A higher proportion of clinical isolates likely had function-altering differences in 
genes (gyrA, nfxB, parC, and parE) (Table 2.2) than environmental isolates. Also, all 
laboratory-evolved mutants, except one, had a single mutation in the gyrA gene T83I, 
a contrast to previous studies (Wong et al., 2012, Cabot et al., 2016), indicating a 
strong association of gyrA T83I with ciprofloxacin resistance. 
Mutations in parE, PA3491, and pil genes, and gyrA novel mutations leading to the 
amino acid change gyrA G81C and S612L were identified in experimentally-evolved 
mutants, which have not been reported in previous experimental evolution studies 
reviewed in Rehman et al. (2018). Among these genes, parE is known to be associated 
with fluoroquinolone resistance in clinical isolates (Akasaka et al., 2001, Lee et al., 
2005), although genetic variations in parE are usually present in lower frequencies in 
clinical isolates (Wang et al., 2014, Rehman et al., 2018). A mutation in gene PA3491 
which encodes probable ferredoxin was found in 11/13 experimentally-evolved 
mutants and has not been associated with ciprofloxacin resistance previously.  
Differences in results between this study and previous experimental evolution-based 
studies could be attributed to the different methods used for experimental evolution 
(Figure 2.1). Previously, experimental evolution has been carried out in L-broth and 




ciprofloxacin-resistant mutants in some studies (Wong et al., 2012, Melnyk et al., 
2017), while in this study, PAO1 was experimentally evolved to ciprofloxacin-
resistant mutants, using an antibiotic gradient agar plate method with alternating 
exposure to L-broth without antibiotic ciprofloxacin. PAO1 is more antibiotic sensitive 
than other reference strains (Cullen et al., 2015). This indicated that different 
environments provided to bacteria and the genotype of the parent strain could result in 
the selection of a variable spectrum of mutations associated with resistance.  
The experimental evolution method used in this study with an intermittent passaging 
of mutants with and without antibiotic selected mutants with mutations that probably 
have a higher antibiotic resistance and a low fitness cost (Buckling et al., 2007, Melnyk 
et al., 2017). Mutants with mutations conferring high resistance were selected under 
antibiotic exposure and out of these mutations, low fitness cost mutations persisted in 
the absence of an antibiotic towards the final steps of experimental evolution. Any 
mutant with mutations which were fitness costly probably did not get selected in the 
absence of an antibiotic (Melnyk et al., 2017). 
5.3 Development of resistance in the experimentally-evolved mutants 
of P. aeruginosa 
The analysis of experimentally evolved intermediate mutants showed the stepwise 
increase in resistance with the accumulation of mutations (Figure 3.2) and led to the 
identification of ciprofloxacin resistance associated genes that have not previously 
been strongly associated with resistance. 
5.3.1 Stepwise increase in ciprofloxacin resistance 
Experimental evolution was carried out to evolve 13 independent ciprofloxacin-
resistant P. aeruginosa lines from the parental strain PAO1. Mutants were selected and 
stored from every successive step of experimental evolution and MIC testing was 
carried out. As expected, the ciprofloxacin resistance level increased at almost every 
step of the experimental evolution (Appendix B1). Mutations were acquired 
sequentially, which resulted in the enhancement of resistance through the evolution 




ciprofloxacin resistance indicated that ciprofloxacin resistance evolution is a 
multifactorial process.  
Genome analysis and MICs indicated the association of mutations in parC and parE 
with a higher level of ciprofloxacin resistance, which is consistent with other studies 
on the clinical isolates of P. aeruginosa (Jorgensen et al., 2013, Rehman et al., 2018) 
and other bacterial species (Belland et al., 1994, Georgiou et al., 1996). Gyrase A is 
the primary target of ciprofloxacin, and topoisomerase IV is a secondary target; 
therefore, parC mutations increase the resistance only in later steps when gyrA is 
mutated (Nouri et al., 2016).  
In agreement with previous experimental evolution studies (Cabot et al., 2016, Melnyk 
et al., 2017), some mutations selected at an early step of experimental evolution did 
not persist and were not found in mutants from the subsequent step of experimental 
evolution (Figure 3.2). One possible explanation could be the alternating environment 
provided to bacteria (with and without antibiotics). Mutations that increase resistance 
are selected when bacteria are exposed to the antibiotic. If such mutations have high 
fitness costs, it is more likely that in the absence of antibiotics, bacteria containing 
high fitness cost mutations could evolve to get rid of costly mutations. A ciprofloxacin-
resistant mutant became re-sensitive to ciprofloxacin when grown in LB without an 
antibiotic through multiple passages (Yen & Papin, 2017).  
Another explanation could be that the antibiotic resistance colony picked from the 
gradient plate (Figure 2.1) was not pure (bacteria with different genotypes) and was 
picked and grown in LB without an antibiotic. Bacteria with a better genotype (high 
resistance-conferring mutations which did not have a fitness cost) likely outcompeted 
the less-fit bacteria with other genotypes (missing mutations in Figure 3.2).  
5.3.2 Additional genes associated with ciprofloxacin resistance 
Mutations in a few genes that have not been strongly associated with ciprofloxacin 
resistance previously, increased ciprofloxacin resistance in this study. The tpiA gene 
which encodes triosephosphate isomerase (Figure 3.2 and Appendix B1) has been 
associated with antibiotic resistance (Cabot et al., 2016). The tpiA mutation has been 




al., 2010). Other genes that increased resistance were ssg and pilT that encode cell 
surface sugar biosynthetic glycosyltransferase ssg and twitching motility protein PilT, 
respectively. Mutations in pil genes have been recently associated with ciprofloxacin 
resistance in experimentally evolved mutants (Ahmed et al., 2018). However, the role 
of mutations in the genes tpiA, pil, and ssg in ciprofloxacin resistance is not clear yet, 
and have not been frequently found. These additional genes found through the analysis 
of experimentally evolved mutants highlighted the potential of experimental evolution 
and whole-genome sequence analysis to identify novel antibiotic resistance-associated 
genes. The quantification of resistance associated with mutations in ssg, tpiA, and pil 
genes by engineering mutants and determining their MIC will further confirm their 
association with resistance. Future studies will include these gene mutations in the 
analysis of clinical isolates genomes for the prediction of ciprofloxacin resistance.  
Taken together from this Section, the effects of the accumulation of mutations on 
resistance and limited possible evolutionary trajectories (Figure 3.2) indicated epistatic 
interactions between genes associated with antibiotic resistance (Wong, 2017). In 
addition, the consistency of MICs between experimentally evolved and engineered 
mutants validated the quantification of resistance conferred by the combination of 
mutations. The involvement of epistatic interactions between mutations in the 
experimental evolution of fluoroquinolone-resistant Francisella (Sutera et al., 2014), 
Streptococcus pneumoniae (Zhang et al., 2015), and Legionella pneumophila 
(Almahmoud et al., 2009) has been observed previously. Epistatic interactions may 
have constrained the number of possible evolutionary trajectories of ciprofloxacin-
resistant bacteria. The limited number of evolutionary trajectories suggested that the 
evolution of ciprofloxacin resistance is probably predictable. Due to this predictability, 
chemotherapeutics could be designed accordingly in advance. For example, antibiotic 
dosages could be set based on the quantification of resistance conferred by mutations.  
5.4 GyrA variants are responsible for the majority of ciprofloxacin 
resistance  
All the experimentally evolved mutants with maximum ciprofloxacin resistance had 
mutations in gyrA, with gyrA T83I being the most frequent amino acid variation 




resistant P. aeruginosa isolates from CF patients (Yonezawa et al., 1995, 
Mouneimne et al., 1999, Wydmuch et al., 2005) and laboratory-evolved mutants 
(Wong et al., 2012, Cabot et al., 2016, Melnyk et al., 2017). Mutation in gyrA 
disrupts the interaction between ciprofloxacin and its target protein gyrase subunit A 
(Figures 1.2 and 1.3). The gyrA T83I has been strongly associated with ciprofloxacin 
resistance for decades in several bacterial species (Conrad et al., 1996, Weigel et al., 
1998), including P. aeruginosa (Kureishi et al., 1994).  
Three different gyrA mutants were constructed and MICs were determined in this 
study (Figure 3.11). The MIC of engineered mutant gyrA T83I (1 mg/mL) showed 
that T83I confers a higher advantage of ciprofloxacin resistance compared to gyrA 
D87G and gyrA D87N. Based on the EUCAST breakpoints (www.eucast.org), P. 
aeruginosa isolates with ciprofloxacin MIC of 0.5 and above 0.5 are resistant. 
Therefore, gyrA T83I leads to a clinical level of resistance in P. aeruginosa PAO1. 
The MICs of engineered mutants were used to predict ciprofloxacin resistance in the 
clinical isolates of P. aeruginosa from genotypes. The clinical isolates with gyrA 
T83I and without any other of the analysed resistance alleles were predicted to have 
an MIC of 1 mg/mL and to be clinically resistant.  
Twenty-eight out of 57 ciprofloxacin-resistant isolates had resistance allele gyrA 
T83I with no other analysed resistance alleles (Tables 3.16 and3.17). Twelve out of 
twenty-eight isolates were predicted correctly to be resistant and to have an MIC of 1 
mg/L. Consistent with this result, the isolates with gyrA genetic variation 163/198 
were designated as resistant in another study (Kos et al., 2015). Four out of 28 
isolates with only gyrA T83I had MIC higher than predicted (more than 1 mg/L) 
which indicated that there are likely additional genes or genetic variations involved 
in ciprofloxacin resistance and further investigations are needed. Higher actual MIC 
than predicted MIC of isolates with only gyrA T83I could be because gyrA T83I on 
different genetic backgrounds leads to different fold increases in resistance. These 
isolates may have a higher expression of multiple efflux pumps than in PAO1. 
Therefore, higher MICs of isolates containing only gyrA T83I than predicted could 




Twelve isolates with only gyrA T83I were incorrectly predicted as resistant and had 
MIC 4-fold less than predicted in the range of 0.05-0.25 mg/L (Table 3.15). No 
resistance in isolates containing only gyrA T83I genetic variations is likely due to the 
low expression level of efflux pumps’ genes in these isolates compared to that in 
PAO1. Another explanation is that the isolates are usually treated with a combination 
of antibiotics and resistance to other antibiotics (such as aminoglycosides which 
could lead to collateral sensitivity to ciprofloxacin) or the MICs are wrong. In future 
studies, the MIC testing will be repeated for isolates that did not have actual MICs 
the same as predicted.  
Overall, antibiotic resistance was predicted correctly in the majority of isolates with 
and without gyrA T83I (Table 3.16). These results indicated that gyrA variants are 
the primary determinant of ciprofloxacin-resistance in clinical isolates, however; it is 
not the only primary determinant of resistance. Isolates with gyrA mutation that 
showed higher actual MICs than predicted, likely have additional resistance alleles 
(i.e., resistance alleles in genes other than known ciprofloxacin resistance-associated 
genes) and their association with resistance is yet to be explored.  
Overall, from Section 5.4, gyrA genetic variations leading to amino acid replacement 
at 83 majorly confer ciprofloxacin resistance, but not in all cases, and this variation is 
not singly responsible for the high level of resistance.  
5.5 Topoisomerase IV variants enhance ciprofloxacin resistance  
Other than gyrase, ciprofloxacin also targets topoisomerase IV subunits A and B 
encoded by genes parC and parE. A higher frequency of laboratory-evolved mutants 
in this study had a mutation in parC compared to parE (Table 2.1) which is 
consistent with reported studies on clinical isolates (Wang et al., 2014, Yang et al., 
2015). Mutants in other experimental evolution based studies did not have a mutation 
in parE, which might be either because of the difference in the resistance level 
achieved in other studies (Drago et al., 2005, Jorgensen et al., 2013, Cabot et al., 
2016) compared to this study, or it might be because of the difference in 
experimental evolution methods or the number of mutants studied. The most frequent 




mutants was S87L, indicating that ciprofloxacin likely interacts with amino acid S at 
the 87 codon position of the ParC protein. Possibly any other amino acid changes in 
ParC do not give the bigger advantage of resistance compared to resistance from the 
ParC variant S87L or have a high fitness cost. It will be interesting to investigate if 
experimental evolution under fluoroquinolones other than ciprofloxacin leads to the 
selection of parC S87L at a high frequency or if different ParC variants would be 
selected. If other fluoroquinolones select ParC variants other than S87L, then these 
fluoroquinolones could potentially be effective against resistant clinical isolates 
containing ParC S87L. Minor changes in the structure of ciprofloxacin might result 
in the interaction of ciprofloxacin with amino acids other than S87, which could 
enhance the activity of ciprofloxacin against ciprofloxacin-resistant P. aeruginosa.  
Only one ParE amino acid change V460G was found in 3/13 experimentally-evolved 
mutants (Table 2.1). In contrast, a diverse range of mutations in parE has been 
reported in clinical fluoroquinolone-resistant P. aeruginosa (Wang et al., 2014). 
Based on the similarity between gyrase and topoisomerase IV and conserved key 
amino acid residue, it is thought that ciprofloxacin interacts with topoisomerase IV in 
the same way as it interacts with Gyrase; however, diverse mutations in parE 
indicated that there is no specific amino acid that strongly interacts with 
ciprofloxacin. The binding site of ciprofloxacin to topoisomerase IV is not 
completely known yet.  
The parC and parE mutations have been associated with high ciprofloxacin 
resistance in clinical isolates (Nouri et al., 2016). The sequencing of experimentally-
evolved intermediate mutants (Figure 3.2) showed that parC S87L or parE V460G 
were selected after a gyrA mutation which leads to an increase in resistance by 8-
fold, indicating that parC S87L and parE V460G increase resistance only in 
combination with gyrA T83I. The quantification of resistance associated with parC 
S87L showed that it does not increase resistance in the absence of a gyrA T83I 
mutation (Figure 3.12), which is consistent with the previous study (Bruchmann et 
al., 2013). This could be the reason that there were no clinical isolates with a 
mutation in parC only, as analysed in this study consistent with other studies (Yang 




resistant to fluoroquinolones with parC mutations only (Kos et al., 2015, Nguyen et 
al., 2018). However, the analysis was not extended to find out if resistance in clinical 
isolates was because of the parC mutation.  
In combination with gyrA T83I, parC S87L and parE V460G enhanced the 
ciprofloxacin resistance above the resistance conferred by gyrA T83I in engineered 
mutants (Figure 3.17). The MICs of engineered quadruple mutants containing 
mutations gyrA T83I, nfxB T39P, PA3491 H87P, and parC S87L/parE V460G 
showed that gene-gene interactions between ciprofloxacin resistance-associated 
genes are involved in the evolution of ciprofloxacin resistance. Furthermore, this 
finding indicated that ciprofloxacin resistance development is a complex and 
multifactorial process. An increase in resistance with parC and parE mutation above 
gyrA T83I was similar to other studies on clinical isolates of P. aeruginosa 
(Mouneimne et al., 1999, Le Thomas et al., 2001, Lomholt & Kilian, 2003, Cho et 
al., 2014, Wang et al., 2014, Nouri et al., 2016) and engineered mutants (Bruchmann 
et al., 2013). However, different fold increases with parC and parE mutations were 
observed on different genetic backgrounds (Figure 3.17 and 3.21). The same parC 
mutation engineered into different clinical isolates increased the resistance with 
different folds (Agnello et al., 2016).  
Based on the MICs of an engineered mutant with gyrA and parC mutations, a 
criterion was set for the prediction of MICs in clinical isolates. Isolates with genetic 
variations gyrA T83I and parC S87L were predicted to have a MIC of 4 mg/L (Table 
3.15). A total of 22 out of 23 isolates with these mutations in gyrA and parC had a 
MIC of 4 or above. Another study on the evaluation of different models to predict 
resistance in clinical isolates using genomes also found mutations in genes gyrA and 
parC as strong determinants of resistance, and isolates with mutations in gyrA and 
parC had MICs in a wide range of 2-256 mg/L (Khaledi et al., 2019). However, 
variable MICs in isolates with mutations in gyrA and parC indicated the presence of 
additional genetic variations associated with ciprofloxacin resistance in the study by 
Khaledi et al. (2019). Further investigations were not carried out to find out the 




Genetic variation in parE, which was found in laboratory-evolved mutants and 
resulted in V to G at the 460 position, was not found in clinical isolates analysed in 
this study. ParE V460G, for which we have quantified the resistance (Figure 3.17), 
has been reported in fluoroquinolone-resistant clinical isolates in other studies (Wang 
et al., 2014, Treepong et al., 2018). However, a few isolates had other variations 
resulting in amino acid changes closer to the 460 codon position A473V, S457R, and 
P438S which have been associated with fluoroquinolone resistance in clinical 
isolates (Bruchmann et al., 2013, Treepong et al., 2018). Isolates with genetic 
variations gyrA T83I and in parE at positions 473, 457, and 438 were predicted to 
have a MIC of 2 mg/L. Five out of 7 isolates with genetic variations in gyrA and 
parE had the actual MIC equal to the predicted one (Table 3.17). However, further 
analysis of a higher number of isolates containing genetic variations in the parE gene 
individually and different combinations is required to identify the parE genetic 
variations that are frequently found in clinical isolates and increase the ciprofloxacin 
resistance. The database CARD (Jia et al., 2017) contains a parE resistance allele 
which results in amino acid change A473V, but the database does not have S457R, 
V460G, and P438S. The addition of experimentally-proven and clinically relevant 
resistance-alleles in the database, which were found in this study, will improve the 
antibiotic predictions. This study proposes to include additional resistance alleles or a 
combination of resistance alleles in the database, for which resistance has been 
quantified and they are also present in clinical isolates such as parC S87L and parE 
V460G.  
5.6 Efflux-mediated fluoroquinolone resistance  
Other than target site modifications, the overexpression of efflux pumps has been 
associated with ciprofloxacin resistance in P. aeruginosa. After gyrA, the second 
most prevalent gene mutated in experimentally-evolved mutants (12/13) was nfxB 
(Table 2.1) which encodes a negative regulator of the efflux pump MexCD-OprJ. 
Another gene mexR was found in one of the laboratory-evolved mutants, which 
encodes a repressor of the efflux pump MexAB-OprM (Table 2.1). Mutation in mexR 
results in an overexpression of MexAB-OprM which is associated with ciprofloxacin 




nfxB leads to the overexpression of MexCD-OprJ which has been associated with 
fluoroquinolone resistance in several studies (Jalal & Wretlind, 1998, Jalal et al., 
2000, Kriengkauykiat et al., 2005, Kiser et al., 2010).  
5.6.1 The variant NfxB T39P increased the expression of mexCD but did not 
increase resistance by itself 
Four amino acid changes in NfxB were identified in experimentally-evolved 
mutants: T39P, small duplication, stop codon to C, and S36N (Table 2.1). Out of 
these, the most frequent changes were stop codon to C and T39P, and which have 
been reported before in experimentally evolved mutants (Monti et al., 2013, Melnyk 
et al., 2017). The effect of nfxB T39P on the expression of mexC and mexD was 
investigated. The expression of mexC and mexD was increased in a mutant with only 
nfxB T39P mutation and in a double mutant with gyrA and nfxB mutations (Figure 
4.13 and 4.14). However, these mutants did not show an increase in ciprofloxacin 
resistance relative to PAO1 and the gyrA mutant (Figures 3.12 and 3.17). This 
finding did not completely match the generalisation that mutations in nfxB lead to the 
overexpression of the efflux pump MexCD-OprJ which consequently leads to 
ciprofloxacin resistance (Poole et al., 1996). One possible explanation is that the 
efflux pump was not active enough to efflux the antibiotic out of the cell. Another 
possibility is that the overexpressed efflux pump transports the antibiotic out of the 
cell but not enough to show the difference in MICs. This led to a question about the 
required threshold level of an increased expression of the efflux pump to increase the 
MICs.  
The intrinsic level of ciprofloxacin resistance in PAO1 (MIC of 0.0625 mg/L) results 
from the basal expression of efflux pumps that can efflux ciprofloxacin such as 
MexAB-OprM. A plausible explanation for the increased expression of mexCD, but 
no increase in resistance in response to the nfxB mutation T39P, was likely due to a 
reduction in the basal expression of MexAB-OprM. Previously, overexpression of 
MexCD-OprJ has been shown to reduce the expression of MexAB-OprM (Li et al., 
2000). Increased MexCD-OprJ and a decreased expression of MexAB-OprM might 




5.6.2 Mutations in nfxB and PA3491 increased resistance in combination 
The co-occurrence of mutations in nfxB with the probable ferredoxin-encoding gene 
PA3491 was observed in 11/13 laboratory evolved mutants (Table 2.1). Mutation in 
PA3491 has not been previously associated with ciprofloxacin resistance. It was 
hypothesised that mutations in two genes nfxB and PA3491 probably were co-
selected because of the bigger resistance advantage conferred by a combination of 
mutations. To test the hypothesis, the triple mutant with a combination of mutations 
gyrAT83I, nfxB T39P, and PA3491 H87P was constructed. The MIC of this triple 
mutant was higher than the double mutant with mutations in gyrA and nfxB/PA3491 
(Figure 3.18). This finding showed that nfxB T39P and PA3491 H87P were 
dependent on each other to increase the ciprofloxacin resistance. It was hypothesised 
that PA3491 H87P in combination with nfxB T39P increases the expression of efflux 
pump genes. 
An expression analysis of mexC and mexD genes was carried out by RT-qPCR. 
Transcripts of mexC and mexD were higher in a triple mutant with mutations in gyrA, 
nfxB, and PA3491 than double mutants with mutations in gyrA and nfxB or gyrA and 
PA3491 (Figure 4.13 and 4.14). This finding suggested that a mutation in the 
PA3491 gene likely increased resistance in P. aeruginosa through an overexpression 
of efflux pump genes mexC and mexD. It is hypothesised that PA3491 is likely 
involved in regulating the efflux pump genes’ expression. The protein encoded by 
mutated PA3491 possibly interacts with mutated NfxB which leads to an inhibition 
of the interaction between DNA and NfxB, and consequently a de-repression of 
MexCD-OprJ. Alternatively, mutated PA3491 may bind to the promotor of efflux 
pump genes and stimulates expression of mexCD efflux pump genes, or the PA3491 
mutation may energetically favour overexpression of the efflux pump. The structural 
model emphasizes that PA3491 has similarity to an oxidoreductase. A known 
example of oxidoreductase involved in the expression of an efflux pump is mexS 
(Sobel et al., 2005). However, there is no experimental proof of PA3491 acting as a 
regulator or an oxidoreductase and further investigations are required to decipher the 




5.6.3 Genotype to phenotype correlations are complex for efflux-mediated 
ciprofloxacin resistance 
Mutations resulting in the overexpression of MexCD-OprJ occur at a range of 
positions in the nfxB gene in the fluoroquinolone-resistant isolates of P. aeruginosa 
(Jalal & Wretlind, 1998, Jalal et al., 2000, Kiser et al., 2010). The association of nfxB 
mutations with fluoroquinolone resistance has long been known (Jalal & Wretlind, 
1998, Jalal et al., 2000). However, there is no study on the quantifying resistance 
associated with different nfxB point mutations to investigate direct correlations 
between the overexpression level of efflux pump genes and MICs. Deleting the nfxB 
gene leads to the overexpression of efflux pump genes and leads to an increase in 
resistance (Bruchmann et al., 2013), whereas this finding could not be extended to 
the assumption that point mutations in nfxB would confer the same level of resistance 
as nfxB deletion. Single nucleotide variations in nfxB and sometimes combinations of 
single nucleotide changes were found in clinical isolates. To enhance the accuracy of 
antibiotic resistance predictions, it is crucial to screen/investigate nfxB mutations to 
identify the ones which lead to an increase in ciprofloxacin resistance.  
Different mutations in nfxB likely give variable effects on MICs i.e., no increase in 
MIC (for example nfxB T39P) or an increase in MIC even without gyrA mutations 
(for example deletion of nfxB). Efflux-mediated fluoroquinolone resistance is 
potentially possible with genetic variations only in the nfxB gene, which inactivates 
NfxB and leads to the overexpression of efflux pump genes. Clinical isolates have 
shown efflux pump-mediated fluoroquinolone resistance without gyrA mutations 
(Reinhardt et al., 2007).  
Clinical isolates analysed in this study had a combination of variations in gyrA, parE, 
and nfxB in few isolates and were predicted to have a MIC of 2 (Table 3.15). Due to 
a small number of isolates (4/237) with genetic variations in nfxB, it was difficult to 
assess nfxB genetic variations as a ciprofloxacin-resistance determinant. Different 
types of nfxB mutations lead to variable effects on the expression of MexCD-OprJ 
genes (Purssell & Poole, 2013). Therefore, genotype to phenotype correlations have 
been considered complex in the past (Wolter et al., 2009, Li & Plésiat, 2016). In 




have highlighted the complexities of efflux-mediated resistance as one of the factors 
of a lower accuracy of predictions (Bruchmann et al., 2013, Jeukens et al., 2017). 
Some isolates with actual MIC higher than predicted in our study had the variant 
NfxB R82L and P22Q (Appendix E). The NfxB variant R82L has been associated 
with resistance in clinical isolates in other studies. The CARD (Jia et al., 2017) has 
the NfxB protein variant H87R listed in protein variants associated with 
ciprofloxacin resistance. In future, NfxB H87R and R82L will be included in the 
analysis to predict ciprofloxacin resistance in clinical isolates.  
5.7 Ciprofloxacin resistance without gyrA T83I 
Fifty out of 167 isolates that did not have the gyrA resistance allele T83I or any other 
analysed resistance alleles, were predicted to be susceptible, while MIC testing 
showed that these isolates were ciprofloxacin-resistant and had MICs of 1-4 mg/L 
(Table 3.17). Several possibilities of ciprofloxacin resistance in isolates without the 
resistant allele gyrA T83I are discussed below. The MICs of these isolates did not 
agree with the MIC of engineered mutants without a gyrA mutation. Consistent with 
our study, there were several examples of resistant P. aeruginosa which did not have 
mutations in gyrA in other studies (Bruchmann et al., 2013, Salma et al., 2013, Kos 
et al., 2015, Nguyen et al., 2018, Telling et al., 2018).  
5.7.1 Additional resistance alleles other than T83I in gyrA and in other genes  
The DNA regions in genes gyrA, gyrB, parC, and parE that acquire mutations 
leading to fluoroquinolone resistance are collectively known as Quinolone resistance 
determining regions (QRDRs). QRDRs were analysed in 390 clinical isolates of P. 
aeruginosa to identify genotype-phenotype correlations (Kos et al., 2015). A total of 
35/390 isolates did not have gyrA genetic variations and were phenotypically 
resistant (Kos et al., 2015). Some of the isolates had both gyrB and parE mutations, 
and others had either parC or parE mutations. It has been speculated that resistant 
samples that did not have gyrA variations were resistant because of genetic variations 
in gyrB and parE. However, in this study parC and parE mutations engineered in 




The MICs of engineered single mutants with mutations in genes nfxB, parC, parE, 
and PA3491 did not lead to ciprofloxacin resistance when gyrA T83 was not mutated 
(Figure 3.12). Based on this finding, a criterion was set that clinical isolates that had 
genetic variations in genes other than gyrA (Table 3.15) were predicted to have an 
MIC below 1 mg/L (susceptible). The majority of isolates 9/13 which did not have 
gyrA T83I and had genetic variations in other genes were predicted accurately as 
susceptible (Table 3.17). In the study by Kos et al. (2015), 16 isolates had only parE 
or combinations of gyrB and parE mutations and were susceptible, which supported 
our finding that other mutations without gyrA mutation do not confer resistance by 
themselves.  
However, in Kos et al., (2015), the presence of genetic variations in parC, parE, and 
gyrB has been observed in both resistant and susceptible isolates of P. aeruginosa. 
Resistance in such isolates that had genetic variations parC, parE, and gyrB was 
likely due to additional genetic variations that were out of the QRDR of genes parC, 
gyrB and parE. It would be interesting to investigate the level of resistance conferred 
by additional alleles found in resistant clinical isolates by engineering mutations in 
PAO1 and determining the MICs. Possible additional resistance alleles for which 
resistance has not been quantified yet, but have been associated with resistance, are 
given below. Resistance alleles other than T83I and D87N in gyrA found in 
experimentally evolved mutants in this study were G81C, S612L, and in clinical 
isolates from other studies were T133M, E153K, G81D, Y86N and Q106L (Salma et 
al., 2013, Kos et al., 2015, Cabot et al., 2016, López-Causapé et al., 2017, Nguyen et 
al., 2018). The NfxB R82L, A38G, A124E (Jalal et al., 2000, Higgins et al., 2003), 
ParE S457G, S457T, E459D and E459K (López-Causapé et al., 2018), and parC 
S87W (Del Barrio-Tofiño et al., 2017) variants have been reported in resistant 
clinical isolates in other studies. Additional resistance alleles in gyrA and other 
ciprofloxacin resistance-associated genes could be the source of resistance in isolates 
that did not have gyrA mutation T83I and D87N. Multiple possible resistance alleles 
highlighted the diversity and complexity of the genetic basis of ciprofloxacin 
resistance in P. aeruginosa. None of these alleles are in the antibiotic resistance 




clinical isolates to predict the ciprofloxacin resistance. However, quantification of 
the resistance conferred by these resistance alleles is not known.  
5.7.2 Overexpression of efflux solely could give ciprofloxacin resistance 
Thirteen out of 180 isolates (Table 3.17) had a wild type gyrA allele in combination 
with genetic variations in nfxB and parE. Four out of 13 isolates had a wild type gyrA 
and had resistance alleles in nfxB and were resistant with the actual MICs of 1-2 
mg/mL, while these were predicted to be susceptible. Two out of 4 isolates had R82L 
and one had P22Q NfxB variants (Appendix E). Resistance in isolates with nfxB 
genetic variations and a wild type gyrA could be attributed to the overexpression of 
efflux pumps. There is evidence of only efflux-mediated fluoroquinolone resistance 
in clinical isolates (Reinhardt et al., 2007), indicating that protein-inactivating 
mutations in nfxB solely could result in fluoroquinolone resistance. The nfxB R82L 
has been reported in quinolone-resistant isolates of P. aeruginosa which did not have 
gyrA T83I (Jalal et al., 2000), although the effects of substitution mutations in nfxB 
found in clinical samples on resistance have not been investigated in detail.  
Different mutations in nfxB could have a diverse effect on ciprofloxacin resistance 
depending on the position of the mutation in the gene. In the engineered mutants 
nfxB T39P did not increase the resistance above the resistance conferred gyrA T83I 
by itself (Figure 3.17). On the other hand, two of the laboratory-evolved mutants CI4 
and CM3 had mutations in nfxB and these mutants did not have a mutation in the 
gyrA gene (Figure 3.2). CI4 had a small insertion in nfxB, and CM3 had stop codon 
replaced by C. The MICs of CI4 and CM3 were 4 and 2 mg/L, respectively, 
indicating that efflux-mediated resistance is likely the source of resistance in these 
mutants. 
5.7.3 Treatment with other antibiotics could result in cross-resistance to 
ciprofloxacin  
Another plausible explanation of ciprofloxacin resistance in fifty isolates without a 
gyrA variant (Table 3.17) could be a cross-resistance after treatment to other 




efflux ciprofloxacin. The nalC and nalD mutants were selected under exposure to 
carbapenems (Wardell et al., 2019). Experimentally evolved meropenem resistant P. 
aeruginosa isolates were cross-resistant to ciprofloxacin (Wardell et al., 2019). The 
genes nalC and nalD are regulators of the efflux pump MexAB-OprM genes. 
Mutations in nalC and nalD lead to an overexpression of the MexAB-OprM efflux 
pump which has been associated with fluoroquinolone resistance (Masuda & Ohya, 
1992, Sacha et al., 2014). Therefore, to predict ciprofloxacin resistance in P. 
aeruginosa isolates, genetic variations in genes nalC and nalD will also be 
considered in the future.  
5.7.4 Additional ciprofloxacin resistance-associated genes  
Several studies suggested the possibility of additional ciprofloxacin resistance-
associated genes, which did not have known genetic variations in gyrA, nfxB, parC 
and parE in clinical P. aeruginosa isolates (Bruchmann et al., 2013, Jeukens et al., 
2019, Khaledi et al., 2019) and in laboratory evolved mutants (Rehman et al., 2018). 
Also, a thorough analysis of the P. aeruginosa PA14 transposon insertion library 
showed that approximately 100-200 genes are involved in ciprofloxacin resistance 
(Breidenstein et al., 2008, Dötsch et al., 2009). In a study, 32 fluoroquinolone-
resistant clinical isolates had genetic variation only in gyrA and did not have known 
genetic variations in gyrB, parC, and parE, and had different MICs ranging from 4-
256 μg/mL (Yang et al., 2015) which indicates that additional genes are involved in 
ciprofloxacin resistance, which needs to be explored. However, efflux-mediated 
fluoroquinolone resistance was not analysed in the study by Yang et al., 2015.  
5.7.5 Plasmid-mediated ciprofloxacin resistance 
Resistance in clinical isolates which did not have a mutated gyrA and any other 
analysed resistance alleles (Appendix E6) could be attributed to plasmid-associated 
ciprofloxacin resistance, which has been reported in previous studies on P. 
aeruginosa (Dunham et al., 2010, Jiang et al., 2014, Michalska et al., 2014, Yang et 
al., 2015, Araujo et al., 2016, Chavez-Jacobo et al., 2018, Hamed et al., 2018). High 
frequency of fluoroquinolone-resistant isolates did not have QRDR mutations and 




resistance genes (PMRG) variant aac(6')-Ib-cr inactivates ciprofloxacin by 
acetylation, and qnrS which encodes protein Qnr, binds to target proteins of 
ciprofloxacin (Gyrase and Topoisomerase IV) and inhibits the interactions between 
ciprofloxacin and target proteins. However, plasmid-mediated resistance genes are 
thought to give a lower level of resistance, and all the reports, except Araujo et al. 
(2016), showed that plasmid-related genes co-occurred with gyrA and parC 
mutations, indicating that the plasmid genes themselves are not likely enough to 
confer a higher level of resistance. Based on the presence of PMRGs with and 
without chromosomal ciprofloxacin resistance-associated genes in other studies, it 
could be hypothesised that variant aac(6')-Ib-cr and qnrS likely confers resistance to 
ciprofloxacin by itself, whereas qnrA, qnrC and crpP genes (phosphorylates the 
ciprofloxacin) possibly lead to a low level of resistance and co-occur with 
chromosomal ciprofloxacin resistance-associated genes. This highlights that PMRGs 
particular variant aac(6')-Ib-cr and qnrS, should be included in the analysis of 
genomes for ciprofloxacin resistance predictions. However, Cayci et al. (2014) did 
not find plasmid-related genes in fluoroquinolone-resistant isolates, indicating that 
plasmid-mediated resistance to ciprofloxacin is not frequent in P. aeruginosa. 
Overall, from Section 5.7, gyrA, mutation is not the only ciprofloxacin resistance 
determinant in all cases and is not responsible singly for a high level of resistance. 
There are several possibilities of ciprofloxacin resistance development without 
genetic variations in gyrA, which need to be investigated further and should be 
incorporated into antibiotic resistance prediction tools. 
5.8 Limitations  
This study emphasised the complex nature of ciprofloxacin resistance in P. 
aeruginosa. A limitation of the study is that the number of clinical isolates genomes 
analysed is likely not enough to reflect the diversity in resistance of P. aeruginosa. 
The high degree of variability of antimicrobial resistance genes in clinical isolates 
makes it more difficult to generalise the mechanisms for multiple isolates, and one 




Therefore, more complex models are needed for antibiotic resistance prediction in P. 
aeruginosa because of its high diversity in resistance.  
In clinics, usually a combination of therapies is given for the treatment of P. 
aeruginosa infections. Therefore, the selection of ciprofloxacin resistance-associated 
genetic variations under exposure to a combination of antibiotics could be dependent 
on the co-occurring genetic variations associated with resistance to other antibiotics. 
However, this study investigated the mutations that were selected under exposure to 
only ciprofloxacin.  
In addition to the bigger advantage of ciprofloxacin resistance, higher virulence 
could be another important factor that could select the fluoroquinolones resistance-
associated genetic variations that give more virulence or co-occur with virulence-
related mutations (Agnello et al., 2016). It will be interesting to investigate the effect 
of ciprofloxacin resistance-associated genetic variations on the virulence of P. 
aeruginosa. 
5.9 Future perspectives 
Antibiotic resistance predictions were correct in most of the isolates; however, 24% 
(58/237) had actual MICs higher than predicted. To investigate the source of 
resistance in these isolates, more genes should be included in the analysis for 
prediction of resistance, i.e. nalC, nalD, gyrB, and mexR, including other genes 
reported in experimental evolution studies reviewed in Rehman et al. (2018). In 
addition, resistance alleles other than those analysed in genes gyrA, nfxB, parC, and 
parE given in Section 5.4.1 should be searched in genomes of clinical isolates and be 
included in criteria to predict resistance. Future studies could include the 
quantification of resistance associated with these genetic variations by constructing 
mutants and determining their MICs. 
It was hypothesised that isolates that did not have any analysed resistance alleles and 
were resistant to ciprofloxacin were likely to have plasmid-mediated ciprofloxacin 
resistance. To search for the plasmid-mediated resistance genes in the genomes of 




on the database CARD (McArthur et al., 2013), which is a curated database. 
However, plasmid-mediated ciprofloxacin resistance is not completely known. 
Future studies will include investigation of the effects of plasmid resistance genes on 
ciprofloxacin MICs.  
To make the data more conclusive on the resistance associated with genetic 
variations in parE and nfxB, more genomes from clinical isolates containing genetic 
variations in these genes should be included in the analysis. It is hypothesised that 
different point mutations in nfxB potentially result in different levels of an increased 
expression of efflux pump genes and would give different MICs. To test the 
hypothesis, the quantification of resistance conferred by multiple nfxB mutations 
other than nfxB T39P will be carried out in the future. Mutations in nfxB increased 
the expression of efflux pump genes mexCD but did not lead to an increase in 
ciprofloxacin resistance, even when present in combination with gyrA genetic 
variations. It is hypothesised that efflux pumps are overexpressed, though likely not 
sufficiently active to efflux enough antibiotics out of the cell. Future studies will 
include ciprofloxacin accumulation assays in mutants with nfxB and PA3491 
mutations and PAO1, which is an indirect approach to measure the efflux pump 
activity (Blair & Piddock, 2016).  
PA3491 H87P was involved in the overexpression of efflux pump genes. To further 
confirm the link between mutation PA3491 H87P, an increased expression of 
mexCD, and increased resistance, the mexCD gene will be deleted in PAO1, in the 
mutant containing gyrA T83I and nfxB T39P, and a mutant containing gyrA T83I, 
nfxB T39P, and PA3491 H87P and MICs will be determined. It is hypothesised that 
the MIC of a triple mutant would decrease with the deletion of mexCD. In addition, 
to evaluate the clinical relevance of PA3491 mutations, genomes of clinical isolates 
will be analysed to identify genetic variations compared to PAO1. PA3491 genetic 
variations found in clinical isolates will be engineered into PAO1, and MICs will be 
determined. Another approach will be to replace mutated alleles in clinical isolates 





5.10 Concluding remarks  
In conclusion, this study outlined clinically relevant ciprofloxacin resistance-
associated genes and mutations in P. aeruginosa and found that fluoroquinolone 
resistance develops in a stepwise manner by acquiring mutations in genes gyrA, 
PA3491, nfxB, parC, and parE. Resistance conferred by ciprofloxacin resistance-
associated genes was thoroughly quantified for the first time. In addition, predictions 
of ciprofloxacin resistance in clinical isolates further supported the idea that the 
majority of resistance could be attributed to genetic variation in gyrA only, and high 
ciprofloxacin resistance is achieved by the combination of genetic variations in gyrA 
and other genes parC, parE and nfxB genes. It was found that PA3491 H87P leads to 
an increase in resistance when present with mutated nfxB and gyrA through an 
overexpression of efflux pump genes. The quantification of resistance conferred by 
mutations and combinations of mutations enhanced insight into ciprofloxacin 
resistance evolution. A unique approach of using MICs of engineered mutants to 
predict resistance in isolates of P. aeruginosa from genome sequences further 
enhanced the understanding of the genetic basis of ciprofloxacin resistance. In 
addition, antibiotic resistance prediction based on criteria designed in this study was 
correct for a higher proportion of clinical isolates, which indicated the potential of 
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Appendix A  
 
Area under the curve calculated from OD600 data for three biological replicates 
of mutants. Bacteria were grown in L-broth and absorbance was measured at 600nm 














AUC 1 AUC 2 AUC 3 
PAO1 1147.484 1150.2331 1170.4315 1156.05 7.23 
CA7 749.9891 742.6046 745.8007 746.1315 2.14 
CB7 1151.495 1138.29 1107.327 1132.371 13.08 
CC6 758.8671 751.936 779.9502 763.5844 8.42 
CF6 981.0665 1000.057 1023.594 1001.573 12.29 
CG6 486.6336 545.025 579.254 536.9709 27.04 
CH8 892.5751 911.7148 957.1443 920.4781 19.14 
CI7 734.0501 762.4021 751.0499 749.1674 8.24 
CJ7 749.9891 742.6046 745.8007 746.1315 2.14 
CK7 599.8238 821.2862 820.9937 747.3679 73.77 
CL6 402.9906 424.7085 455.7321 427.8104 15.30 
CM6 702.5401 779.8104 823.2986 768.5497 35.31 
CO5 450.2646 520.1717 571.0531 513.8298 35.01 
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B1: Minimum inhibitory concentrations of ciprofloxacin for different mutants 
from subsequent steps of few representative lines out of 13 independent 
experimentally-evolved P. aeruginosa lines. Laboratory reference strain PAO1 was 
evolved. Stepwise increase in ciprofloxacin resistance was observed throughout the 
experimental evolution, and a maximum 500 to 2000-fold increase in ciprofloxacin 
resistance was achieved in 13 different lines.  
B2 (next page): Genotypes and minimum inhibitory concentrations of multiple 
mutants from experimentally-evolved ciprofloxacin resistant P. aeruginosa lines. 
A subsequent/stepwise increase in ciprofloxacin resistance was observed with the 
accumulation of mutations during the experimental evolution of high-level ciprofloxacin 
resistance. Amino acid variations are shown in subscript. Green text is representing the 
mutations that occurred/got added to the parent mutant in the respective step. Mutations 











Control strain PAO1 0.0625 
CK line 
CK1 PA3491H87P, nalC 0.0625 
CK2 PA3491H87P, gyrAT83I 1 
CK3 PA3491H87P, gyrAT83I, nfxBT39P 4 
CK4 PA3491H87P, gyrAT83I, nfxBT39P, parCS87L 32 
CK5 PA3491H87P, gyrAT83I, nfxBT39P, parCS87L, pilT 128 
CK6 PA3491H87P, gyrAT83I, nfxBT39P, parCS87L, pilT 128 
CK7 PA3491H87P, gyrAT83I, nfxBT39P, parCS87L, pilT, rpSH, aruE 128 
CF line 
CF3 PA3491H87P, gyrAT83I, nfxBdup 4 
CF4 PA3491H87P, gyrAT83I, nfxBdup 4 
CF5 PA3491H87P, gyrAT83I, nfxBT39P, parCS87L, pilTΔ12bp, fptAΔ9bp, pfeAG535D 128 
CF6 




CL3 gyrAS612L, mexR Δ20bp, PA2940 Δ12bp 2 
CL6 gyrAS612L, mexR Δ20bp, PA2940 Δ12bp, gyrAG81C, PA5438 Δ9bp 32 
CM line 
CM3 PA3491H87P, nfxBstop codon to C, tpiAC 6 to 5, pilM (CGTCC)1 to 2  
CM6 PA3491H87P, nfxBstop codon to C, tpiAC6 to 5, pilM(CGTCC) 1 to 2,  gyrAT83I, >32 
CO line 
CO3 gyrAD87N, PA3491H87P, nfxB stop codon to C  
CO5 gyrAD87N, PA3491H87P, nfxB stop codon to C, tpiA © 6 tp 7 >16 
CA line 
CA3 gyrAD87G, rpsC (GGTGGC)1 to 2, nfxB Δ4bp 2 
CA7 gyrAT83I, PA3491H87P, nfxBT39P, parCS87L, pilB Δ300bp, obg Δ3bp 128 
CB line 
CB3 
gyrAD87G, nalD Δ11bp, nfxB Δ12bp, sdhA Δ9bp, sdhAR452G, PA1740 Δ16bp, PA2613 
Δ11bp,  
1 
CB7 gyrAT83I, nfxBT39P, PA3491H87P, parCS87L, pilEΔ11bp, mexS Δ6bp 64 
CC line 
CC3 
gyrAD87G, nalD Δ11bp, nfxB Δ12bp, PA0715-PA0716 Δ3394bp, sdhA Δ9bp, 
sdhAR452G, PA1740 Δ16bp, PA2613 Δ11bp,  
2 
CC6 gyrAT83I, PA3491H87P, nfxBT39P, parCS87L 32 
CG line 
CG3 gyrAD87G, nfxBΔ12bp, nalDΔ11bp, fha1small duplication, PA1291Δ15bp, sdhAΔ9bp, 
sdhAR452G, PA2613 Δ11bp, pilR Δ498bp, spoT Δ3bp, PA1740 Δ16bp 
1 
CG4 gyrAT83I, nfxBsmall duplication, parEV460G, PA3491H87P, pilF Δ17bp 32 






*Mutants were named as; C represents ciprofloxacin, alphabets represent independently 
evolved lines and number denotes number of passages carried out for experimental 
evolution. 
 
B3 (next page): List of genes and their descriptions which got mutated in 








CH4 gyrAD87G, nfxB Δ12bp, nalD Δ11bp, fha1, PA1291 Δ15bp, sdhA Δ9bp, PA2613 
Δ11bp, pilR Δ498bp, spoT Δ3bp, PA1740 Δ16bp 
2 
CH5 gyrAT83I, nfxBT39P, PA3491H87P, parCS87L 32 
CH8 gyrAT83I, nfxBT39P, PA3491H87P, parCS87L, PA0093 Δ13bp, pilT Δ12bp, pscD 




gyrAD87G, nfxB Δ12bp, nalD Δ11bp, PA1291 Δ15bp, sdhAdel, sdhAR452G, PA1740 
Δ16bp, PA2613 Δ11bp, fha1Small duplication 
2 
CI4 nfxBSmall duplication 4 
CI5 gyrAT83I, nfxBT39P, PA3491H87P, parCS87L 64 
CI7 gyrAT83I, PA3491H87P, nfxBSmall duplication, parEV460G, pilF Δ17bp, ssg Δ13bp 64 
 CJ line  
CJ3 
gyrAD87G, nalD Δ11bp, nfxB Δ12bp, sdhA Δ9bp, sdhAR452G, PA1740 Δ16bp, 
PA2613 Δ11bp 
4 




Genes Gene description 
aruE N-Succinylglutamate desuccinylase 
fha1 Fha domain-containing protein 
fptA 




signal recognition particle receptor FtsY 
 
gyrA DNA gyrase subunit A 
mexS MexS 
mexR Multidrug resistance operon repressor MexR 
nalC NalC 
nalD NalD 
nfxB Transcriptional regulator NfxB 
obg 
GTP-binding protein Obg 
 
PA0093 Tse6 
PA0715-16 Hypothetical protein 
PA1291 Hypothetical protein 
PA1740 Hypothetical protein 
PA2613 Recombinant factor protein RarA 
PA2940 Acyl-CoA thiolase 
PA3491 Probable ferredoxin 
ssg Cell surface-sugar biosynthetic glycosyltransferase, Ssg 
PA5438 
































Type 4 fimbrial biogenesis protein PilF 
 
pilM Type 4 fimbrial biogenesis protein pilM 
pilR Two component response regulator PilR 
pilT Twitching motility protein PilT 
pfeA Ferric enterobactin receptor, outer membrane protein PfeA precursor 
pscD 
 
Type III export protein PscD 
 
pheS Phenylalanyl-tRNA synthetase, alpha-subunit 
rpsC 30S ribosomal protein S3 
rpSH 
 
30S ribosomal protein S8 
 
sdhA Succinate dehydrogenase flavoprotein subunit 
spoT Guanosine-3’,5’-bis (diphosphate) 3’-pyrophosphohydrolase 







Schematic representation of cloning DNA insert of gene parE in vector pEX18Tc 
(details in Figure 3.3). The Cut DNA fragment is shown as a red bar. In gel picture 















Growth analysis of mutants 
D1: Average area under the growth curve of experimentally evolved and 
equivalent engineered mutants.  
Experimentally evolved mutants  Average Area under curve 
PAO1 wild type 1150 
CK1 (PA3491, nalC) 1091.985 
CK2 (PA3491, gyrA) 1114.1758 
CK3 (PA3491, gyrA, nfxB) 989.302 
CK4 (PA3491, gyrA, nfxB, parC) 766.55 
CK5 (PA3491, gyrA, nfxB, parC, pilT) 852.93 
CK6 (PA3491, gyrA, nfxB, parC, pilT) 866.201 
CK7 (PA3491, gyrA, nfxB, parC, pilT, rpsH, aruE) 774.128 
Engineered mutants Average Area under curve 
PAO1 wild type 1123.169 
PA3491 1106.44 
gyrA + PA3491 1041.68 
gyrA + PA3491 + nfxB 784.7158 






Appendix E1 to E5: Isolates with actual MIC equal to the predicted MIC 
 
E1 (next page): Wild type gyrA T83, nfxB T39, parC S87, parE 460, 473, 457, 438 
 List of clinical isolates used in this study, their IPCD IDs, actual MICs, and 



















1.  111 0.5 no no no no WTgyrA S (<1) 
2.  113 0.5 no no no 
no 
WTgyrA S (<1) 
3.  114 0.125 no no no 
no 
WT gyrA S (<1) 
4.  115 0.125 no no no 
no 
WT gyrA S (<1) 
5.  116 0.05 no no no no WT gyrA S (<1) 
6.  122 0.5 no no no 
no 
WTgyrA S (<1) 
7.  124 0.125 no no no 
no 
WT gyrA S (<1) 
8.  125 0.125 no no no 
no 
WT gyrA S (<1) 
9.  127 0.25 no no no 
no 
WTgyrA S (<1) 
10.  130 0.5 no no no 
no 
WTgyrA S (<1) 
11.  131 0.05 no no no 
no 
WT gyrA S (<1) 
12.  132 0.05 no no no no WT gyrA S (<1) 
13.  144 0.5 no no no 
no 
WTgyrA S (<1) 
14.  145 0.5 no no no 
no 
WTgyrA S (<1) 
15.  146 0.5 no no no 
no 
WTgyrA S (<1) 
16.  147 0.5 no no no 
no 
WTgyrA S (<1) 
17.  149 0.5 no no no 
no 
WTgyrA S (<1) 
18.  152 0.125 no no no 
no 
WT gyrA S (<1) 
19.  153 0.25 no no no no WTgyrA S (<1) 
20.  154 0.25 no no no 
no 
WTgyrA S (<1) 
21.  155 0.25 no no no 
no 
WTgyrA S (<1) 
22.  156 0.5 no no no 
no 
WTgyrA S (<1) 
23.  157 0.5 no no no 
no 
WTgyrA S (<1) 
24.  158 0.25 no no no 
no 
WTgyrA S (<1) 
25.  161 0.25 no no no 
no 
WTgyrA S (<1) 
26.  162 0.25 no no no no WTgyrA S (<1) 
27.  163 0.5 no no no 
no 
WTgyrA S (<1) 
28.  164 0.05 no no no 
no 
WT gyrA S (<1) 
29.  167 0.125 no no no 
no 
WT gyrA S (<1) 
30.  169 0.25 no no no 
no 
WTgyrA S (<1) 
31.  171 0.5 no no no 
no 
WTgyrA S (<1) 
32.  176 0.25 no no no 
no 
WTgyrA S (<1) 
33.  177 0.05 no no no no WT gyrA S (<1) 
34.  178 0.25 no no no 
no 
WTgyrA S (<1) 
35.  182 0.5 no no no 
no 
WTgyrA S (<1) 
36.  183 0.05 no no no 
no 
WT gyrA S (<1) 
37.  184 0.25 no no no 
no 
WTgyrA S (<1) 
38.  185 0.05 no no no 
no 
WT gyrA S (<1) 
39.  186 0.5 no no no 
no 
WTgyrA S (<1) 
40.  369 0.125 no no no no WTgyrA S (<1) 
41.  688 0.25 no no no 
no 
WTgyrA S (<1) 
42.  689 0.25 no no no 
no 
WTgyrA S (<1) 
43.  690 0.5 no no no 
no 
WTgyrA S (<1) 
44.  691 0.5 no no no 
no 
WTgyrA S (<1) 
45.  692 0.25 no no no 
no 
WTgyrA S (<1) 
46.  693 0.25 no no no 
no 




47.  694 0.25 no no no 
no 
WTgyrA S (<1) 
48.  695 0.25 no no no no WTgyrA S (<1) 
49.  696 0.25 no no no 
no 
WTgyrA S (<1) 
50.  698 0.25 no no no 
no 
WTgyrA S (<1) 
51.  699 0.25 no no no 
no 
WTgyrA S (<1) 
52.  703 0.25 no no no 
no 
WTgyrA S (<1) 
53.  710 0.5 no no no 
no 
WTgyrA S (<1) 
54.  714 0.5 no no no 
no 
WTgyrA S (<1) 
55.  725 0.25 no no no no WTgyrA S (<1) 
56.  727 0.25 no no no 
no 
WTgyrA S (<1) 
57.  728 0.25 no no no 
no 
WTgyrA S (<1) 
58.  729 0.25 no no no 
no 
WTgyrA S (<1) 
59.  730 0.25 no no no 
no 
WTgyrA S (<1) 
60.  731 0.25 no no no 
no 
WTgyrA S (<1) 
61.  733 0.25 no no no 
no 
WTgyrA S (<1) 
62.  734 0.25 no no E215Q no parE S (<1) 
63.  736 0.25 no no no 
no 
WTgyrA S (<1) 
64.  738 0.5 no no no 
no 
WTgyrA S (<1) 
65.  742 0.25 no no no 
no 
WTgyrA S (<1) 
66.  744 0.25 no no no 
no 
WTgyrA S (<1) 
67.  747 0.25 no no no 
no 
WTgyrA S (<1) 
68.  748 0.25 no no no 
no 
WTgyrA S (<1) 
69.  749 0.25 no no no no WTgyrA S (<1) 
70.  750 0.25 no no no 
no 
WTgyrA S (<1) 
71.  751 0.25 no no no 
no 
WTgyrA S (<1) 
72.  752 0.25 no no no 
no 
WTgyrA S (<1) 
73.  754 0.25 no no no 
no 
WTgyrA S (<1) 
74.  755 0.25 no no no 
no 
WTgyrA S (<1) 
75.  756 0.25 no no no 
no 
WTgyrA S (<1) 
76.  757 0.25 no no no no WTgyrA S (<1) 
77.  758 0.25 no no no 
no 
WTgyrA S (<1) 
78.  759 0.25 no no no 
no 
WTgyrA S (<1) 
79.  760 0.25 no no no 
no 
WTgyrA S (<1) 
80.  761 0.25 no no no 
no 
WTgyrA S (<1) 
81.  762 0.25 no no no 
no 
WTgyrA S (<1) 
82.  769 0.25  no no 
no 
WTgyrA S (<1) 
83.  775 0.25 no no no 
no 
WTgyrA S (<1) 
84.  776 0.25 no no no 
no 
WTgyrA S (<1) 
85.  780 0.5 no no no 
no 
WTgyrA S (<1) 
86.  785 0.5 no no no 
no 
WTgyrA S (<1) 
87.  786 0.25 no no no 
no 
WTgyrA S (<1) 
88.  789 0.25 no no no 
no 
WTgyrA S (<1) 
89.  790 0.25 no no no 
no 
WTgyrA S (<1) 
90.  792 0.25 no no no 
no 
WTgyrA S (<1) 
91.  796 0.25 no no no 
no 
WTgyrA S (<1) 
92.  824 0.5 no no no 
no 
WTgyrA S (<1) 
93.  828 0.25 no no no 
no 
WTgyrA S (<1) 
94.  831 0.25 no no no 
no 
























1.  89 4 yes yes no no gyrA+parC R (4) 
2.  664 4 yes yes no no gyrA+parC R (4) 
3.  669 4 yes yes no no gyrA+parC R (4) 
4.  706 4 yes yes no no gyrA+parC R (4) 
5.  718 4 yes yes no no gyrA+parC R (4) 
6.  871 4 yes yes no no gyrA+parC R (4) 
7.  1053 4 yes yes no no gyrA+parC R (4) 
8.  1112 4 yes yes no no gyrA+parC R (4) 
9.  1122 4 yes+D87H yes E215Q no gyrA+parC R (4) 
10.  1124 4 yes yes E215Q no gyrA+parC R (4) 
11.  1130 4 yes yes no no gyrA+parC R (4) 
12.  1133 4 Yes yes no no gyrA+parC R (4) 
13.  1152 4 Yes+D87N yes no no gyrA+parC R (4) 
14.  1182 4 yes yes no no gyrA+parC R (4) 
15.  1184 4 yes yes no no gyrA+parC R (4) 
16.  1241 4 yes yes no no gyrA+parC R (4) 
17.  1242 4 yes yes no no gyrA+parC R (4) 
18.  1243 4 yes yes no no gyrA+parC R (4) 
19.  1244 4 yes yes no no gyrA+parC R (4) 
20.  1245 4 yes yes no no gyrA+parC R (4) 
21.  1269 4 yes yes no no gyrA+parC R (4) 
 
95.  856 0.25 no  no 
no 
WTgyrA S (<1) 
96.  860 0.25 no no no 
no 
WTgyrA S (<1) 
97.  867 0.25 no no no 
no 
WTgyrA S (<1) 
98.  875 0.25 no  no 
no 
WTgyrA S (<1) 
99.  877 0.25 no  no 
no 
WTgyrA S (<1) 
100.  878 0.25 no  no 
no 
WTgyrA S (<1) 
101.  881 0.25 no no no 
no 
WTgyrA S (<1) 
102.  884 0.25 no no no 
no 
WTgyrA S (<1) 
103.  885 0.25 no no no 
no 
WTgyrA S (<1) 
104.  1108 0.125 no  no 
no 
WTgyrA S (<1) 
105.  1530 0.25 no  no 
no 
WTgyrA S (<1) 
106.  1533 0.5 no  no 
no 
WTgyrA S (<1) 
107.  1535 0.25 no  no 
no 
WTgyrA S (<1) 
108.  1536 0.25 no  no 
no 
WTgyrA S (<1) 
109.  1537 0.5 no  no 
no 
WTgyrA S (<1) 
110.  1538 0.5 no no no 
no 
WTgyrA S (<1) 
111.  1539 0.25 no  no 
no 
WTgyrA S (<1) 
112.  1540 0.5 no no no 
no 
WTgyrA S (<1) 
113.  1541 0.12 no no no 
no 
WTgyrA S (<1) 
114.  1542 0.25 no no no 
no 
WTgyrA S (<1) 
115.  1579 0.25 no no no 
no 
WTgyrA S (<1) 
116.  1580 0.25 no no no 
no 
WTgyrA S (<1) 
117.  1581 0.25 no no no 
no 






















1.  179 1 yes no no no gyrAT83I R (1) 
2.  797 1 yes no no no gyrA R (1) 
3.  811 2 yes no D142N no gyrA+parE R (1) 
4.  852 2 yes no no no gyrA R (1) 
5.  858 2 yes no no no gyrA R (1) 
6.  934 2 yes no no no gyrAT83I R (1) 
7.  946 2 yes no no no gyrAT83I R (1) 
8.  948 2 yes no no no gyrAT83I R (1) 
9.  1074 1 yes no D142N no gyrAT83I R (1) 
10.  1506 1.25 yes no no no gyrAT83I R (1) 
11.  1590 2 yes no no no gyrAT83I R (1) 
12.  1603 1 yes no no no gyrAT83I R (1) 
 































nfxB S (<1) yes 
2.  38 0.5 no no no 
R21H+A16
8D+D56G 
WTgyrA S (<1) yes 
3.  88 0.5 D87N no yes R82L gyrA D87N S (<1) yes 
4.  723 0.25 no no no 
R21H+D56
G 
nfxB S (<1) yes 
5.  737 0.25 no no A473T R21H parE+nfxB S (<1) yes 
6.  740 0.25 no no no 
R21H+D56
G 
nfxB S (<1) yes 
7.  825 0.25  no yes  parE S (<1) yes 
8.  830 0.25 no  yes  parE S (<1) yes 
9.  1578 0.25 no no  R82L WTgyrA S (<1) yes 
 
E5: gyrAT83I and parE473/457/460/438 








































4.  954 4 yes no P438S  gyrA+parE R (≥2) yes 
5.  1594 2 yes no YES (S457C)  gyrA+parE R (≥2) yes 
 
Appendix E6-E8: Isolates with actual MIC higher than predicted MIC 
















1.  117 1 no no no no WTgyrA <1 
2.  118 1 no no no no WTgyrA S 
3.  119 1 no no no no WTgyrA S 
4.  120 1 no no no no WTgyrA S 
5.  121 1 no no no no WTgyrA S 
6.  126 1 no no no no WTgyrA S 
7.  128 1 no no no no WTgyrA S 
8.  129 1 no no no no WTgyrA S 
9.  133 1 no no no no WTgyrA S 
10.  135 2 D87N no no no gyrAD87N 0.5 
11.  148 1 no no no no WTgyrA S 
12.  150 1 no no no no WTgyrA S 
13.  151 1 no no no no WTgyrA S 
14.  159 1 no no no no WTgyrA S 
15.  170 1 no no no no WTgyrA S 
16.  700 2 no no no no WTgyrA S 
17.  713 1 no no no no WTgyrA S 
18.  715 1 no no no no WTgyrA S 
19.  720 1 no no no no WTgyrA S 
20.  782 1 no no no no WTgyrA S 
21.  826 4 no no no no WTgyrA S 
22.  838 2 no no no no WTgyrA S 
23.  879 4 no no  no WTgyrA S 
24.  880 1 no no no no WTgyrA S 
25.  1532 2 no N170S no no WTgyrA S 
26.  1534 2 no no no no WTgyrA S 
27.  1543 2 no no(N170S) no no WTgyrA S 





29.  1545 2 no no(N170S) no no WTgyrA S 
30.  1546 2 no no no no WTgyrA S 
31.  1547 2 no no no no WTgyrA S 
32.  1548 2 no no no no WTgyrA S 





34.  1550 1 no no no no WTgyrA S 
35.  1551 2 no no no no WTgyrA S 





37.  1554 2 no no no no WTgyrA S 



















39.  1557 2 no N170S no no WTgyrA S 





41.  1559 2 no no no no WTgyrA S 
42.  1560 2 no  no no WTgyrA S 






























49.  1577 1 no no no no WTgyrA S 
50.  1582 2 no no no no WTgyrA S 
 



















1.  123 1 no no no R82L WTgyrA S 
2.  168 2 no no no R82L WTgyrA S 
3.  532 1 no no 
YES (A473V) + 
533 
 parE S 
4.  810 1 no no no P22Q nfxB S 
 



















1.  166 8 yes no no  gyrA 1 
2.  175 4 yes no no  gyrA 1 
3.  976 4 yes no no no gyrA R (1) 
4.  1180 4 yes  no  gyrA R (1) 
 

















E9: Only gyrAT83I 
1.  65 0.5 yes no no  gyrAT83I R (1) 
2.  66 0.25 yes no no  gyrAT83I R (1) 
3.  112 0.5 yes no no  gyrAT83I R (1) 
4.  142 0.25 yes no no A167D gyrAT83I R (1) 
5.  143 0.5 yes no no A167D gyrAT83I R (1) 




7.  173 0.05 yes no no  gyrAT83I R (1) 
8.  174 0.5 yes no no  gyrAT83I R (1) 
9.  180 0.5 yes no no  gyrAT83I R (1) 
10.  181 0.5 yes no no  gyrAT83I R (1) 
11.  977 0.25 yes  no  gyrAT83I R (1) 
12.  1296 0.125 yes  no  gyrAT83I R (1) 
E10: gyrA T83I + parE 
13.  141 0.05 yes no T562A A167D gyrAT83I R (1) 
14.  534 0.5 yes no yes  gyrA+parE R (2) 
E11: gyrA T83I + parC S87L 






























F1: Sequencing chromatogram of PCR product to amplify mutation containing region in 
gene PA3491 to find mutant nfxB T39P + PA3491 H87P. DNA region of interest was 
amplified using primers given in Table 3.6 from sucrose resistant and tetracycline sensitive 
colonies and purified PCR products were sent for sequencing (Section 3.3.2.20). Red arrow 
points at the position of mutation and sequence alignment with mutation (A to C at 
genome position 3908671) is shown in a red box.  
 
F2: Sequencing chromatogram of PCR product to amplify mutation containing 
region in gene nfxB to find mutant. DNA region of interest was amplified using 
primers given in Table 3.6 from sucrose resistant and tetracycline sensitive colonies and 
purified PCR products were sent for sequencing (Section 3.3.2.20). Red arrow points at the 
position of mutation and sequence alignment with mutation (A to C at genome position 







G1: Primer efficiency of clpX  
 
G2: Primer efficiency of oprL 
 
G3: Primer efficiency of mexC 
G1-G3: Primer efficiencies calculated (method given in Section 4.3.2.1) from 
standard curves between log concentrations of DNA (along the x-axis) and 
crossing points (along the y-axis) using LightCycler 480 thermocycler software 




G4: RT-qPCR crossing points for mexC and mexD in different mutants with 
mutations in nfxB and PA3491 gene: The experiment was repeated three times with 
three different biological replicates for each strain (2 technical replicates each).  
 
RT-qPCR was carried out as described in section 4.3.3.5. These data were validated by running controls (RT-) 
and running RTqPCR products on agarose gel and Tm analysis was done. The oprL and clpX were reference 
genes. 
*The mexC and mexD genes encodes efflux pump proteins MexCD to make an efflux pump MexCD-oprJ. 
**nfxB gene encodes negative regulator NfxB of efflux pump MexCD-oprJ encoding genes. 
clpX 
Strains Replicate 1 Replicate 2 Replicate 3 
PAO1 21.90 21.95 19.11 19.02 21.30 21.26 
gyrAT83I 21.81 21.58 20.87 20.79 21.48 21.05 
PA3491H87P 22.56 22.62 24.46 24.13 22.8 22.68 
nfxBT39P** 20.44 20.13 22.12 21.8 20.16 20.17 
gyrAT83I + nfxBT39P 21.82 21.73 24.24 23.67 20.99 20.96 
PA3491H87P + nfxBT39P 23.62 23.65 23 22.76 23.52 23.50 
gyrAT83I + nfxBT39P + PA3491H87P 20.73 20.31 20.57 20.57 20.19 20.01 
gyrAT83I + nfxBT39P + PA3491KO 24.46 24.56 24.24 24.49 24.33 23.46 
oprL 
PAO1 22.83 22.87 20.46 20.50 22.62 22.64 
gyrAT83I 22.62 22.62 21.05 21.23 21.95 21.90 
PA3491H87P 23.48 23.73 26 26 23.61 23.59 
nfxBT39P** 20.94 21.00 22.73 22.80 20.93 21.03 
gyrAT83I + nfxBT39P 21.58 21.59 22.77 22.76 21.14 21.14 
PA3491H87P + nfxBT39P 25.62 25.32 23.88 23.79 24.79 24.57 
gyrAT83I + nfxBT39P + PA3491H87P 20.91 20.97 21.72 21.72 20.90 20.87 
gyrAT83I + nfxBT39P + PA3491KO 27 26.20 25.47 25.64 26.17 26.17 
mexC* 
PAO1 37.09 40.0 36.21 37.33 38.37 37.97 
gyrAT83I 36.86 36.46 36.92 37.59 36.41 37.12 
PA3491H87P 37 38 - - 34.95 35.34 
nfxBT39P** 28.85 28.87 30.01 30.79 29.64 29.73 
gyrAT83I + nfxBT39P 29.31 29.31 30.88 30.99 29.56 29.59 
PA3491H87P + nfxBT39P 32 31.82 31 31.6 30.9 31 
gyrAT83I + nfxBT39P + PA3491H87P 27.43 27.55 27.46 27.23 27.80 27.89 
gyrAT83I + nfxBT39P + PA3491KO 33.52 33.3 32.8 32.6 32.19 32.29 
mexD* 
PAO1 30.24 30.61 28.09 28.20 27.14 27.06 
gyrAT83I 30.00 30.09 29.13 29.08 29.70 29.71 
PA3491H87P 30 30 32 31.8 29.97 30.55 
nfxBT39P** 23.73 23.76 24.67 24.67 23.60 23.60 
gyrAT83I + nfxBT39P 24.84 24.85 25.84 25.73 24.09 24.11 
PA3491H87P + nfxBT39P 28 28 26.8 26.8 27.8 27.8 
gyrAT83I + nfxBT39P + PA3491H87P 21.27 21.24 21.48 21.52 20.74 20.72 




G5: Relative quantification of mexC in different mutants to find the effect of nfxB 
mutation on the expression level of mexC by RT-qPCR. Values represent target/reference 
ratios of crossing points after normalisation of data in three biological replicates.  
 
G6: Relative quantification of mexD in different mutants to find the effect of nfxB 
mutation on the expression level of mexD by RT-qPCR. Values represent target/reference 






Strains  Replicate 1 Replicate 2 Replicate 3 SEM 
PAO1 1.37E-5 7.65E-6 1.32E-5 9.0E-06 
gyrAT83I 4.31E-5 1.26E-5 2.71E-5 8.8E-06 
PA3491H87P 2.2E-5 Invalid 2.49E-4 0.0001 
nfxBT39P 3.31E-3 3.80E-3 1.80E-3 0.0006 
gyrA T83I, nfxB T39P 5.05E-3 5.25E-3 2.72E-3 0.0008 
PA3491H87P, nfxBT39P 3.5E-3 3.77E-3 9.06E-3 0.001 
gyrAT83I, nfxBT39P, PA3491H87P 9.21E-3 1.36E-2 6.14E-3 0.002 
gyrAT83I, nfxBT39P, PA3491KO 3.46E-3 4.46E-3 6.89E-3 0.001 
Strains Replicate 1 Replicate 2 Replicate 3 SEM 
PAO1 3.81E-3 3.01E-3 2.83E-3 0.0003 
gyrAT83I 4.23E-3 3.60E-3 3.60E-3 0.0002 
PA3491H87P 4.45E-3 8.94E-3 7.36E-3 0.0013 
nfxBT39P 0.1150 0.2016 0.1222  0.027 
gyrA T83I, nfxB T39P 0.1114 0.1855 0.1215 0.023 
PA3491H87P, nfxBT39P 3.33E-2 9.20E-2 7.93E-2 
0.0178 
gyrAT83I, nfxBT39P, PA3491H87P 0.6956 0.7824 0.8478 
0.044 






G7: Analysis of RT-qPCR products on agarose gel 
The RT qPCR products using cDNA and RT- samples were visualized on an agarose gel to 
ensure that there were no non-intended amplifications. From left to right, the first lane of 
gel is 1 Kb plus DNA ladder. Lanes 1 and 2 have technical replicates of RT-qPCR product 
with PAO1 cDNAs using clpX primers (Table). Lanes 4 and 5 have technical replicates of 
RT-qPCR product with gyrA T83I cDNAs, Lanes 7 and 8 have technical replicates of RT-




















Amino acid changes in NfxB, Adapted from (Monti et al., 2013). Amino acid 
change (T39P) is in the proposed alpha-helix (α4) of NfxB, which normally interacts with 
DNA to repress the efflux pump gene expression. 
 
 
 
 
 
